 EXHIBIT 10.1      



  

Exhibit 10.1

  



  

Portions of this exhibit have been omitted and filed separately with the
Secretary of the Securities and Exchange Commission (the "Commission")
pursuant to an application for confidential treatment filed with the
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended. Such portions are marked as indicated below.

  



  

EQUITY INTEREST PURCHASE AGREEMENT

  



  

BY AND AMONG

  



  

NEUROFIX THERAPEUTICS, INC.

  



  

NEUROFIX, LLC

  



  

PHILIP HARPER

  



  

HAKON HAKONARSON

  



  

THE CHILDREN'S HOSPITAL OF PHILADELPHIA

  



  

MEDGENICS, INC.

  



  

DATED AS OF SEPTEMBER 9, 2015

  



    



 



    



  

 _TABLE OF CONTENTS_

  



     ARTICLE I SALE OF LLC EQUITY INTERESTS  | 2 
---|--- 
     |   | 
   1.1.  | Purchase and Sale of the LLC Equity Interests  | 2 
   1.2.  | Method of Conveyance  | 2 
     |   | 
   ARTICLE II CONSIDERATION  | 2 
     |   | 
   2.1.  | Consideration  | 2 
   2.2.  | Payment of Base Purchase Price  | 2 
   2.3.  | Milestone Consideration  | 3 
   2.4.  | Earnout Consideration  | 5 
   2.5.  | Adjustments to Milestone Consideration or Earnout Consideration;
Maintenance of Records; Audits   | 5 
   2.6.  | Provisions Related to the Issuance of Purchaser Shares  | 9 
     |   | 
   ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE SELLERS  | 10 
     |   | 
   3.1.  | Authorization and Enforceability  | 10 
   3.2.  | Non-contravention; Consents  | 10 
   3.3.  | The Legacy Corporation  | 11 
   3.4.  | Title to LLC Equity Interests  | 11 
   3.5.  | Brokers  | 11 
   3.6.  | Compliance with Law; Permits  | 12 
   3.7.  | Representations Regarding Equity Consideration  | 12 
     |   | 
   ARTICLE IV REPRESENTATIONS AND WARRANTIES RELATING TO THE COMPANY AND THE
LEGACY CORPORATION  | 13 
     |   | 
   4.1.  | Organization and Power  | 13 
   4.2.  | Authorization and Enforceability  | 14 
   4.3.  | Non-contravention; Consents  | 14 
   4.4.  | Capitalization; Subsidiaries  | 15 
   4.5.  | Financial Information; Indebtedness  | 15 
   4.6.  | Absence of Changes  | 16 
   4.7.  | Absence of Undisclosed Liabilities  | 16 
   4.8.  | Title to and Adequacy of Assets  | 16 
   4.9.  | Real Property  | 16 
   4.10.   | Intellectual Property  | 16 
   4.11.   | Contracts, Leases, Etc  | 19 
   4.12.   | Compliance with Law; Permits  | 19 
   4.13.   | Taxes  | 20 
   4.14.   | Employee Relations  | 22 
   4.15.   | Environmental Laws  | 22 
   4.16.   | Legal Proceedings  | 22 
   4.17.   | Transactions with Affiliates  | 23 
   4.18.   | Insurance  | 23 
  



    

-i-

 



    



     4.19.   | Brokers  | 24 
---|---|--- 
   4.20.   | Corporate Records  | 24 
   4.21.   | Bank Accounts  | 24 
   4.22.   | Powers of Attorney  | 24 
   4.23.   | Statements and Other Documents Not Misleading  | 24 
     |   | 
   ARTICLE V REPRESENTATIONS AND WARRANTIES OF PURCHASER  | 24 
     |   | 
   5.1.  | Organization  | 24 
   5.2.  | Authority  | 24 
   5.3.  | Conflict with other Instruments; Absence of Restrictions  | 25 
   5.4.  | Government Approvals  | 25 
   5.5.  | Brokers  | 25 
   5.6.  | Purchaser SEC Documents  | 25 
   5.7.  | Valid Issuance of Purchaser Shares  | 26 
   5.8.  | No Additional Representations  | 26 
     |   | 
   ARTICLE VI CLOSING  | 26 
     |   | 
   6.1.  | Closing  | 26 
   6.2.  | Closing Deliveries  | 26 
     |   | 
   ARTICLE VII COVENANTS  | 28 
     |   | 
   7.1.  | The Legacy Corporation's Business Following the Closing  | 28 
   7.2.  | Assistance in Defense  | 29 
   7.3.  | Public Announcements  | 29 
   7.4.  | General Release  | 29 
   7.5.  | Future Sale of Purchaser  | 29 
   7.6.  | Third Party Consents  | 30 
   7.7.  | Further Assurances  | 30 
   7.8.  | Right of First Refusal  | 30 
     |   | 
   ARTICLE VIII INDEMNIFICATION  | 31 
     |   | 
   8.1.  | Survival  | 31 
   8.2.  | The Selling Parties' Indemnification  | 31 
   8.3.  | Purchaser Indemnification  | 33 
   8.4.  | Payment; Procedure for Indemnification  | 34 
   8.5.  | Limitation on Indemnification  | 36 
   8.6.  | Characterization of Indemnity Payments  | 37 
   8.7.  | Sole Remedy  | 37 
     |   | 
   ARTICLE IX TAXES; BULK SALES  | 37 
     |   | 
   9.1.  | Preparation and Filing of Pre-Closing and Post-Closing Tax
Returns for LLC  | 37 
   9.2.  | Allocation  | 38 
  



    

-ii-

 



    



     9.3.  | Cooperation on Tax Matters  | 38 
---|---|--- 
   9.4.  | Transfer Taxes  | 38 
   9.5.  | Tax Advice  | 38 
     |   | 
   ARTICLE X RESTRICTIVE COVENANTS  | 39 
      | 
   10.1.  | Confidentiality  | 39 
   10.2.  | Restrictive Covenants  | 39 
   10.3.  | Specific Enforcement  | 40 
   10.4.  | Disclosure  | 40 
   10.5.  | Interpretation  | 41 
   10.6.  | Acknowledgment  | 41 
     |   | 
   ARTICLE XI REGISTRATION RIGHTS  | 41 
     |   | 
   11.1.  | Registration  | 41 
   11.2.  | Expenses of Registration  | 41 
   11.3.  | Obligations of Purchaser  | 41 
   11.4.  | Furnishing Information  | 44 
   11.5.  | Indemnification; Contribution  | 44 
     |   | 
   ARTICLE XII STOCKHOLDER REPRESENTATIVE  | 46 
     |   | 
   12.1.  | Appointment of the Stockholder Representative; Duties; and
Power of Attorney  | 46 
   12.2.  | Reliance  | 47 
   12.3.  | Limitation of Liability; Indemnification  | 47 
   12.4.  | Fees and Expenses  | 47 
     |   | 
   ARTICLE XIII MISCELLANEOUS  | 48 
     |   | 
   13.1.  | Severability  | 48 
   13.2.  | Amendment and Waivers  | 48 
   13.3.  | Entire Agreement  | 48 
   13.4.  | Expenses  | 48 
   13.5.  | Notice  | 49 
   13.6.  | Governing Law and Jurisdiction  | 50 
   13.7.  | Waiver of Jury Trial  | 50 
   13.8.  | Assignment; Binding Effect; No Third Party Rights  | 51 
   13.9.  | Counterparts; Execution by Electronic Means  | 51 
     |   | 
   ARTICLE XIV INTERPRETATION; DEFINITIONS  | 51 
     |   | 
   14.1.  | Rules of Construction  | 51 
   14.2.  | Certain Terms  | 52 
  



    

-iii-

 



    



  

EQUITY INTEREST PURCHASE AGREEMENT

  



  

THIS EQUITY INTEREST PURCHASE AGREEMENT ("Agreement") is entered into as of
September 9, 2015, by and among neuroFix therapeutics, inc., a Delaware
corporation (the "Legacy Corporation"), neuroFix, LLC, a Delaware limited
liability company (the "Company"), Philip Harper, an individual resident in
the Commonwealth of Pennsylvania ("Harper"), Hakon Hakonarson, an individual
resident in the Commonwealth of Pennsylvania ("Hakonarson"), The
Children's Hospital of Philadelphia, a Pennsylvania non-profit corporation
("CHOP"), and Medgenics, Inc., a Delaware corporation ("Purchaser"). The
Legacy Corporation, the Company, Harper, Hakonarson, CHOP, and Purchaser are
sometimes referred to herein individually as "Party" and collectively as the
"Parties." Capitalized terms not otherwise defined herein have the respective
meanings assigned to such terms in _Article XIV_ hereof.

  



  

BACKGROUND

  



  

WHEREAS, the Legacy Corporation and the Company are engaged in the Business;

  



  

WHEREAS, Harper and Hakonarson (the "Legacy Stockholders") are the owners of
all of the issued and outstanding equity Securities of the Legacy Corporation
(collectively, the "Legacy Equity Interests");

  



  

WHEREAS, prior to the date hereof, the Legacy Corporation formed the Company,
to which the Legacy Corporation contributed all of its assets (including the
option to enter into the CHOP License Agreement and all regulatory filings)
and liabilities, and pursuant to which the Legacy Corporation became the sole
holder of equity Securities of the Company (the "Reorganization");

  



  

WHEREAS, the Company and CHOP have entered into the License Agreement
attached hereto as _Exhibit A_ (the "CHOP License Agreement");

  



  

WHEREAS, upon entering into the CHOP License Agreement, CHOP became a holder
of LLC Equity Interests of the Company and, together, CHOP and the
Legacy Corporation (the "Equityholders") are the only owners of all of the
issued and outstanding equity Securities of the Company (collectively, the
"LLC Equity Interests");

  



  

WHEREAS, the Equityholders desire to sell the LLC Equity Interests to
Purchaser, and Purchaser desires to purchase the LLC Equity Interests from the
Equityholders, on the terms and subject to the conditions hereinafter set
forth; and

  



  

WHEREAS, to induce Purchaser to enter into this Agreement and consummate the
Contemplated Transactions, each of the Legacy Stockholders and the
Equityholders agrees to be bound by the Restrictive Covenants applicable to
such Party contained herein.

  



    

 | -1-| 
---|---|--- 

 



    



  

AGREEMENT

  



  

NOW, THEREFORE, in consideration of the representations, warranties,
covenants and agreements contained herein, and for other good and valuable
consideration, the receipt and adequacy of which are conclusively
acknowledged, the Parties, intending to be legally bound, hereby agree as
follows:

  



  

ARTICLE I

  

SALE OF LLC EQUITY INTERESTS

  



  

1.1. _Purchase and Sale of the LLC Equity Interests_. On and subject
to the terms and conditions of this Agreement, each of the Equityholders
hereby sells, transfers and delivers to Purchaser, and Purchaser hereby
purchases and acquires from the Equityholders, the LLC Equity Interests, free
and clear of any Encumbrances. The LLC Equity Interests sold and
purchased hereunder constitute one hundred percent (100%) of the issued and
outstanding equity Securities of the Company.

  



  

1.2. _Method of Conveyance_. The sale, transfer, and delivery of the
LLC Equity Interests by the Equityholders to Purchaser in accordance with
this _Article I_ shall be effected by each Equityholder's delivery of
membership interest transfer powers being duly executed in blank for transfer
of all of the LLC Equity Interests owned by such Equityholder to Purchaser at
Closing.

  



  

ARTICLE II

  

CONSIDERATION

  



  

2.1. _Consideration_. In full consideration of the sale and transfer
of the LLC Equity Interests and entry into the Restrictive
Covenants, Purchaser shall pay and deliver, or cause to be paid and delivered
on Purchaser's behalf, to the Equityholders an amount equal to (a) (i) with
respect to the Legacy Corporation, One Million Six Hundred Thousand Dollars
($1,600,000) and (ii) with respect to CHOP, Four Hundred Thousand Dollars
($400,000) (the sum of (i) and (ii), the "Base Purchase Price"), _plus_ (b)
the Milestone Consideration (as set forth in _Section 2.3_ and subject to
adjustment pursuant to _Sections 2.5_ and _2.6_ ), if any, _plus_ (c) the
Earnout Consideration (as set forth in _Section 2.4_ and subject to
adjustment pursuant to _Section 2.5_ ), if any. The Base Purchase Price,
_plus_ the Milestone Consideration, if any, _plus_ the Earnout Consideration,
if any, is the "Consideration." The Equityholders acknowledge and agree that
the Consideration will be paid as set forth in this _Article II_ , and to
the extent applicable, to the account of each Equityholder in accordance with
their respective Pro Rata Share and in accordance with instructions delivered
to Purchaser at least ten (10) Business Days prior to the date hereof or any
subsequently scheduled payment date as agreed by the Parties, as applicable
(the "Equityholder Instructions").

  



  

2.2. _Payment of Base Purchase Price_.

  



  

(a) The Legacy Corporation hereby directs that Purchaser pay the
portion of the Base Purchase Price that is payable to the Legacy Corporation
hereunder to Legacy Corporation, by wire transfer of immediately available
funds, by no later than the end of the second Business Day following the date
hereof to an account designated by Legacy Corporation.

  



    

 | -2-| 
---|---|--- 

 



    



  

(b) Purchaser shall pay the CHOP portion of the Base Purchase Price
to CHOP by wire transfer of immediately available funds, by no later than the
end of the second Business Day following the date hereof to an account
designated by CHOP.

  



  

2.3. _Milestone Consideration_.

  



  

(a) Subject to the satisfaction of the conditions precedent set
forth in this _Section 2.3_ (each, a "Milestone Event," and the time periods
described therein, the "Milestone Periods"), the Final Reports pursuant to
_Section 2.5_ and adjustment pursuant to _Section 2.6_ , Purchaser or an
Affiliate of Purchaser shall pay to the Equityholders the following payments
(each, a "Milestone Payment" and together, the "Milestone Payments"), payable
in the manner set forth in this _Section 2.3_ (in the aggregate, the
"Milestone Consideration"), subject at all times to any offset thereto in
accordance with _Section 8.4(c)_. Except with respect to the Milestone Event
described in _Section 2.3(a)(iii)_ (which may be paid more than once), all
Milestone Payments shall only be paid once upon the initial achievement of
the particular Milestone Event. Purchaser shall notify the Stockholder
Representative and CHOP within ten (10) Business Days from when a Milestone
Event has occurred. Within ten (10) Business Days from Purchaser's receipt of
Equityholder Instructions in response to such notice, Purchaser shall pay
the following Milestone Payments:

  



  

(i) following the earlier of (A) the consummation date of the
successful completion of a firm underwritten or registered direct offering
of Purchaser Common Shares with proceeds to Purchaser, net of underwriters'
fees and expenses, of at least Thirty-Five Million Dollars ($35,000,000) (the
"Qualified Offering"), and (B) March 31, 2016 (in either case (A) or (B), the
"Offering Date"), a Milestone Payment equal to:

  



  

(A) with respect to the Legacy Corporation, (x) One Million Six
Hundred Thousand Dollars ($1,600,000), by wire transfer of
immediately available funds and in accordance with the Equityholder
Instructions, and (y) a number of Purchaser Common Shares, deliverable to the
Legacy Corporation in accordance with the Equityholder Instructions, equal to
Three Million Two Hundred Thousand Dollars ($3,200,000) divided by the
Purchaser Stock Price (rounded to the nearest whole share); and

  



  

(B) with respect to CHOP, One Million Two Hundred Thousand Dollars
($1,200,000), by wire transfer of immediately available funds and in
accordance with the Equityholder Instructions;

  



  

(ii) [ *** ]:

  



  

(A) [ *** ]; and

  



  

(B) [ *** ];

  



  

  



  

  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



    

 | -3-| 
---|---|--- 

 



    



  

(iii) [ *** ];

  



  

(iv) [ *** ] payable to the Equityholders, by wire transfer of
immediately available funds and in accordance with their respective Pro
Rata Share and the Equityholder Instructions; and

  



  

(v) upon the first instance of cumulative Annual Net Sales from all
Products, Improved Products and NCEs in any calendar year (each, an "Annual
Period") as follows, payable to the Equityholders by wire transfer of
immediately available funds and in accordance with their respective Pro Rata
Share and the Equityholder Instructions:

  



     Cumulative Annual Net Sales  |   | Milestone Payment 
---|---|--- 
     |   | 
   > = $[ *** ]  |   | $[ *** ] 
     |   | 
   > = $[ *** ]  |   | $[ *** ] 
     |   | 
   > = $[ *** ]  |   | $[ *** ] 
     |   | 
   > = $[ *** ]  |   | $[ *** ] 
     |   | 
   > = $[ *** ]  |   | $[ *** ] 
  



  

(b) Except with respect to the Milestone Event described in _Section
2.3(a)(iii)_ (which may be paid more than once), once Purchaser (or its
Affiliates) has made any particular Milestone Payment under this _Section 2.3_
, Purchaser shall not be obligated to make any payment under this _Section
2.3_ with respect to the re-occurrence of the same Milestone Event, whether
or not such re-occurrence is with respect to a different or the same Product,
Improved Product or NCE (or any combination thereof), or a different or the
same Annual Period. If a Milestone Event is achieved in terms of Annual
Net Sales, all Milestone Payments for lower Annual Net Sales Milestone Events
shall become due and payable to the extent not previously paid.

  



  

(c) From and after the Closing, Purchaser shall, and shall cause its
controlled Affiliates to, use Commercially Reasonable Efforts to (i) Develop
the Product for the Primary Indication, and (ii) following the FDA's approval
of a NDA for a Product for the Primary Indication, Commercialize the Product
in the United States.

  



  

  



  

  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



  

   

 | -4-| 
---|---|--- 

 



    



  

2.4. _Earnout Consideration_. Subject to the conditions set forth in
this _Section 2.4_ and the Product Reports and Final Reports pursuant to
_Section 2.5_ , Purchaser or an Affiliate of Purchaser shall pay to the
Equityholders the following payments (each, an "Earnout Payment" and
together, the "Earnout Payments"), payable in the manner set forth in this
_Section 2.4_ (in the aggregate, the "Earnout Consideration"), subject at all
times to any offset thereto in accordance with _Section 8.4(c)_. The Earnout
Payments are based on the Net Sales, as defined and subject to the provisions
set forth in _Section 14.2(a)_. The Earnout Consideration shall consist of
the following Earnout Payments, payable no later than the due date for the
applicable Product Reports with any additional payments reflected in the
corresponding Final Report payable no later than thirty (30) Business Days
after the earliest date on which the corresponding Final Reports are
available, and payable to the Equityholders, by wire transfer of immediately
available funds and in accordance with their respective Pro Rata Share and the
Equityholder Instructions:

  



  

(a) [ *** ]:

  



     Increment of Annual  |   | Percentage of Annual Net Sales from
such 
---|---|--- 
   Net Sales from a Product  |   | Product Payable as Earnout Payment 
   <= $[ *** ]  |   | [ *** ] 
   > $[ *** ]  |   | [ *** ] 
   > $[ *** ]  |   | [ *** ] 
   > $[ *** ]  |   | [ *** ] 
  



  

(b) [ *** ]:

  



     Increment of Annual Net Sales  |   | 
---|---|--- 
   from Improved Products and  |   | Percentage of Annual Net Sales from
Improved 
   NCEs  |   | Products and NCEs Payable as Earnout Payment 
     |   | 
   <= $[ *** ]  |   | [ *** ]  | [ *** ] 
     |   |   | 
   > $[ *** ]  |   | [ *** ]  | [ *** ] 
     |   |   | 
   >$[ *** ]  |   | [ *** ]  | [ *** ] 
  



  



  

2.5. _Adjustments to Milestone Consideration or Earnout
Consideration; Maintenance of Records; Audits_.

  



  

(a) [ *** ].

  



  

(b) _Reports and Payments_. Within sixty (60) days after the end of
each Reporting Period commencing in the Reporting Period immediately
following the Reporting Period in which there was the First Commercial Sale,
Purchaser shall deliver to the Stockholder Representative and CHOP a report
setting forth for the most recently completed Reporting Period the
following information on a Product-by-Product, Improved Product-by-Improved
Product, NCE-by-NCE and country-by-country basis (the "Product Reports"): (i)
the gross sales and Net Sales of each Product, Improved Product or NCE; (ii)
the number of units sold by Purchaser and all of its Affiliates, licensees
and sublicensees; (iii) the Milestone Payment or Earnout Payment due
hereunder, if any; (iv) the applicable exchange rate as determined pursuant to
_Section 2.5(e)_ ; and (v) the calculation of any true-up required with
respect to Net Sales reported and payments made in the Reporting Period(s).

  



  

  



  

  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



    

 | -5-| 
---|---|--- 

 



    



  

(c) _Setoff_. Notwithstanding anything to the contrary in this
Agreement, if the Legacy Stockholders or the Equityholders breach
this Agreement (including with respect to indemnification obligations set
forth in _Article VIII_ ), Purchaser may offset the Milestone Payments and
Earnout Payments payable under this Agreement to the breaching party pursuant
to _Section 8.4(c)_  against such Losses until such time as Purchaser has
been paid such Losses in full (net of offset).

  



  

(d) _Taxes and Withholding_. If Purchaser is required to make a
payment to the Equityholders subject to a deduction of tax or withholding
tax, the sum payable by Purchaser (in respect of which such deduction or
withholding is required to be made) shall be made to the Equityholders after
deduction of the amount required to be so deducted or withheld, which deducted
or withheld amount shall be remitted in accordance with applicable Laws. Any
such withholding taxes required under applicable Laws to be paid or withheld
shall be an expense of, and borne solely by the Equityholders. To the extent
Purchaser is required to deduct and withhold taxes on any payments to the
Equityholders, Purchaser shall pay the amounts of such taxes to the proper
governmental authority in a timely manner and promptly transmit to the
Stockholder Representative and CHOP an official tax certificate or other
evidence of such withholding sufficient to enable the Equityholders to claim
such payments of taxes. The Equityholders shall provide to Purchaser any tax
forms that may be reasonably necessary in order for Purchaser not to withhold
tax or to withhold tax at a reduced rate under an applicable bilateral income
tax treaty. The Equityholders shall use reasonable efforts to provide any
such tax forms to Purchaser at least thirty (30) days prior to the due date
for any payments for which the Equityholders desire that Purchaser apply a
reduced withholding rate. Each Party will reasonably assist the other Party
in claiming tax refunds, deductions, or credits at the other Party's request
and will reasonably cooperate to minimize the withholding tax, if available,
under various treaties applicable to any payment made under this Agreement.

  



  

(e) _Payment and Currency Exchange_. All amounts payable and
calculations hereunder shall be in U.S. Dollars and shall be paid by
bank wire transfer in immediately available funds to such bank account as may
be designated in writing by the Stockholder Representative and CHOP from time
to time. In the event that Net Sales are generated in a currency other than
United States Dollars, the Net Sales shall be converted into United States
Dollars in accordance with the accounting practices, principles, judgments
and methodologies (which shall be in accordance with GAAP or IFRS) with
respect to the conversion of transactions conducted in a foreign currency to
United States Dollars used by Purchaser for the preparation of its
financial statements.

  



    

 | -6-| 
---|---|--- 

 



    



  

(f) _Record-Keeping_. Purchaser shall keep, and shall cause its
Affiliates and sublicensees to keep, books and accounts of record in
connection with the sale of Products, Improved Products and NCEs and in
sufficient detail to permit accurate determination of all figures necessary
for verification of Milestone Payments and Earnout Payments to be paid
hereunder. Purchaser shall maintain, and shall cause its Affiliates,
licensees and sublicensees to maintain, such records for a period of at least
three (3) years after the end of the Reporting Period for which they were
generated. At the conclusion of each Reporting Period, Purchaser shall
promptly deliver Product Reports to the Stockholder Representative and CHOP
with respect to each such Reporting Period on Purchaser's Net Sales,
Milestone Payments status and Earnout Payments status.

  



  

(g) _Disagreements_.

  



  

(i) If the Stockholder Representative and/or CHOP disagrees with
Purchaser's calculation of Net Sales, Milestone Payments or Earnout Payments
in a Product Report, then, within sixty (60) calendar days after receipt
thereof, the Stockholder Representative and/or CHOP (as applicable, the
"Disagreeing Party") shall provide Purchaser with notice in writing of such
disagreement (the "M/E Notice of Disagreement"), setting forth in reasonable
detail the particulars of such disagreement, including a copy of the Product
Report marked to indicate those specific items that are in dispute (the "M/E
Disputed Items") and the Disagreeing Party's calculation of each of the
M/E Disputed Items. To the extent the Disagreeing Party provides an M/E
Notice of Disagreement within such sixty (60) calendar day period, only those
items that are not M/E Disputed Items shall be non-appealable, final, binding
and conclusive for all purposes hereunder. If neither the Stockholder
Representative nor CHOP provides a M/E Notice of Disagreement within
such sixty (60) calendar day period, the Parties shall be deemed to have
accepted in full the Product Report as prepared by Purchaser, which shall be
non-appealable, final, binding and conclusive for all purposes hereunder. If
any M/E Notice of Disagreement is timely provided, Purchaser and the
Disagreeing Party shall, for a period of twenty (20) calendar days (or such
longer period as they may mutually agree), in good faith try to resolve any
M/E Disputed Items. During the twenty (20) calendar day period following the
delivery by the Disagreeing Party of the M/E Notice of Disagreement, Purchaser
and the Disagreeing Party, along with their respective Representatives, shall
have access to the working papers, schedules and calculations of the other
used in the preparation of the Product Report and the M/E Notice of
Disagreement and the determination of the Net Sales, Milestone Payments,
Earnout Payments and the M/E Disputed Items. If, during the aforesaid twenty
(20) calendar day period, the Parties have reached written agreement with
respect to all M/E Disputed Items covered by the Notice of Disagreement, the
calculations of Net Sales, Milestone Payments and Earnout Payments shall be
adjusted to reflect such written agreement and shall become non-appealable,
final, binding and conclusive upon the Parties for all purposes hereunder.

  



    

 | -7-| 
---|---|--- 

 



    



  

(ii) If, at the end of the aforesaid twenty (20) calendar day period,
Purchaser and the Disagreeing Party shall have failed to reach written
agreement with respect to all M/E Disputed Items covered by a M/E Notice of
Disagreement, then those M/E Disputed Items that remain in dispute at the end
of such period (the "M/E Unresolved Changes") shall be submitted to BDO USA,
LLP (the "Settlement Arbitrator") to examine, at the Equityholders' sole
expense, the relevant books and records of Purchaser or any of its Affiliates,
licensees and sublicensees (the "Audited Party") as may be reasonably
necessary to verify the amounts reported in accordance with _Section 2.5(f)_
and the payment of Milestone Payments or Earnout Payments; _provided, however_
, that if BDO USA, LLP shall be unable or unwilling to do so, Purchaser and
the Disagreeing Party shall select another independent firm of
nationally recognized financial experts to serve as the Settlement
Arbitrator. The Settlement Arbitrator shall consider only the M/E Unresolved
Changes. An examination by the Disagreeing Party under this _Section 2.5(g)_
shall be limited to the pertinent books and records for the relevant
Reporting Period. The Settlement Arbitrator shall be provided access to
such books and records at the Audited Party's facility(ies) where such books
and records are normally kept and such examination shall be conducted during
the Audited Party's normal business hours; no other information pertaining to
the Audited Party's books and records shall be provided to the Disagreeing
Party. The Audited Party may require the Settlement Arbitrator to sign a
standard non-disclosure agreement before providing the Settlement Arbitrator
access to the Audited Party's facilities or records. Upon completion of the
audit, the Settlement Arbitrator shall provide Purchaser, the Disagreeing
Party and the Audited Party a written report disclosing any discrepancies in
the reports submitted by the Audited Party and in each case, the specific
details concerning any discrepancies. The determination of the
Settlement Arbitrator shall be non-appealable, final, binding and conclusive
for all purposes hereunder. The Parties shall request that the Settlement
Arbitrator use its commercially reasonable efforts to reach a resolution of
the M/E Unresolved Changes within ninety (90) calendar days after the
submission of the M/E Unresolved Changes to the Settlement Arbitrator.

  



  

(iii) The Product Reports, as determined pursuant to this _Section
2.5(g)_ after all actions and procedures described herein have been
completed, are hereinafter referred to as the "Final Reports."

  



  

(h) _Confidentiality_. All financial information of an Audited
Party that is subject to review under this _Section 2.5_ shall be deemed to
be confidential information of such Audited Party subject to the provisions
of _Section 10.1_ , and the Legacy Stockholders and the Equityholders shall
not disclose such confidential information to any Third Party or use such
confidential information for any purpose other than verifying payments to be
made by Purchaser to the Equityholders hereunder.

  



    

 | -8-| 
---|---|--- 

 



    



  

2.6. _Provisions Related to the Issuance of Purchaser Shares_.

  



  

(a) Notwithstanding anything contained in this Agreement, Purchaser
shall not, without the prior approval of its stockholders as
required pursuant to the rules and regulations of the NYSE MKT, be required
to pay any of the Consideration in Purchaser Common Stock under this
Agreement: (i) if the aggregate number of Purchaser Common Shares to be issued
hereunder would exceed 19.99% of the outstanding Purchaser Common Shares as
of the date hereof (as such ownership is calculated pursuant to the rules of
the NYSE MKT); or (ii) to any Equityholder that, together with such
Equityholder's Affiliates and any other persons acting as a group together
with such Equityholder and any of such Equityholder's Affiliates, (x)
immediately prior to the applicable payment date, does not beneficially own
more than 19.99% of the outstanding Purchaser Common Shares (as
such ownership is calculated pursuant to the rules of the NYSE MKT), if as a
result of such issuance of Purchaser Common Shares, such Equityholder
(together with such Equityholder's Affiliates and any other persons acting as
a group together with such Equityholder's and any of such Equityholder's
Affiliates) would beneficially own more than 19.99% of the outstanding
Purchaser Common Shares (as such ownership is calculated pursuant to the rules
of the NYSE MKT) immediately after giving effect to the issuance of such
Purchaser Common Shares; or (y) immediately prior to the applicable payment
date beneficially owns more than 19.99% of the outstanding Purchaser Common
Shares (as such ownership is calculated pursuant to the rules of the NYSE
MKT), if such Equityholder (together with such Equityholder's Affiliates and
any other persons acting as a group together with such Equityholder and any
of such Equityholder's Affiliates) is not the largest beneficial owner of the
Purchaser Common Shares (as such ownership is calculated pursuant to the rules
of the NYSE MKT) immediately prior to the applicable payment date, but, as a
result of such issuance of Purchaser Common Shares to such Equityholder, such
Equityholder (together with such Equityholder's Affiliates and any other
persons acting as a group together with such Equityholder's and any of such
Equityholder's Affiliates) would (X) become the largest beneficial owner of
the Purchaser Common Shares (as such ownership is calculated pursuant to the
rules of the NYSE MKT) immediately after giving effect to the issuance of
such Purchaser Common Shares or (Y) become the beneficial owner of a number
of Purchaser Common Shares (as such ownership is calculated pursuant to the
rules of the NYSE MKT) immediately after giving effect to the issuance of
such Purchaser Common Shares which, had such Purchaser Common Shares been
received by such Equityholder as of the date such Equityholder entered into
this Agreement, would have caused such Equityholder to become the largest
beneficial owner of Purchaser Common Shares (as such ownership is calculated
pursuant to the rules of the NYSE MKT) as of such earlier date. Immediately
following the date (if ever) that Purchaser obtains the requisite stockholder
approval required pursuant to the rules and regulations of the NYSE MKT, the
restrictions in this _Section 2.6(a)_ shall terminate and be of no further
force or effect.

  



  

(b) Notwithstanding anything contained in this Agreement, in no
event shall the number of Purchaser Common Shares issuable hereunder exceed
at any time in the aggregate 49.99% of the outstanding Purchaser Common
Shares as of the date hereof.

  



  

(c) The applicable amount of the Purchaser Common Shares to be
issued in connection with this Agreement to either the Legacy Stockholders or
the Legacy Corporation, as applicable, may be either (i) registered securities
pursuant to the Securities Act, or (ii) issued in a transaction exempt from
registration under the Securities Act, by reason of Section 4(a)(2)
thereof and/or Regulation D promulgated under the Securities Act and may not
be re-offered or resold other than in conformity with the registration
requirements of the Securities Act and such other laws or pursuant to an
exemption therefrom (with the certificates issued by Purchaser with respect
to such Purchaser Common Stock legended to the effect described above and
shall include such additional legends as necessary to comply with applicable
U.S. federal securities laws and Blue Sky laws).

  



  

(d) The Legacy Stockholders and the Equityholders shall use
commercially reasonable efforts to cause the Legacy Stockholders and
the Equityholders to provide such information, take such further actions and
execute such documents as Purchaser may determine to be necessary to ensure
that the Purchaser Common Shares to be issued in connection with this
Agreement are issued in a transaction exempt from registration under the
Securities Act, by reason of Section 4(a)(2) thereof and/or Regulation
D promulgated under the Securities Act, including requiring that the Legacy
Stockholders and the Equityholders make the representations to Purchaser set
forth in _Section 3.7_ hereof as of the date(s) of issuance of the Purchaser
Common Shares to be issued in connection with this Agreement.

  



    

 | -9-| 
---|---|--- 

 



    



  

(e) To the extent that any Consideration otherwise payable in
Purchaser Common Stock would exceed the limitations set forth in
_Sections 2.6(a)_ or _2.6(b)_ as of the time such Consideration is due and
payable, the portion of such Consideration that exceeds the limitations set
forth in _Sections 2.6(a)_ or _2.6(b)_ shall be paid in cash, in lieu of
Purchaser Common Stock. Such amount shall be paid by Purchaser or an
Affiliate of Purchaser to the Equityholders by wire transfer of immediately
available funds and in accordance with their respective Pro Rata Share and the
Equityholder Instructions, in an amount equal to the product of the Purchaser
Stock Price and the applicable number of shares of Purchaser Common Stock.

  



  

(f) Purchaser shall deliver any Purchaser Common Shares it is
obligated to deliver upon the occurrence of a Milestone Event within ten
(10) Business Days after the occurrence of such Milestone Event. Such
delivery of Purchaser Common Shares shall be in book-entry form with the
Purchaser's transfer agent.

  



  

ARTICLE III

  

REPRESENTATIONS AND WARRANTIES OF THE SELLERS

  



  

Except as disclosed to Purchaser in a letter (the "Disclosure Schedule")
delivered to them on behalf of the Equityholders and the Legacy Stockholders
(together, the "Sellers") prior to the execution of this Agreement, each
Seller (to the extent applicable), severally and not jointly, hereby
represents and warrants to Purchaser that each of the representations and
warranties contained in this _Article III_ are true and correct on the date
hereof (except to the extent that such representations and warranties speak
as of another date, in which case, as of such date).

  



  

3.1. _Authorization and Enforceability_. Each such Seller has the
full right, power and authority and capacity to enter into and perform
this Agreement and each of the other Transaction Documents to which it is a
party and to consummate the Contemplated Transactions. This Agreement and
each of the other Transaction Documents to which such Seller is a party have
been duly executed and delivered by such Seller and constitutes legal, valid
and binding obligations of such Seller, enforceable against such Seller in
accordance with its respective terms, except as such enforceability may be
limited by applicable bankruptcy, insolvency, moratorium or similar Laws
affecting the rights of creditors generally and general equity principles
(regardless of whether enforceability is considered in a proceeding at or in
equity) (the "Bankruptcy and Equity Exceptions").

  



  

3.2. _Non-contravention; Consents_.

  



  

(a) The execution, delivery and performance by such Seller of this
Agreement and each of the other Transaction Documents to which such Seller is
a party and the consummation of the Contemplated Transactions do not and will
not: (i) result in a Default of or under (A) any Law, Permit or Order
applicable to or binding upon such Seller, or (B) any Contract to which such
Seller is a party or by which he is bound; or (ii) (1) result in the
termination, amendment or modification of, or give any party the right to
terminate, amend, modify, abandon, cancel or refuse to perform any Contract or
Permit to which such Seller is a party or by which he, or any of his
properties or assets, are bound, or (2) result in the acceleration or
modification, or give any party the right to accelerate or modify, the time
within which, or the terms under which, any duties or obligations are to be
performed, or any rights or benefits are to be received under any Contract or
Permit to which such Seller is a party or by which he, or any of his
properties or assets, is bound.

  



    

 | -10-| 
---|---|--- 

 



    



  



  

(b) No Consent of any Governmental Entity or other Person (including
any party to any Contract with such Seller) is required (i) for the
execution, delivery and performance by such Seller of this Agreement or any of
the other Transaction Documents to which such Seller is a party; or (ii) in
connection with the consummation by such Seller of the Contemplated
Transactions.

  



  

3.3. _The Legacy Corporation_.

  



  

(a) _Authorized Legacy Equity Interests_. The authorized Legacy
Equity Interests consist of 10,000,000 shares of common stock, $0.0001
par value per share of the Legacy Corporation, of which 80,000 are issued and
outstanding and held as set forth on _Section_ _3.3(a)_ of the Disclosure
Schedule. The Legacy Equity Interests constitute the only issued and
outstanding equity Securities of the Legacy Corporation and are owned of
record and beneficially solely by the Legacy Stockholders. There are no
outstanding warrants, options or other rights, commitments, Contracts or
understandings to purchase or acquire any equity Securities of the Legacy
Corporation and there are no outstanding debt Securities of the Legacy
Corporation convertible into equity Securities or otherwise containing equity
provisions.

  



  

(b) Other than the Company, the Legacy Corporation does not have any
Subsidiaries. The Legacy Corporation has not acquired any business or Person,
whether by merger or consolidation, purchase of assets or equity Securities or
otherwise.

  



  

(c) The Harper Indebtedness is Indebtedness of the Legacy
Corporation and not the Company and is the only Indebtedness of the
Legacy Corporation.

  



  

3.4. _Title to LLC Equity Interests_.

  



  

(a) The Equityholders have good and valid title to its LLC Equity
Interests free and clear of all Encumbrances, other than restrictions on
transfer under applicable securities Laws and restrictions set forth in the
Company's Organizational Documents, as applicable.

  



  

(b) Such Equityholder has not entered into or granted any
outstanding warrants, options, commitments, voting trusts, Contracts
or understandings with respect to any LLC Equity Interests.

  



  

3.5. _Brokers_. No broker, investment banker, financial advisor or
other Person is entitled to any broker's, finder's, financial advisor's or
other similar fee or commission in connection with the Contemplated
Transactions based upon arrangements made by or on behalf of such Seller or
any Person acting on his behalf.

  



    

 | -11-| 
---|---|--- 

 



    



  

3.6. _Compliance with Law; Permits_.

  



  

(a) Such Seller has not (i) directly or indirectly given or agreed
to give any illegal gift, contribution, payment or similar benefit to any
supplier, customer, governmental official or employee or other Person who was,
is or may be in a position to help or hinder the Company (or assist the
Company in connection with any actual or proposed transaction) or made or
agreed to make any illegal contribution, or reimbursed any illegal political
gift or contribution made by any other Person, to any candidate for federal,
state, local or foreign public office (x) which could reasonably be expected
to subject the Company, Purchaser or the Business to any damage or penalty in
any civil, criminal or governmental litigation or proceeding, or (y) the non-
continuation of which has had or could reasonably be expected to have an
adverse effect; (ii) established or maintained any unrecorded fund or asset
or made any false entries on any Books or Records for any purpose or (iii)
engaged in price fixing, bid rigging or any other anticompetitive activity.

  



  

(b) Such Seller has complied with every, and is not presently in
violation of any, Law or Order to which he, she or it is subject related to,
and has not failed to obtain, or to adhere to the requirements of, any Permit
necessary to, such Seller's ownership of the Company, or the Company's
operation of the Business. Such Seller has not received, nor does such Seller
have Knowledge of the issuance of, any notice from any Governmental Entity, or
other Third Party of any such violation or alleged violation by him or it of
any Laws or Orders applicable to the Business or his or its ownership thereof.
To the Knowledge of such Seller, there is no investigation relating to the
Company, such Seller's ownership or the Business in progress by any
Governmental Entity.

  



  

(c) Such Seller has not engaged in any anticompetitive or unlawful
activity or unfair business practice relating to the Business. With respect
to the Company's and such Seller's past business practices relating to the
Business, such Seller has not received any written notice of any
investigation of the Company, the Business, such Seller, or the Company's
respective officers, employees or representatives by any Governmental Entity
and, to the Knowledge of such Seller, no such investigation is under
consideration or threatened.

  



  

3.7. _Representations Regarding Equity Consideration_. Each Seller,
to the extent that it receives unregistered Purchaser Common Shares
pursuant to this Agreement:

  



  

(a) is acquiring the Consideration Shares being issued to it
pursuant to this Agreement solely for its own account and not with a view to
resale or distribution of all or any part thereof, and has no present
arrangement, understanding or agreement for transferring or disposing of all
or any part of the Consideration Shares being issued to it pursuant to this
Agreement, except as such Consideration Shares may be distributed by the
Legacy Corporation to the Legacy Stockholders upon a dissolution or
liquidation of the Legacy Corporation;

  



  

(b) has such knowledge and experience in financial and business
matters that he, she or it is capable of evaluating the merits and risks of
an investment in the Consideration Shares being issued to it pursuant to this
Agreement and to form an investment decision with respect thereto, and it and
its advisers, if any, have also made such investigation, review, examination
and inquiry concerning Purchaser and its business and affairs as they have
deemed appropriate;

  



    

 | -12-| 
---|---|--- 

 



    



  

(c) is an "accredited investor" within the meaning of Rule 501 of
Regulation D under the Securities Act;

  



  

(d) recognizes that an investment in Purchaser is speculative and
involves certain risks and such party has taken full cognizance of
and understands and can evaluate all of the risks of the investment in the
Consideration Shares being issued to it pursuant to this Agreement;

  



  

(e) has adequate net worth and means of providing for its current
needs and personal contingencies to sustain a complete loss of such party's
investment in Purchaser;

  



  

(f) understands that the Consideration Shares are being offered and
sold in reliance on specific exemptions from the registration requirements of
federal and state securities laws and that Purchaser is relying upon the truth
and accuracy of the representations, warranties, agreements, acknowledgments
and understandings set forth herein in order to determine the applicability
of such exemptions and the suitability of such party to acquire the
Consideration Shares being issued to it pursuant to this Agreement; and

  



  

(g) understands that, neither Purchaser nor any other Person has any
obligation or intention to effect the registration of the
Consideration Shares being issued to it pursuant to this Agreement for sale,
transfer or disposition by such party under the Securities Act, or applicable
state securities laws and any other applicable Law, or to take any action or
provide any information (including, without limitation, the filing of reports
or the publication of information required by Rule 144) which would make
available any exemption from the registration requirements of the Securities
Act or applicable state securities laws and any other applicable Law.

  



  

ARTICLE IV

  

REPRESENTATIONS AND WARRANTIES RELATING TO THE COMPANY AND THE

  

LEGACY CORPORATION

  



  

Except as disclosed to Purchaser in the Disclosure Schedule, the Company
hereby represents and warrants to Purchaser that each of the
representations and warranties contained in this _Article IV_ are true and
correct on the date hereof (except to the extent that such
representations and warranties speak as of another date, in which case, as of
such date).

  



  

4.1. _Organization and Power_.

  



  

(a) The Company is duly organized, validly existing and in good
standing under the laws of the state of Delaware. The Company has the full
power and authority (corporate or otherwise) to own its property and to carry
on the Business as presently conducted and as proposed to be conducted. The
Company is duly qualified and authorized to conduct business and are in good
standing under the laws of each jurisdiction in which the nature of the
business conducted by them makes such qualification necessary. All of such
jurisdictions are listed on _Section 4.1(a)_ of the Disclosure Schedule.

  



    

 | -13-| 
---|---|--- 

 



    



  

(b) The Company has delivered to Purchaser correct and complete
copies of the Organizational Documents of the Company, as amended through the
Closing Date. The Company is not in violation of any term of their respective
Organizational Documents, as amended through the Closing Date. A true and
complete listing of the officers and directors of the Company is set forth in
_Section 4.1(b)_ of the Disclosure Schedule.

  



  

4.2. _Authorization and Enforceability_. The Company has the full
power and authority to enter into and perform this Agreement and each of
the other Transaction Documents to which it is a party and to consummate the
Contemplated Transactions. The execution, delivery and performance by the
Company of this Agreement and each of the other Transaction Documents to which
it is a party, and the consummation by the Company of the Contemplated
Transactions, have been duly authorized by all necessary action (corporate
or otherwise) on the part of the Company. This Agreement and each of the
other Transaction Documents to which the Company is a party have been duly
executed and delivered by the Company and, assuming due authorization,
execution and delivery by the other parties thereto, constitute legal, valid
and binding obligations of the Company, enforceable against the Company
in accordance with their respective terms, except as such enforceability may
be limited by the Bankruptcy and Equity Exceptions.

  



  

4.3. _Non-contravention; Consents_.

  



  

(a) Except as set forth in _Section 4.3(a)_ of the Disclosure
Schedule, the execution, delivery and performance by the Company of
this Agreement and each of the other Transaction Documents to which it is a
party and the consummation of the Contemplated Transactions do not and will
not: (i) result in a Default of or under (A) any of the terms of the
Organizational Documents of the Company, (B) any Law, Permit or Order
applicable to or binding upon the Company, or (C) any Contract (1) to which
the Company is a party or by which they, or any of their properties or
assets, are bound or (2) which otherwise relates to, or was entered into on
behalf of, the Business (or any portion thereof); (ii) result in the creation
or imposition of any Encumbrance upon any of the assets or properties of the
Company; or (iii) (A) result in the termination, amendment or modification of,
or give any party the right to terminate, amend, modify, abandon, cancel or
refuse to perform any Contract or Permit (1) to which the Company is a party
or by which they, or any of their properties or assets, are bound or (2)
which otherwise relates to, or was entered into on behalf of, the Business
(or any portion thereof), or (B) result in the acceleration or modification,
or give any party the right to accelerate or modify, the time within which,
or the terms under which, any duties or obligations are to be performed, or
any rights or benefits are to be received under any Contract or Permit (1) to
which the Company is a party or by which they, or any of their properties or
assets, are bound or (2) which otherwise relates to, or was entered into on
behalf of, the Business (or any portion thereof).

  



  

(b) Except as listed on _Section 4.3(b)_ of the Disclosure Schedule,
no Consent of any Governmental Entity or other Person (including any party to
any Material Contract with the Company) is required (i) for the execution,
delivery and performance by the Company of this Agreement or any of the other
Transaction Documents to which it is a party; or (ii) in connection with the
consummation by the Company of the Contemplated Transactions.

  



    

 | -14-| 
---|---|--- 

 



    



  

4.4. _Capitalization; Subsidiaries_.

  



  

(a) _Authorized LLC Equity Interests_. The authorized LLC Equity
Interests that are issued and outstanding are held as set forth in
_Section 4.4(a)_ of the Disclosure Schedule. The LLC Equity Interests
constitute the only issued and outstanding equity Securities of the Company
and are owned of record and beneficially solely by the Equityholders. Each of
the LLC Equity Interests has been validly issued and is fully paid and non-
assessable and the issuance thereof did not create any Encumbrances
thereon. None of the LLC Equity Interests have been issued in violation of
any preemptive or similar right. All of the LLC Equity Interests were sold in
compliance with all Laws and have been exempt from registration pursuant to
the registration provisions of the Securities Act and applicable national or
state securities Laws, and no such equity Securities were registered under
any such act or Laws. No private offering memorandum or other information
furnished (whether orally or in writing) to any offeree or purchaser of such
LLC Equity Interests contained any untrue statement of a material fact
or omitted to state any material fact required to be stated therein or
necessary to make the statements therein not misleading.

  



  

(b) _No Equityholder Agreements; Obligations_.

  



  

(i) There are no outstanding warrants, options or other rights,
commitments, Contracts or understandings to purchase or acquire any equity
Securities of the Company and there are no outstanding debt Securities of the
Company convertible into equity Securities or otherwise containing equity
provisions. There are no rights of first refusal, rights of first
offer, subscription rights, preemptive rights or other similar rights with
respect to the issuance or sale of the LLC Equity Interests. Except as set
forth in _Section 4.4(b)_ of the Disclosure Schedule, (A) no Contract exists
between or among any of the Legacy Stockholders or Equityholders with respect
to any of the LLC Equity Interests; and (B) there are no outstanding or
authorized stock appreciation, phantom stock, profit participation or similar
rights with respect to the Company.

  



  

(ii) There are no voting trusts or other similar agreements or
understandings to which the Company is a party with respect to the voting of
equity of the Company. There are no restrictions on the transfer of any equity
Securities or other ownership interest in the Company, other than those
arising from federal and state securities Laws and there are no understandings
or agreements respecting the ownership interests of the Company.

  



  

(c) _Subsidiaries_. The Company does not have any Subsidiaries. The
Company has not acquired any business or Person, whether by merger
or consolidation, purchase of assets or equity Securities or otherwise. There
are no equity or debt securities of any Subsidiary issued or outstanding.

  



  

4.5. _Financial Information; Indebtedness_.

  



  

(a) Reserved.

  



  

(b) Attached to _Section 4.5(b)_ of the Disclosure Schedule is a
true and accurate list setting forth all assets transferred to the Company by
the Legacy Corporation and all liabilities assumed by the Company and assigned
by the Legacy Corporation, in connection with the Reorganization.

  



    

 | -15-| 
---|---|--- 

 



    



  

(c) The Company does not have any Indebtedness other than
Indebtedness, if any, that has been taken into consideration in
calculating the Base Purchase Price.

  



  

4.6. _Absence of Changes_. Since its formation, the Company has
conducted the Business in the ordinary course of business consistent with
past practices (including the payment of payables and the making of capital
expenditures) and there has not occurred any event or condition which,
individually or in the aggregate, has had or could reasonably be expected to
have a Material Adverse Effect on the Company or the Business. Without
limiting the generality of the foregoing, since its formation, the Company
has used commercially reasonable efforts to preserve the Business, to keep its
business organizations intact, to retain its Permits, and to preserve the
existing Contracts and goodwill of its suppliers, vendors, service
providers, manufacturers, personnel and others with which they have business
relations.

  



  

4.7. _Absence of Undisclosed Liabilities_. Except as set forth in
_Section 4.7_ of the Disclosure Schedule, there is no Liability of or by the
Company or any other Person in respect of the Business of any nature except
Liabilities arising since the formation of the Company in the ordinary course
of business consistent with past practices that, individually or in
the aggregate, are (i) not material or (ii) could not reasonably be expected
to have a Material Adverse Effect on the Company or the Business.

  



  

4.8. _Title to and Adequacy of Assets_. The Company has good, valid
and marketable title to, or in the case of leased properties and assets,
valid leasehold interests in, all of the properties and assets (whether
tangible or intangible), real, personal and mixed, used or held for use in
the Business (the "Property"), free and clear of any and all
Encumbrances. The tangible personal property included in such Property
(including equipment), taken as a whole, is in good working order and fit for
its intended use, reasonable wear and tear excepted. The Property, taken as a
whole, is adequate to conduct the Business as currently conducted or as
proposed to be conducted. No Property used by the Company in connection with
the Business is held under any Lease or Encumbrance or is located other than
in the possession of the Company. All of the leases of personal property to
which the Company is a party are valid and in effect and afford the Company
peaceful and undisturbed possession of the subject matter of such leases.

  



  

4.9. _Real Property_. The Company does not own or lease any Real
Property, and the Company is not a party to any option, Contract or other
document pursuant to which the Company has the right or obligation to lease,
purchase or acquire title to or any interest in any Real Property.

  



  

4.10. _Intellectual Property_.

  



  

(a) Set forth in _Section 4.10(a)_ of the Disclosure Schedule is a
true and complete list of all (i) Registered Intellectual Property of the
Company; and (ii) un-registered Intellectual Property of the Company or its
Affiliates that is material to the Business, including, a brief description
of each listed Intellectual Property item, including, the owner, including
the chain of title as evidenced by reel/frame numbers of recorded
assignments, or by non-recorded assignments, from each inventor to owner; the
applicable jurisdiction; the registration number; the application number; the
patent number or issuance number; and the filing date of the application or
registration.

  



    

 | -16-| 
---|---|--- 

 



    



  

(b) To the Company's Knowledge, neither the Company nor any Legacy
Stockholder or any current or former director, officer, employee, consultant
or independent contractor of the Company owns or has any rights, with respect
to any Intellectual Property that may be necessary for the operation of the
Business and the research, development, manufacture or commercialization of
the Product. The execution, delivery and performance of this Agreement, and
the transfer of the LLC Equity Interests contemplated hereby, will not affect
Purchaser's ownership rights in or use of such Intellectual Property after
Closing in any manner. The Company has, and Purchaser will have after Closing,
the right to bring actions for the infringement or other violations of all
Intellectual Property owned or exclusively licensed by the Company, or
purported by the Company to be owned or exclusively licensed by the Company.

  



  

(c) The operation of the Business does not infringe, dilute, or
otherwise violate the Intellectual Property rights of any Person in any
material respect. No Legal Proceeding is pending or, to the Knowledge of the
Company, threatened, and the Company has not received written notice to the
effect that: (i) the Company infringes upon, misappropriates or conflicts with
the rights of any other Person under any Intellectual Property; or (ii) the
Company's interest in any Intellectual Property owned or licensed by the
Company or which the Company otherwise has the right to use, is invalid or
unenforceable by the Company. To the Knowledge of the Company, no Person is
infringing upon, misappropriating or using in any unauthorized manner, any of
the Company's rights to its Intellectual Property or Proprietary Information.
No Third Party has exercised any rights to indemnification granted by the
Company against infringement of Intellectual Property rights.

  



  

(d) The Company has complied and is in compliance with all
applicable Laws of all Governmental Entities, or any self-
regulating organization, regarding privacy, security and/or data protection
(collectively, "Privacy Laws"), in each case in all material respects. The
Company has maintained, enforce and have enforced and complied with in all
respects written privacy, security and data protection policies (the "Privacy
Policies") with respect to any Proprietary Information providing for, without
limitation: (i) clear and conspicuous disclosure of the Company's privacy,
security and data protection practices, including the Company's collection,
storage, use and disclosure of, and provision of access and corrections to
any Proprietary Information, and (ii) protection from loss,
misappropriation, disclosure or corruption of, and unauthorized access to any
Proprietary Information. Neither this Agreement nor the Contemplated
Transactions violate or will violate the terms and conditions of any Privacy
Policies, any applicable Privacy Laws or the privacy rights of any Person.
The current and former consultants and contractors of the Company have
executed proprietary information and confidentiality agreements, none of
which will be terminated as a result of the Contemplated Transactions and all
of which shall be enforceable by or on behalf of the Company after the
Closing.

  



  

(e) To the Knowledge of the Company, no Proprietary Information has
been subject to any breach, misappropriation, unauthorized disclosure, or
unauthorized access or use by any Person. There are no Legal Proceedings
pending or threatened, or complaints filed, against the Company, and the
Company is not subject to any settlement agreements, directives or orders, at
Law or in equity before or by a Governmental Entity or self-regulating
organization, regarding the Company's Privacy Policies and/or Proprietary
Information.

  



    

 | -17-| 
---|---|--- 

 



    



  

(f) Set forth in _Section 4.10(f)_ of the Disclosure Schedule is a
true and correct list of all Contracts (including licenses and sublicenses)
pertaining to any Intellectual Property by which the Company licenses, or by
which a Third Party licenses or otherwise authorizes the Company to use, any
Intellectual Property. None of the Company or any other party is in breach of
or Default under any such license or other Contract, and each such license
and other Contract is valid and in full force and effect. The Company owns
and has owned all licenses necessary to use the COTS Software as actually used
in the operation of the Business without Claims of infringement or other
violation of rights of the owner of the COTS Software. The Company has not
received any written notice claiming that any of them is, was or could be
using any COTS Software in violation of the rights of any Third Party or been
the subject of an investigation or audit by any Third Party in relation to
their respective use of COTS Software. The Company is not in breach or
Default under any Contract governing the use of COTS Software, and each such
Contract is valid and in full force and effect.

  



  

(g) All Intellectual Property developed by or for the Company was
conceived, invented, reduced to practice, reduced to tangible form, written
or otherwise created solely by either (i) employees of the Company acting
within the scope of their employment; or (ii) persons or entities who have
executed a written confidentiality and assignment agreement that irrevocably
assigns and transfers all right, title and interest in and to such
Intellectual Property (including the right to seek past and future damages
with respect to such Intellectual Property) to the Company, and the Company is
the sole and exclusive owner of such Intellectual Property. Each past or
present Employee and independent contractor performing material activities
related to the manufacture, use, sale, offer for sale or importation of
products or services marketed by or under development by the Company has
entered into a proprietary information and confidentiality agreement. The
Company has made available to Purchaser's legal advisor copies of such
agreements.

  



  

(h) None of the Registered Intellectual Property is subject to the
payment of any registration, maintenance or renewal fees or Taxes or actions
and/or responses falling due within ninety (90) calendar days following the
Closing Date, and none of the Registered Intellectual Property has expired,
been cancelled or abandoned.

  



  

(i) The Company has never agreed to indemnify any Person for or
against any interference, proceeding with the Patent Trial and Appeal Board
(PTAB) of the U.S. Patent and Trademark Office, opposition, infringement,
misappropriation, or other conflict with respect to Intellectual Property.

  



  

(j) The Company has taken commercially reasonable steps to provide
for the archival, back-up, recovery and restoration of their critical
business data.

  



  

(k) _Section 4.10(k)_ of the Disclosure Schedule describes all
instances in which the Company (i) has received government funding, (ii) has
Knowledge that the Intellectual Property licensed by the Company from CHOP was
made using government funding; and (iii) has contracted for the use of
facilities of a university, college, other educational institution or research
center in the development of any Intellectual Property of the Company where,
as a result of such funding or the use of such facilities, the government or
any university, college, other educational institution or research center has
any rights in such Intellectual Property of the Company.

  



    

 | -18-| 
---|---|--- 

 



    



  

4.11. _Contracts, Leases, Etc_.

  



  

(a) Set forth in _Section 4.11(a)_ of the Disclosure Schedule is a
true and complete list (organized by subclause) of all Contracts to which the
Company is a party, or by which any of their respective property or assets are
bound (each, a "Material Contract").

  



  

(b) The Company has provided to Purchaser true and correct copies of
all Material Contracts (or descriptions thereof, in the case of oral
Contracts). Each Material Contract (or description) sets forth the entire
agreement and understanding between the parties thereto. The Company is not
(with or without the lapse of time or the giving of notice or both) in Default
under any Material Contract and, to the Knowledge of the Company, no other
party to any such Material Contract is (with or without the lapse of time or
the giving of notice or both) in Default thereunder. No party to any Material
Contract has threatened, or provided notice to the Company of its intent to
terminate or withdraw its participation in any such Material Contract.
The Company does not have any Knowledge of any event or condition which has
occurred or exists which would cause the acceleration of any obligations or
loss of any rights of any party to any Material Contract or give rise to any
right of termination or cancellation thereof. All of the Material Contracts
are in full force and effect and are valid and binding obligations of
the Company (to the extent binding obligations of the other parties thereto)
enforceable in accordance with their respective terms, except as such
enforceability may be limited by the Bankruptcy and Equity Exceptions.

  



  

(c) The execution, delivery and performance of this Agreement and
the other Transaction Documents and the consummation of the Contemplated
Transactions will not result in or give to any Person any additional rights or
entitlement to increased, additional, accelerated or guaranteed payments
under any Material Contract. None of such Material Contracts contain
any provisions that would cause the Company to be liable to any other party
thereto for any amount (or any increased price for goods or services being
provided by the other party thereto) as a result of the consummation of the
Contemplated Transactions.

  



  

4.12. _Compliance with Law; Permits_.

  



  

(a) The Company has complied with every, and is not presently in
violation of any, Law or Order applicable to the Company or the Business.
Neither the Company nor the Legacy Corporation has received, nor does the
Company have Knowledge of the issuance or threat of, any notice from any
Governmental Entity or Third Party of any such violation.

  



    

 | -19-| 
---|---|--- 

 



    



  

(b) Set forth in _Section 4.12(b)_ of the Disclosure Schedule is a
true and correct list of all Permits issued in favor of the Company which are
material to the Company or the Business. All of such Permits are in full force
and effect, and the Business is currently being operated in compliance, in
all respects, with the terms of each of such Permit. Neither Purchaser nor
any of its Affiliates (including after the Closing, the Company) will be
required, following the Closing, to file, apply for or obtain any Permit in
order to purchase the Equity Interests pursuant to this Agreement and to
operate the Business as currently operated. The Company has not taken any
action, or failed to take any action, which could reasonably be expected
to result in or enable, with or without notice or lapse of time or both, the
revocation or termination of any of such Permits or the imposition of any
restrictions thereon. No Legal Proceeding is pending or, to the Knowledge of
the Company, threatened, to revoke, refuse to renew or modify any of the
Permits. There are no other Permits which are material to the Company or
the Business which the Company is required to obtain or, to the Knowledge of
the Company, which, in good industry practice, the Company should hold for
the conduct of the Business. The Company does not have any Knowledge of any
threatened suspension, revocation or invalidation of any such Permits, or any
reasonable basis therefor.

  



  

4.13. _Taxes_.

  



  

(a) All Tax Returns required to have been filed by or with respect
to the Company and the Legacy Corporation have been duly and timely filed,
and each such Tax Return correctly and completely reflects liability for Taxes
and all other information required to be reported thereon. All Taxes owed by
the Company or the Legacy Corporation (whether or not shown on any
Tax Return) have been timely paid. Both the Company and the Legacy
Corporation have adequately provided for, in their books of account and
related records, liability for all unpaid Taxes of the Company or the Legacy
Corporation, as the case may be, being current Taxes not yet due and payable.
Neither the Company nor the Legacy Corporation have been a member of a
Relevant Group.

  



  

(b) There is no action, audit, dispute or Claim now in process or
pending or, to the Knowledge of the Company or the Legacy Corporation,
proposed or threatened against, or with respect to, the Company or the Legacy
Corporation in respect of any Taxes. Neither the Company nor the Legacy
Corporation is the beneficiary of any extension of time within which to file
any Tax Return that has not been filed. No Claim has been made by an
authority in a jurisdiction where the Company or the Legacy Corporation does
not file Tax Returns that such entity is, or may be, subject to taxation by
that jurisdiction. There are no Encumbrances on the stock or assets of the
Company or the Legacy Corporation with respect to Taxes other than
Permitted Encumbrances.

  



  

(c) Both the Company and Legacy Corporation have withheld and timely
paid all Taxes required to have been withheld and paid and has complied with
all information reporting and backup withholding requirements.

  



  

(d) _Section 4.13(d)_ of the Disclosure Schedule lists all Tax
Returns filed with respect to the Company and the Legacy
Corporation, respectively, indicates those Tax Returns that have been
audited, and indicates those Tax Returns that currently are the subject of an
audit. Both the Company and the Legacy Corporation have delivered to Purchaser
correct and complete copies of all Tax Returns, examination reports, and
statements of deficiencies assessed against or agreed to by it. Neither the
Company nor the Legacy Corporation is subject to a waiver of any statute of
limitations in respect of Taxes or any extension of time with respect to a
Tax assessment or deficiency.

  



    

 | -20-| 
---|---|--- 

 



    



  

(e) None of the Equityholders is a "foreign person" within the
meaning of Section 1445 of the Code.

  



  

(f) Both the Company and the Legacy Corporation have not been the
"distributing corporation" or the "controlled corporation" with respect to a
transaction described in Section 355 of the Code. Both the Company and
Legacy Corporation are not subject to any private ruling from any taxing
authority or any agreement with a taxing authority.

  



  

(g) Neither the Company nor the Legacy Corporation is a party to any
Tax allocation or sharing agreement. The Company and the Legacy Corporation
do not have any Liability for the Taxes of any Person (other than themselves)
(i) as a transferee or successor, (ii) by Contract, (iii) under Section
1.1502-6 of the Treasury Regulations (or any similar provision of state, local
or foreign Law), or (iv) otherwise.

  



  

(h) The Company and the Legacy Corporation will not be required to
include any item of income in, or exclude any item of deduction from, taxable
income for any taxable period (or portion thereof) ending after the Closing
Date as a result of any: (i) installment sale or open transaction disposition
made on or prior to the Closing Date; (ii) prepaid amount received or accrued
on or prior to the Closing Date; (iii) cancellation of debt income or (iv)
method of accounting that defers the recognition of income to any period (or
portion thereof) ending after the Closing Date or accelerates any deduction to
any period (or portion thereof) ending on or before the Closing Date.

  



  

(i) The Company has validly been treated for income Tax purposes as
a disregarded entity at all times since its inception, until such time as
CHOP became an Equityholder, at which time the Company became a partnership
for income Tax purposes and is currently a partnership for income Tax
purposes. The Legacy Corporation had a valid election to be treated as an S
corporation in effect and has validly been treated for federal and state
income Tax purposes as a S corporation at all times since January 1, 2014.
Neither the Legacy Corporation nor the Company will be liable for any Taxes
pursuant to Sections 1374 or 1375 of the Code (or any corresponding provision
of state, local or non-US Tax law) as a result of the transactions
contemplated by this Agreement

  



  

(j) There is no power of attorney in effect with respect to the
Company or the Legacy Corporation with respect to Taxes.

  



  

(k) Neither the Company nor the Legacy Corporation has engaged in
any transaction that is, or is substantially similar to, any listed
or reportable transaction within the meaning of Treasury Regulation Section
1.6011-4.

  



    

 | -21-| 
---|---|--- 

 



    



  

4.14. _Employee Relations_.

  



  

(a) _Labor Matters_. Set forth in _Section 4.14(a)(i)(A)_ of the
Disclosure Schedule is a complete and accurate list of all officers and
directors of the Company. The Company has no employees and has never had any
employees. Set forth in _Section 4.14(a)(i)(B)_ of the Disclosure Schedule is
a complete and accurate list of all Persons who have ever performed any
type of work or service for the Legacy Corporation or the Company and, if
applicable, the amount of consideration owed and due to such Persons for such
work or services. Neither the Legacy Corporation nor the Company are, nor have
they ever been, bound by or subject to (and none of their respective assets
or properties is or has ever been bound by or subject to) any
collective bargaining or other relationship with any labor organization. The
Company has complied and is in compliance with all Laws which relate to equal
opportunity and non-discrimination, wage and hour, and terms and conditions of
employment. No Employees or independent contractors of the Legacy Corporation
or the Company are represented by any labor organization or covered by any
collective bargaining agreement. No campaign to establish such representation
is or has ever been in progress and there is no pending or, to the Knowledge
of the Company, threatened, labor dispute involving the Company, and any group
of their respective employees or independent contractors.

  



  

(b) _Status_. The Company has properly classified all independent
contractors and leased employees who have rendered services to the Company as
non-employees for all federal, state, local and foreign Tax purposes, as well
as ERISA and employee benefits purposes.

  



  

(c) _Employee Benefit Plans_.

  



  

(i) There are not currently and there have never been any Employee
Benefit Plans. There are no pending or threatened Claims by or on behalf of
any Employee Benefit Plan.

  



  

(ii) The execution of and performance of the Contemplated
Transactions will not (either alone or upon the occurrence of any
additional or subsequent events) result in any payment to or acceleration,
vesting or increase in the rights of any current or former employee or
service provider of the Company. No payment or benefit which is or may be made
in connection with the transactions contemplated by this Agreement to any
current or former employee or service provider of the Company or any
ERISA Affiliate could constitute an "excess parachute payment" under Section
280G of the Code.

  



  

(iii) No service provider of the Company is, or can reasonably in the
future expect to be, subject to additional Tax or interest imposed under
Section 409A of the Code.

  



  

4.15. _Environmental Laws_. The ownership and use of the Company's
premises and assets, the occupancy and operation thereof, and the conduct of
the Company's operations and Business, are in compliance in all material
respects with all Environmental Laws and, the Company has not received any
notice of any alleged violation or noncompliance. There is no Liability
attaching to the Company or any of their premises or assets or the ownership
or operation thereof as a result of any Hazardous Materials that may have
been discharged on or released from such premises, or disposed of on-site or
off-site, or any other circumstance occurring prior to the Closing or
existing as of the Closing.

  



  

4.16. _Legal Proceedings_.

  



  

(a) Except as set forth in _Section 4.16(a)_ of the Disclosure
Schedule, there is no Order outstanding and/or no Legal Proceeding pending
or, to the Knowledge of the Company, threatened, against or affecting, the
Company or the Business or the assets or properties, tangible or intangible,
of the Company, nor has there been any such Legal Proceeding. The Company is
not currently planning to initiate any Legal Proceeding. The matters
disclosed on _Section 4.16(a)_ of the Disclosure Schedule will be fully
covered by the Company's insurance policies, subject to applicable
deductibles.

  



    

 | -22-| 
---|---|--- 

 



    



  

(b) To the Knowledge of the Company, there are no currently existing
events, facts or circumstances that could reasonably be expected to form the
basis for any Legal Proceeding or Order.

  



  

4.17. _Transactions with Affiliates_. Except as set forth in _Section
4.17_ of the Disclosure Schedule, no director, manager, officer, key
employee, Equityholder of the Company or any Affiliate of any of the
foregoing: (a) has received or earned; (b) has had an ownership interest
(whether direct or indirect) in any business, corporate or otherwise, which
has or had any business arrangement or relationship of any kind under which
it has received or earned, payments from the Company; or (c) is a party to a
Related Party Agreement with the Company. All transactions required to be
listed in _Section 4.17_ of the Disclosure Schedule have been recorded in the
Books and Records of the Company at their full value, as if they were
rendered in arm's length transactions.

  



  

4.18. _Insurance_.

  



  

(a) The Company has maintained in effect and presently has in
effect, all errors and omissions, directors and officers,
employee professional liability and fiduciary liability insurance policies,
and all other insurance policies, required by Law and reasonably appropriate
in connection with the operation of the Business. Set forth in _Section
4.18(a)_ of the Disclosure Schedule is a true and complete list of each
insurance policy (including policies providing property, casualty, liability,
errors and omissions, and workers compensation coverage) to which the Company
has been a party, the named insured, additional insured(s) or otherwise the
beneficiary of coverage at any time.

  



  

(b) The Company has provided to Purchaser a correct and complete
copy of each insurance policy listed on _Section 4.18(a)_ of the Disclosure
Schedule and in effect immediately prior to the Closing. With respect to each
such insurance policy: (i) such policy is legal, valid, binding, enforceable
in accordance with its terms, and in full force and effect in all respects
and all premiums due thereunder have been paid, and no notice of cancellation
or termination has been received by the Company or any Equityholder with
respect to such policies; (ii) to the Knowledge of the Company, no other party
to the policy is in a material breach or Default (including with respect to
the payment of premiums or the giving of notices), and no event has occurred
which would permit termination, modification, or acceleration, under such
policy; and (iii) no other party to such policy has repudiated any provision
thereof.

  



  

(c) The Company has notified all applicable insurance companies that
have issued the policies listed on _Section 4.18(a)_ of the Disclosure
Schedule of any and all potential incidents, events or circumstances of which
the Company has Knowledge that could reasonably give rise to a covered Claim
under such policy.

  



    

 | -23-| 
---|---|--- 

 



    



  

4.19. _Brokers_. No broker, investment banker, financial advisor or
other Person is entitled to any broker's, finder's, financial advisor's or
other similar fee or commission in connection with the Contemplated
Transactions based upon arrangements made by or on behalf of the Company or
any Person acting on their behalf.

  



  

4.20. _Corporate Records_. The Books and Records of the Company
accurately and completely record and reflect all transactions material to the
operations of the Company and the Business.

  



  

4.21. _Bank Accounts_. Set forth in _Section 4.21_ of the Disclosure
Schedule is the name, address and account number of each bank, financial
institution, fund, investment or money manager, brokerage house and similar
institution in which the Company maintains any account (whether checking,
savings, investment, trust or otherwise), lock box or safe deposit box and
the account numbers and name of all Persons having authority to affect
transactions with respect thereto. All such accounts are solely in the
Company's name and solely owned and controlled by the Company.

  



  

4.22. _Powers of Attorney_. There are no outstanding powers of attorney
executed on behalf of the Company, any Legacy Stockholder or any Equityholder
relating to the Company or the Business.

  



  

4.23. _Statements and Other Documents Not Misleading_. Neither this
Agreement, including the Disclosure Schedule and all other schedules
hereto, nor any other Transaction Document or other instrument heretofore or
hereafter furnished by the Company or the Equityholders to Purchaser in
connection with the Contemplated Transactions contains or will contain any
untrue statement of any material fact or omits or will omit to state any
material fact required to be stated in order to make such statement, document
or other instrument not misleading.

  



  

ARTICLE V

  

REPRESENTATIONS AND WARRANTIES OF PURCHASER

  



  

Purchaser represents and warrants to the Equityholders that each of the
representations and warranties contained in this _Article V_ are true
and correct as of the date hereof (except to the extent that such
representations and warranties speak as of another date, in which case, as of
such date):

  



  

5.1. _Organization_. Purchaser is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware.

  



  

5.2. _Authority_. Purchaser has the requisite corporate power and
authority to enter into and perform this Agreement and each of
the Transaction Documents to which it is a party and to consummate the
Contemplated Transactions. The execution, delivery and performance by
Purchaser of this Agreement and each of the Transaction Documents to which it
is a party, and the consummation by it of the Contemplated Transactions have
been duly authorized by all necessary limited liability company action on
the part of Purchaser. This Agreement and each of the Transaction Documents
to which Purchaser is a party have been duly executed and delivered by
Purchaser and, assuming due authorization, execution and delivery by the
Company and the Equityholders (as the case may be) constitute legal, valid
and binding obligations of Purchaser enforceable against Purchaser in
accordance with their respective terms, except as such enforcement may be
limited by the Bankruptcy and Equity Exceptions.

  



    

 | -24-| 
---|---|--- 

 



    



  

5.3. _Conflict with other Instruments; Absence of Restrictions_. The
execution, delivery and performance of this Agreement and each of the
Transaction Documents, and the consummation of the Contemplated Transactions,
by Purchaser do not and will not: (a) result in a Default of or under (i) any
of the terms of the Organizational Documents of Purchaser, or (ii) any Law,
Permit, Order or material Contract applicable to or binding upon Purchaser;
or (b) (1) result in the termination, amendment or modification of, or give
any party the right to terminate, amend, modify, abandon, or refuse to perform
any material Contract or Permit to which Purchaser is a party or by which it,
or any of its respective properties or assets, is bound, or (2) result in the
acceleration or modification, or give any party the right to accelerate or
modify, the time within which, or the terms under which, any duties or
obligations are to be performed, or any rights or benefits are to be received
under any material Contract or Permit to which Purchaser is a party or by
which it, or any of its respective properties or assets, is bound.

  



  

5.4. _Government Approvals_. No Consent of any Governmental Entity is
required (a) for the execution, delivery and performance by Purchaser of this
Agreement or any of the Transaction Documents to which Purchaser is a party,
or (b) in connection with Purchaser's consummation of the Contemplated
Transactions.

  



  

5.5. _Brokers_. Purchaser has not employed any broker, finder or
investment banker or incurred any Liability for any brokerage
fees, commissions or finder's fees in connection with the Contemplated
Transactions. Purchaser has not made any arrangement or taken any other
action that might cause the Equityholders to become liable for a broker's fee,
commission or finder's fee as a result of the Contemplated Transactions.

  



  

5.6. _Purchaser SEC Documents_. Purchaser has filed with or furnished
to the Securities and Exchange Commission (the "SEC") all forms, reports,
statements, certifications and other documents required to be filed by it
with the SEC since January 1, 2014 (collectively, and in each case including
all exhibits and schedules thereto and documents incorporated by reference
therein, the "Purchaser SEC Documents"). As of their respective effective
dates (in the case of Purchaser SEC Documents that are registration
statements filed pursuant to the requirements of the Securities Act) and as
of their respective SEC filing dates (in the case of all other Purchaser SEC
Documents), Purchaser SEC Documents complied in all material respects with
the requirements of the Securities Act, the Securities Exchange Act of 1934,
as amended, (the "Exchange Act") and the Sarbanes-Oxley Act of 2002 (the
"Sarbanes-Oxley Act"), as the case may be, and the rules and regulations of
the SEC thereunder applicable to such Purchaser SEC Documents, and none of
Purchaser SEC Documents as of such respective dates (or, if amended prior to
the date of this Agreement, the date of the filing of such amendment, with
respect to the disclosures that are amended) contained any untrue statement
of a material fact or omitted to state a material fact required to be stated
therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading. As of the date of
this Agreement, no Subsidiary of Purchaser is subject to the reporting
requirements of Section 13(a) or 15(d) under the Exchange Act. Each of the
audited consolidated financial statements and unaudited consolidated financial
statements of Purchaser included in Purchaser SEC Documents (including the
related notes and schedules), as of their respective effective dates (in the
case of Purchaser SEC Documents that are registration statements filed
pursuant to the requirements of the Securities Act) and as of their
respective SEC filing dates (in the case of all other Purchaser SEC
Documents), complied as to form in all material respects with all applicable
accounting requirements and with the published rules and regulations of the
SEC with respect thereto (except, in the case of unaudited statements, as
permitted by Quarterly Report Form 10-Q of the SEC), were prepared in
accordance with GAAP and applicable accounting requirements and published
rules and regulations of the SEC consistently applied during the periods
involved (except (i) with respect to financial statements included in
Purchaser SEC Documents filed as of the date of this Agreement, as may be
indicated in the notes thereto, or (ii) as permitted by the rules and
regulations of the SEC, including Regulation S-X), and fairly present in all
material respects the consolidated financial position of Purchaser and its
consolidated Subsidiaries as of the dates thereof and the consolidated
statements of operations, changes in stockholders' equity and cash flows of
such companies as of the dates and for the periods shown therein.

  



    

 | -25-| 
---|---|--- 

 



    



  

5.7. _Valid Issuance of Purchaser Shares_. Upon their receipt of the
Purchaser Common Shares, the Equityholders will acquire good and valid title
to such Purchaser Common Shares, free and clear of all Encumbrances. The
Purchaser Common Shares will, when issued in accordance with the provisions
of this Agreement, be validly issued, fully paid and non-assessable.

  



  

5.8. _No Additional Representations_. Except for the representations
and warranties contained in this _Article V_ , neither Purchaser nor any
other Person makes any express or implied representation or warranty on behalf
of Purchaser, and Purchaser hereby disclaims any representations, warranties
or other statements made by it or any of its direct or indirect
directors, equity holders, subsidiaries, Affiliates or Representatives with
respect to the subject matter hereof.

  



  

ARTICLE VI

  

CLOSING

  



  

6.1. _Closing_. The closing of the Contemplated Transactions (the
"Closing") shall take place on the date hereof (the "Closing Date"), at the
offices of Pepper Hamilton LLP, 3000 Two Logan Square, 18th and Arch Streets,
Philadelphia, PA 19103, or remotely via the exchange of documents and
signatures, or such other location or date as the Parties may mutually agree.
The Closing shall be effective as of 11:59 p.m. local time on the Closing
Date.

  



  

6.2. _Closing Deliveries_.

  



  

(a) _Deliveries by the Equityholders and the Company_. At or prior
to the Closing, the Equityholders and the Company shall have delivered to
Purchaser:

  



  

(i) membership interest powers and other instruments as may be
necessary to transfer record ownership of the LLC Equity Interests
into Purchaser's name on the books of the Company;

  



  

(ii) the Books and Records of the Company, including all minute
books, stock books, stock transfer ledgers, employment records, financial and
accounting records and files; _provided_ , that, the Parties acknowledge and
agree that delivery of such Books and Records shall be satisfied by the
Company making the Books and Records available to Purchaser;

  



    

 | -26-| 
---|---|--- 

 



    



  

(iii) as to the Legacy Corporation, a certificate dated as of the
Closing Date and signed on its behalf by its secretary to the effect that:
(A) the resolutions of the Legacy Stockholders and the board of directors of
the Legacy Corporation, as applicable, authorizing the actions taken in
connection with the Contemplated Transactions were duly adopted at a duly
convened meeting thereof, at which a quorum was present and acting
throughout, or by unanimous written consent, remain in full force and effect,
and have not been amended, rescinded or modified; (B) each officer or other
individual executing this Agreement and each of the Transaction Documents to
which the Legacy Corporation, as applicable, is a party is an incumbent
officer or otherwise duly authorized to execute such agreements and documents
on behalf of the Legacy Corporation, as applicable, and the specimen
signature on such certificate is his or her genuine signature; and (C) the
Legacy Corporation is in good standing in all jurisdictions in which it is
required to be registered. The certificates referred to in this
_Section 6.2(a)(iii)_ shall attach good standing certificates with respect to
the Legacy Corporation in such jurisdictions certified by the Secretaries of
State or other appropriate officials, dated as of a date not more than ten
(10) calendar days prior to the Closing Date;

  



  

(iv) as to the Company, a certificate dated as of the Closing Date and
signed on its behalf by its secretary to the effect that: (A) (1) the copies
of Organizational Documents attached to the certificate are true and complete,
(2) such Organizational Documents have been in full force and effect in the
form attached to the certificate since the date of the adoption of
the resolutions referred to in _clause (3)_ below and no amendment to such
Organizational Documents has occurred since the date of the last amendment
annexed thereto, (3) the resolutions of the Equityholders authorizing the
actions taken in connection with the Contemplated Transactions were duly
adopted, remain in full force and effect, and have not been
amended, rescinded or modified; (B) each officer or other individual
executing this Agreement and each of the Transaction Documents to which the
Company, as applicable, is a party is an incumbent officer or otherwise duly
authorized to execute such agreements and documents on behalf of the Company,
as applicable, and the specimen signature on such certificate is his or her
genuine signature; and (C) the Company is in good standing in all
jurisdictions in which it is required to be registered. The certificates
referred to in this _Section_ _6.2(a)(iv)_ shall attach good standing
certificates with respect to the Company in such jurisdictions certified by
the Secretaries of State or other appropriate officials, dated as of a date
not more than ten (10) calendar days prior to the Closing Date;

  



  

(v) evidence in form and substance acceptable to Purchaser that all
Transaction Expenses of the Company have been paid in full;

  



  

(vi) evidence in form and substance acceptable to Purchaser of the
termination of all Related Party Agreements;

  



  

(vii) those Consents in connection with the consummation of the
Contemplated Transactions set forth in _Schedule 6.2(a)(vii)_ , in form and
substance acceptable to Purchaser;

  



    

 | -27-| 
---|---|--- 

 



    



  

(viii) the written resignations of all of the officers, directors and
managers of the Company (effective as of the Closing Date);

  



  

(ix) pay-off letters, in form and substance acceptable to Purchaser
from all holders of any secured Indebtedness of the Legacy Corporation, in
each case, stating (A) the amount as being sufficient to repay in full all
such secured Indebtedness owing to such holder, (B) that, effective upon
Purchaser's tender to such holder of the pay-off amount, all Encumbrances
in favor of such holder on the Company's behalf, if applicable, assets shall
be terminated, released and discharged and that such holder shall deliver to
Purchaser any instruments, certificates, statements and other documents
necessary to evidence such termination, release and discharge and (C)
authorizing Purchaser to make all filings necessary or desirable to terminate
any financing statement or other notice or evidence of any such Encumbrance;

  



  

(x) evidence in form and substance acceptable to Purchaser that all
existing board resolutions regarding banking of the Company have been revoked
and replaced with the board resolutions regarding banking as set forth in
_Schedule 6.2(a)(x)_ ;

  



  

(xi) evidence in form and substance acceptable to Purchaser that all
Encumbrances (other than Permitted Encumbrances) affecting any assets of the
Business have been released;

  



  

(xii) a copy of the CHOP License Agreement, duly executed by the
Company and CHOP; and

  



  

(xiii) such other documents, instruments of sale, transfer, conveyance,
and assignment as Purchaser and its counsel may reasonably request in order to
carry out the Contemplated Transactions.

  



  

(b) _Deliveries by Purchaser_. At or prior to the Closing,
Purchaser shall have delivered or shall have caused to be delivered the
Base Purchase Price payable pursuant to _Section 2.1_ hereof.

  



  

ARTICLE VII

  

COVENANTS

  



  

7.1. _The Legacy Corporation 's Business Following the Closing_.

  



  

(a) Following the Closing, the Legacy Corporation and the Legacy
Stockholders agree to promptly change the name of the Legacy Corporation so
as not to use (i) the name "neuroFix therapeutics," (ii) any name that
includes "neuroFix" or (iii) any variation of

  

(i) or (ii) likely to cause confusion.

  



  

(b) The Legacy Stockholders will not dissolve or otherwise liquidate
the Legacy Corporation until, at the earliest, six (6) months from the
Closing Date; _provided, that_ the Legacy Corporation has satisfied its
obligations under _Section 7.6_  hereof and _provided_ _further that_ any
obligation of the Legacy Corporation under this Agreement shall be treated as
an __ obligation of the Legacy Stockholders on a joint and several basis after
such dissolution or liquidation. To the extent that the Legacy Stockholders
dissolve or otherwise liquidate the Legacy Corporation, the Parties agree that
any shares of Purchaser Common Stock issued or to be issued to the Legacy
Corporation in connection with this Agreement shall be transferred to, or
issued to, as applicable, the Legacy Stockholders in accordance with their
Legacy Pro Rata Amount.

  



    

 | -28-| 
---|---|--- 

 



    



  

7.2. _Assistance in Defense_. If, after the Closing Date, any Party
shall require the participation of officers and employees then employed by
any other Party to aid in the investigation, defense or prosecution of Legal
Proceedings, and so long as there exists no conflict of interest between the
Parties, the Party receiving the request shall make such officers and
employees reasonably available to participate in such Legal Proceeding at the
expense of the requesting Party.

  



  

7.3. _Public Announcements_. No Party shall issue any public report,
statement or press release or similar item or make any other public
disclosure with respect to the substance of this Agreement prior to the
consultation with and written approval of, in the case of such disclosure by
Purchaser, the approval of the Stockholder Representative and CHOP, and in the
case of such disclosure by any Equityholders or the Legacy Stockholders, the
approval of Purchaser, except as may be required by Law or the rules of any
applicable stock exchange or self-regulatory organization, in which case the
Parties shall reasonably cooperate as to the timing and contents of such
report, statement or press release, _provided, however_ , that the
Party subject to such required disclosure shall nonetheless be permitted to
make any disclosure necessary to satisfy the applicable Law or the rule of
any applicable stock exchange or self-regulatory organization without the
applicable prior approval required by this _Section 7.3_.

  



  

7.4. _General Release_. Effective as of the Closing, each of the
Legacy Stockholders and the Equityholders, on behalf of itself and each of
its Affiliates, voluntarily, knowingly and irrevocably releases and forever
discharges the Company and its Affiliates, and each of their respective
Representatives from any and all actions, agreements, amounts, Claims,
damages, expenses, Liabilities and obligations of every kind, nature or
description, known or unknown, arising or existing prior to the
Closing, except for any rights of the Legacy Stockholders and the
Equityholders against the Company under this Agreement and any
other Transaction Document.

  



  

7.5. _Future Sale of Purchaser_. If after the Closing Purchaser
intends to sell all or substantially all of its assets related to
this Agreement in any one or more related transactions, Purchaser must assign
this Agreement and the CHOP License Agreement and all of Purchaser's rights
and obligations thereunder to the purchaser in such transaction or
transactions. Purchaser's obligations under this _Section 7.5_ are in
addition to and not in limitation of its obligations set forth in _Section
13.8_ hereof.

  



    

 | -29-| 
---|---|--- 

 



    



  

7.6. _Third Party Consents_. To the extent that the Legacy
Corporation's rights with respect to any asset, including Intellectual
Property, Contracts or Permits, relating to the Business may not be assigned
by the Legacy Corporation to the Company without the consent of another
Person which has not been obtained, the Legacy Corporation, at its expense,
shall use its best efforts to obtain any such required consent(s) as promptly
as possible. If any such consent shall not be obtained or if any attempted
assignment would be ineffective or would impair Purchaser's or the Company's
rights under such asset(s) in question so that neither the Purchaser nor the
Company would in effect acquire the benefit of all such rights, the Legacy
Corporation, to the maximum extent permitted by law and such asset(s) and
Purchaser desires to do so, shall act after the Closing as the Company's
agent in order to obtain for it and the Purchaser the benefits thereunder and
shall cooperate, to the maximum extent permitted by Law and such asset(s),
with the Purchaser and the Company in any other reasonable arrangement
designed to provide such benefits to the Purchaser and the Company.

  



  

7.7. _Further Assurances_. Each Party agrees, without further
consideration, from time to time after the Closing to (a) execute and deliver
further instruments of transfer, assumption and assignment and take such other
actions as the other Party may reasonably require to transfer, assign to and
vest in Purchaser the LLC Equity Interests, including, obtaining the
Consents or waivers identified in the Disclosure Schedule; (b) cooperate with
and provide assistance to the other Parties in transferring possession of the
assets to Purchaser and (c) do, execute, acknowledge and deliver or cause to
be done, executed, acknowledged and delivered all and every further
reasonable act, deed, conveyance, transfer and assurance necessary to assure
their compliance with the terms, provisions, purposes and intents of this
Agreement and the effectiveness of the rights, benefits and remedies provided
for hereby; it being understood that no Party, nor any of their respective
Affiliates, shall be required to expend money, commence any litigation or
offer or grant any accommodation (financial or otherwise) to any Third Party
in connection with this _Section 7.7_.

  



  

7.8. _Right of First Refusal_ If Legacy Corporation or CHOP (each a
"Payment Stream Seller") (i) receives a bona fide offer from a Third Party or
another Party to this Agreement other than Purchaser (a "Payment
Stream Buyer") to acquire such Payment Stream Seller's portion of any Earnout
Payments (a "Payment Stream") or (ii) in good faith determines to offer to
sell such Payment Stream Seller's portion of a Payment Stream to a Payment
Stream Buyer (each of (i) and (ii) being an "Offer"), such Payment Stream
Seller shall provide a written notice to the Purchaser informing Purchaser of
such Payment Stream Seller's intention to sell a Payment Stream (a
"Payment Stream Sale Notice"). Purchaser shall have thirty (30) days
following the date Purchaser receives the Payment Stream Sale Notice to
decide whether or not it is interested in participating in the Payment Stream
sale process. If Purchaser is interested, the Payment Stream Seller shall
include Purchaser in the Payment Stream sale process with no less information
than provided to any other potential bidder. Legacy Corporation and the
Payment Stream Seller shall again comply with this _Section 7.8_ (in all
respects) if no definitive agreement for a Payment Stream sale is entered into
by the Payment Stream Seller within 180 days after the Payment Stream Sale
Notice delivery. In the event Legacy Corporation shall have dissolved or
otherwise transferred the right to receive Earnout Payments to Harper and
Hakonarson, Harper and Hakonarson shall be bound by this _Section 7.8_ as a
Payment Stream Seller in the event either one of them receives or negotiates
any Offer(s). Nothing herein shall require any Payment Stream Seller from
completing any sale of the Payment Stream to Purchaser or any Third Party.

  



    

 | -30-| 
---|---|--- 

 



    



  

ARTICLE VIII

  

INDEMNIFICATION

  



  

8.1. _Survival_.

  



  

(a) _Representations and Warranties_. Notwithstanding any
investigation or receipt of information by or on behalf of Purchaser, the
Legacy Stockholders, the Equityholders or any of their respective directors,
managers, officers, employees, Affiliates, agents, equityholders, members,
successors and assigns and Representatives on or before the Closing Date:

  



  

(i) representations and warranties made by any Party which were both
(A) not true when made and (B) were made by such Party with intent to defraud
or mislead, shall survive in accordance with the applicable statute of
limitations;

  



  

(ii) representations and warranties set forth in _Sections 3.1_
(Authorization and Enforceability), _3.2_ (Non-contravention; Consents), _3.3_
(The Legacy Corporation), _3.4_ (Title to LLC Equity Interests), _3.5_
(Brokers), _3.7_ (Representations Regarding Equity Consideration), _4.1_
(Organization and Power), _4.2_ (Authorization and Enforceability), _4.3_
 (Non-contravention; Consents), _4.4_ (Capitalization; Subsidiaries),
_4.5(c)_ (Indebtedness), _4.10_  (Intellectual Property), _4.13_ (Taxes),
_4.19_ (Brokers), _5.1_ (Organization), _5.2_ (Authority) and _5.5_
 (Brokers) (collectively, the "Fundamental Representations") shall survive
the Closing and continue in full force and effect until thirty (30) calendar
days after the expiration of the applicable statute of limitations (including
any applicable extension thereof); and

  



  

(iii) all other representations and warranties of the Legacy
Stockholders and the Equityholders contained in _Article III,_ of the Company
contained in _Article_ _IV_ , and of Purchaser contained in _Article V_ shall
survive the Closing and continue in full force and effect until the date that
is twenty-four (24) months after the Closing Date.

  



  

Notwithstanding anything to the contrary, all representations and warranties
shall survive after their applicable Survival Date as to any Losses identified
in, or that arise out of, relate to or are based on any Loss Event identified
in an Indemnity Notice or a Third Party Claim Notice (as applicable and
defined below) given prior to the applicable Survival Date.

  



  

(b) _Covenants and Agreements_. All covenants and agreements made
by any Party which are to be performed after the Closing Date shall survive
until the applicable statute of limitations (including any applicable
extension thereof) therefore has expired with respect to any breach thereof
or to the extent necessary to fulfill or satisfy the obligations with respect
to such covenant or agreement in their entirety (each such date set forth in
this _Section_ _8.1(a)_ or _8.1(b)_ , a "Survival Date").

  



  

8.2. _The Selling Parties ' Indemnification_.

  



  

(a) Any obligation of the Legacy Corporation under this _Section
8.2_ or otherwise under this Agreement shall be treated as a joint and
several obligation of the Legacy Corporation, on the one hand, and the Legacy
Stockholders, on the other hand. To the extent that the Legacy Stockholders
shall be responsible for any obligation of the Legacy Corporation under this
_Section 8.2_ or otherwise under this Agreement pursuant to the immediately
prior sentence, such responsibility, as between the two Legacy Stockholders,
shall be treated as a joint and several obligation.

  



    

 | -31-| 
---|---|--- 

 



    



  

(b) Subject to the provisions of this _Article VIII_ , regardless of
any investigation undertaken or made or receipt of information by Purchaser,
or any of its directors, managers, officers, employees, Affiliates, agents,
equityholders, members and Representatives prior to the Closing Date, each of
the Equityholders, severally and not jointly, shall defend, indemnify
and hold Purchaser and each of its directors, managers, officers, employees,
Affiliates, agents, equityholders, members, successors and assigns and
Representatives and each Person who controls (within the meaning of the
Securities Act) any of them (the "Purchaser Indemnitees") harmless from and
against any and all Claims or Losses (including Claims or Losses arising out
of facts or circumstances that have occurred on or prior to the Closing
Date, even though such Claim or Loss may not be filed or come to light until
after the Closing Date) that may be imposed upon, incurred by or asserted
against any Purchaser Indemnitee arising out of, based upon or resulting from:

  



  

(i) any inaccuracy or breach of any representation or warranty of
the Company contained in this Agreement, any Transaction Document or in any
certificate, document or instrument delivered by or on behalf of the Company
at the Closing;

  



  

(ii) any breach or nonfulfillment of any covenant or agreement of the
Company contained in this Agreement, any Transaction Document or in any
certificate, document or instrument delivered by or on behalf of the Company
at the Closing;

  



  

(iii) any breach by any officer or director of the Company of any
fiduciary duty owed by such officer, manager or director to any Equityholder,
which breach occurred prior to, in connection with or as a result of the
Closing and the Contemplated Transactions;

  



  

(iv) any Liability or Claim for Taxes imposed on or relating to (A)
the Company with respect to any taxable period or portion thereof ending on
or before the Closing Date, (B) a Person for which the Company has Liability
under Law by reason of the Company's relationship with such Person on or
before the Closing Date (including any Tax imposed upon the
Legacy Corporation or Company pursuant to Sections 1374 or 1375 of the Code
(or any corresponding provision of state, local or non-US Tax law) as a
result of the transactions contemplated by this Agreement), (C) the Company as
a transferee or successor, by Contract or otherwise to the extent the Taxes
are with respect to, or the events or transactions giving rise to the Taxes
occur in, a taxable period or portion thereof ending on or before the Closing
Date, and (D) the Legacy Corporation relating to its status as an S
corporation; _provided,_ _however_ , that Legacy Corporation shall be
solely responsible for any Liabilities or Claims for __ Taxes arising from
any Tax imposed upon the Legacy Corporation or Company pursuant to Sections
1374 or 1375 of the Code (or any corresponding provision of state, local or
non-US Tax law) as a result of the transactions contemplated by this
Agreement;

  



    

 | -32-| 
---|---|--- 

 



    



  

(v) any Liability or Claim relating to the Indebtedness of the
Company to the extent that such Indebtedness was not accounted for in the
calculation of Base Purchase Price at Closing;

  



  

(vi) any Liability or Claim relating to the Transaction Expenses of
the Legacy Corporation that the Company is expected to pay;

  



  

(vii) any Liability or Claim of the Legacy Corporation (including the
Harper Indebtedness); and

  



  

(viii) any Third Party Claim relating to any of the foregoing.

  



  

(c) Subject to the provisions of this _Article VIII_ , regardless of
any investigation undertaken or made or receipt of information by Purchaser
or any of its directors, managers, officers, employees, Affiliates, agents,
equityholders, members, successors and assigns and Representatives prior to
the Closing Date, each of the Equityholders and the Legacy Stockholders,
severally and not jointly, shall defend, indemnify and hold the Purchaser
Indemnitees harmless from and against any and all Claims or Losses (including
Claims or Losses arising out of facts or circumstances that have occurred on
or prior to the Closing Date, even though such Claim or Loss may not be filed
or come to light until after the Closing Date) that may be imposed
upon, incurred by or asserted against any Purchaser Indemnitee arising out
of, based upon or resulting from:

  



  

(i) any inaccuracy or breach of any representation or warranty of
such Seller, as applicable, contained in _Article III_ , any Transaction
Document or in any certificate, document or instrument delivered by or on
behalf of such Seller at the Closing;

  



  

(ii) any breach or nonfulfillment of any covenant or agreement of
such Seller, as applicable, contained in this Agreement, any Transaction
Document or in any certificate, document or instrument delivered by or on
behalf of such Seller at the Closing; and

  



  

(iii) any Third Party Claim related to any of the foregoing.

  



  

8.3. _Purchaser Indemnification_. Subject to the provisions of this
_Article VIII_ , regardless of any investigation undertaken or made or
receipt of information by the Equityholders, or any of their respective
directors, managers, officers, employees, Affiliates, agents, equityholders,
members and Representatives prior to the Closing Date, Purchaser shall defend,
indemnify and hold each of the Legacy Stockholders and the Equityholders and
each of their directors, managers, officers, employees, Affiliates, agents,
equityholders, members, successors and assigns and Representatives (the
"Equityholder Indemnitees"), harmless from and against any and all Losses
that may be imposed upon, incurred by or asserted against any the
Equityholder Indemnitee arising out of, based upon or resulting from:

  



  

(a) any inaccuracy or breach of any representation or warranty of
Purchaser contained in _Article V_ of this Agreement, any Transaction
Document or in any certificate, document or instrument delivered by or on
behalf of Purchaser at the Closing;

  



    

 | -33-| 
---|---|--- 

 



    



  

(b) any breach or nonfulfillment of any covenant or agreement of
Purchaser contained in this Agreement, any Transaction Document or in any
certificate, document or instrument delivered by or on behalf of Purchaser at
the Closing;

  



  

(c) any Liability or Claim relating to the operation of the Business
after the Closing; and

  



  

(d) any Third Party Claim related to any of the foregoing.

  



  

8.4. _Payment; Procedure for Indemnification_.

  



  

(a) _Claim or Loss_. In the event that a Purchaser Indemnitee or an
Equityholder Indemnitee entitled to indemnification under this _Article VIII_
(each, an "Indemnified Party") shall suffer a Loss or identify any Loss Event,
such Indemnified Party shall promptly, after obtaining knowledge of the
incurrence of any such indemnifiable Loss or Loss Event, send a written
notice prior to the applicable Survival Date of its intent to seek indemnity,
describing the Loss or Loss Event in reasonable detail (an "Indemnity
Notice") to the Party from whom indemnification under this _Article VIII_ is
sought (the "Indemnifying Party"). Provided the Indemnity Notice is given
prior to the applicable Survival Date, the failure of any Indemnified Party
to give the Indemnifying Party the Indemnity Notice shall not release the
Indemnifying Party of Liability under this _Article VIII_ , except to the
extent that the Indemnifying Party's ability to defend such Loss is actually
and materially prejudiced by the failure to give such Indemnity Notice. Within
fifteen (15) calendar days after the receipt by the Indemnifying Party of the
Indemnity Notice, the Indemnifying Party shall either (i) pay to the
Indemnified Party an amount equal to the indemnifiable Loss, or, if the
Indemnity Notice identifies a Loss Event in respect of which all
potential Losses thereunder have not been incurred by the applicable
Indemnified Party, agree in writing that any such prospective Losses are,
when incurred, indemnifiable by such Indemnified Party, or (ii) object to such
Indemnity Notice, in which case the Indemnifying Party shall give written
notice to the Indemnified Party of such objection together with the reasons
therefor, it being understood that the failure of the Indemnifying Party to
so object shall preclude the Indemnifying Party from asserting any Loss,
defense or counterclaim relating to the Indemnifying Party's failure to pay
any indemnifiable Loss. The Indemnifying Party's objection shall not, in and
of itself, relieve the Indemnifying Party from its obligations under this
_Article VIII_. Within fifteen (15) calendar days after the giving of such
notice of objection, the Indemnified Party and the Indemnifying Party
shall negotiate in a bona fide attempt to resolve the subject of the
Indemnity Notice. In the event that the Parties are unable to resolve the
subject of the Indemnity Notice, within fifteen (15) calendar days after the
giving of such notice of objection, the subject of such Indemnity Notice
shall be submitted to a court of competent jurisdiction for resolution as set
forth in this Agreement.

  



    

 | -34-| 
---|---|--- 

 



    



  

(b) _Third Party Claim or Loss_.

  



  

(i) Notwithstanding anything set forth in _Section 8.4(a)_ , in the
event the facts giving rise to the Claim for indemnification under this
_Article VIII_ shall involve any action, or threatened Claim or demand, or
other notice of the commencement of a proceeding, audit, investigation,
review, suit or other action, by any Third Party (each, a "Third Party
Claim"), the Indemnified Party shall, promptly after obtaining knowledge of
such Third Party Claim or demand giving rise to the Claim for
indemnification, send written notice prior to the applicable Survival Date of
its intent to seek indemnity, describing such action or Claim in reasonable
detail (a "Third Party Claim Notice") to the Indemnifying Party. Provided the
Third Party Claim Notice is given prior to the applicable Survival Date, the
failure of the Indemnified Party to give the Indemnifying Party the Third
Party Claim Notice shall not release the Indemnifying Party of Liability under
this _Article VIII_ , except to the extent that the Indemnifying Party's
ability to defend such Third Party Claim or Loss is actually and materially
prejudiced by the failure to give such Third Party Claim Notice. Subject to
the last sentence of this _subparagraph (b)(i)_ , if the Indemnifying Party
shall acknowledge in writing that, subject to the limitations in _Section 8.5_
, it is responsible to indemnify the applicable Indemnified Party for any
Losses arising out of the Third Party Claim identified in such Third Party
Claim Notice, the Indemnifying Party shall be entitled to defend such Third
Party Claim in the name of the Indemnified Party at its own expense and
through counsel of its own choosing that is reasonably acceptable to the
Indemnified Party; _provided_ , that if the applicable Third Party Claim is
against, or if the defendants in any such Legal Proceeding shall include, both
the Indemnified Party and the Indemnifying Party and the Indemnified Party
reasonably concludes that there are defenses available to it that are
different or additional to those available to the Indemnifying Party or if
the interests of the Indemnified Party may be reasonably deemed to conflict
with those of the Indemnifying Party, then the Indemnified Party shall have
the right to select separate counsel and to assume the Indemnified Party's
defense of such Legal Proceeding, with the fees, expenses and disbursements of
such counsel to be reimbursed by the Indemnifying Party as incurred. The
Indemnifying Party shall give the Indemnified Party notice in writing within
ten (10) calendar days after receiving the Third Party Claim Notice from the
Indemnified Party in the event of Legal Proceeding or otherwise of its intent
to exercise its right to assume the defense of such Third Party Claim together
with the requisite acknowledgment of responsibility for related Losses. If
the Indemnified Party has received no such notice within such time period or
in the case of any (A) Claims resulting from, relating to or arising out of
the provisions of (1) _Section 4.13_ (Taxes), (2) _Section 8.2(b)(iv)_ with
respect to a breach related to _Article IX_ or (3) _Section 8.2(b)(iv)_ ; (B)
any Third Party Claim which seeks an Order, injunction or other equitable
relief against any Purchaser Indemnitee; and (C) any Third Party Claim
which reasonably could be expected, when aggregated with all other unresolved
indemnifiable Claims, to result in Losses in excess of the Representation
Cap, the Indemnified Party may take control of the defense of such Third Party
Claim but the Indemnifying Party shall pay the costs of such defense incurred
by the Indemnified Party (and all such costs shall be deemed to be Losses for
purposes of this _Article VIII_ ).

  



  

(ii) Whenever the Indemnifying Party is entitled to defend any Third
Party Claim hereunder, the Indemnified Party may elect, by notice in writing
to the Indemnifying Party, to continue to participate through its own counsel,
at its expense, but the Indemnifying Party shall have the right to control
the defense of the Legal Proceeding; _provided_ , that the Indemnifying
Party retains counsel reasonably acceptable to the Indemnified Party;
otherwise, the Indemnified Party shall have the right to control the defense
of the Legal Proceeding.

  



    

 | -35-| 
---|---|--- 

 



    



  

(iii) Notwithstanding any other provision contained in this Agreement,
the party controlling the defense of the Legal Proceeding shall not
settle any such Legal Proceeding without the prior written consent of the
other party; _provided_ , that if the Indemnified Party is controlling the
defense of the Legal Proceeding and shall have, in good faith, negotiated a
settlement thereof, which proposed settlement contains terms that are
reasonable under the circumstances, then the Indemnifying Party shall
not withhold, condition or delay the giving of such consent (and in the event
the Indemnifying Party and Indemnified Party are unable to agree as to
whether the proposed settlement terms are reasonable, the Indemnifying Party
and Indemnified Party will submit the disagreement to a court of competent
jurisdiction for resolution as set forth in this Agreement); and
_provided further_ , that the Purchaser Indemnitees shall not be required to
consent to a proposed settlement that could reasonably be expected to affect
Taxes for a taxable period, or portion thereof, beginning after the Closing
Date.

  



  

(c) _Right of Set-Off_. Purchaser may (but is not obligated to)
satisfy any portion of indemnification obligations of the Legacy Stockholders
and the Equityholders by setting off any such Claims against any unpaid
Milestone Payments or Earnout Payments due to such Legacy Stockholders and
Equityholders, as applicable.

  



  

8.5. _Limitation on Indemnification_.

  



  

(a) Subject to _Section 8.5(c)_ , no Purchaser Indemnitee or
Equityholder Indemnitee shall make a Claim for indemnifiable Losses pursuant
to _Sections 8.2(b)(i)_ , _8.2(c)(i)_ or _8.3(a)_ , respectively, unless and
until the aggregate amount of indemnifiable Losses of all Purchaser
Indemnitees, on the one hand, or the Equityholder Indemnitees, on the
other hand, as the case may be, under this _Article VIII_ exceeds Seventy-
Five Thousand Dollars ($75,000) (the "Threshold Amount"), and then, such
Party shall be entitled to recover all indemnifiable Losses in excess of the
Losses incurred in achieving the Threshold Amount, and in no event shall the
aggregate amount of the indemnifiable Losses pursuant to _Sections 8.2(b)(i)_
, _8.2(c)(i)_ or _8.3(a)_ , respectively, for which all
Purchaser Indemnitees, on the one hand, or Equityholder Indemnitees, on the
other hand, as the case may be, shall be indemnified hereunder exceed twenty-
five percent (25%) of the aggregate amount paid by Purchaser to the
Equityholders as Base Purchase Price or Milestone Payments, if any, at
Closing or thereafter (the "Representation Cap"). Subject to _Section 8.5(c)_
, in no event shall the aggregate amount of the indemnifiable Losses for which
any Equityholder shall be liable pursuant to this Agreement exceed the value
of cash and Purchaser securities received by such Equityholder under the terms
of this Agreement at Closing or thereafter (the "Overall Cap").

  



  

(b) Subject to _Section 8.5(c)_ , in no event shall the aggregate
amount of the indemnifiable Losses for which Purchaser shall be liable
pursuant to this Agreement to indemnify the Equityholder Indemnitees exceed
the Base Purchase Price.

  



  

(c) Notwithstanding the foregoing, neither the Threshold Amount nor
the Representation Cap shall apply to breaches or inaccuracies of any of
the Fundamental Representations (other than with respect to _Section 4.10_
(Intellectual Property), to which the Threshold Amount shall apply).
Notwithstanding the foregoing, neither the Threshold Amount nor the
Representation Cap nor the Overall Cap shall apply to, or shall in any way
limit or impair the right of any Party to pursue, any rights, remedies or
Claims against any other Party based on fraud by such Party. For purposes
only of calculating the amount of Losses incurred by a Purchaser Indemnified
Party arising out of or resulting from any breach of a representation or
warranty, covenant or agreement (but not for purposes of determining the
existence of a breach), the references to a "Material Adverse Effect" or
materiality (or other correlative terms) shall be disregarded.

  



    

 | -36-| 
---|---|--- 

 



    



  

(d) No Claim under this _Article VIII_ shall be made unless an
Indemnity Notice or a Claim Notice (as applicable) has been given prior to
the applicable Survival Date.

  



  

8.6. _Characterization of Indemnity Payments_. Except as otherwise
required by Law, any payment made pursuant to this _Article VIII_ shall be
treated, for financial accounting and Tax purposes, as an adjustment to the
Consideration (except to the extent treated as interest pursuant to Law) and
will be allocated in accordance with GAAP, as consistently applied by the
Legacy Corporation in accordance with past practices.

  



  

8.7. _Sole Remedy_. Notwithstanding anything to the contrary
contained in this Agreement and notwithstanding any otherwise available right
or remedy of the Parties, at Law or in equity, from and after the Closing, the
Parties agree that the sole and exclusive remedy for any breach of this
Agreement by another Party, including any misrepresentation, breach of
covenant or warranty, or for any other Loss, cost damage or expense relating
to, arising out of or otherwise connected with this Agreement or the
Contemplated Transactions (other than in connection with _Sections 2.1, 2.2,
2.3, 2.4, 2.5_ , _Article I_ , _Article IX_ and _Article X_ ), shall be the
right of indemnification as and to the extent set forth in this
_Article VIII_ , and in all events subject to all of the limitations herein,
the Parties waiving all and each other remedy available to it at Law or in
equity. This provision is not intended and will not be construed as limiting
in any fashion the right of any of the Parties to assert and pursue any
claims based on fraud.

  



  

ARTICLE IX

  

TAXES; BULK SALES

  



  

9.1. _Preparation and Filing of Pre-Closing and Post-Closing Tax
Returns for LLC_. Purchaser shall prepare or cause to be prepared and file
or cause to be filed (i) all Tax Returns of the Company for all periods
ending on or prior to the Closing Date, and (ii) all Tax Returns of the
Company for all periods beginning on or before the Closing Date and ending
after the Closing Date. Except as required by Law, such Tax Returns shall be
prepared in a manner consistent with the past custom and practice of the
Legacy Corporation and its Subsidiaries with respect to the preparation of
their Tax Returns. Purchaser shall deliver all such Tax Returns to
the Stockholder Representative at least fifteen (15) days prior to their
filing for the Stockholder Representative's review and comment. Purchaser
shall incorporate all reasonable comments of the Stockholder Representative
therein. The Stockholder Representative (on behalf of the Equityholders)
thereafter shall pay, or cause to be paid, an amount of Taxes owed with
respect to such Tax Returns equal to: _(x)_ in the case of a taxable period
ending on or before the Closing Date, all Taxes owed with respect to such Tax
returns, and _(y)_ in the case of a taxable period beginning on or before the
Closing Date and ending after the Closing Date, the portion of such Taxes
which relates to the portion of such taxable period ending on the Closing Date
determined pursuant to _Section 9.2_. The Stockholder Representative shall
pay or cause to be paid such amounts of Taxes within ten (10) Business Days
of receiving demand therefor from Purchaser. The Legacy Company shall, to the
extent needed, sign any Tax Return for the Company prepared in accordance
with this section for any period that ends of the Closing Date.

  



    

 | -37-| 
---|---|--- 

 



    



  

9.2. _Allocation_. In the case of any Taxes that are imposed on a
periodic basis and are payable for a taxable period that includes, but
does not end on, the Closing Date, the portion of such Tax which relates to
the portion of such taxable period ending on the Closing Date shall (a) in
the case of any Taxes, other than Taxes based upon or related to income or
receipts or expenses ( _e.g._ , payroll Taxes), be deemed to be the amount of
such Tax for the entire taxable period multiplied by a fraction the numerator
of which is the number of days in the taxable period ending on the Closing
Date and the denominator of which is the number of days in the entire taxable
period, and (b) in the case of any Tax based upon or related to income or
receipts or expenses, other than as set forth in _Section 9.2_ , be deemed
equal to the amount which would be payable if the relevant taxable period
ended as of the end of the Closing Date.

  



  

9.3. _Cooperation on Tax Matters_. The Parties shall, and shall each
cause its Affiliates to, provide to the other such cooperation
and information, as and to the extent reasonably requested by the other, in
connection with the filing of Tax Returns, determining liability for Taxes,
and any audit or other Legal Proceeding with respect to Taxes. Such
cooperation shall include the retention and (upon the other Party's request)
the provision of records and information reasonably relevant to any such Tax
Returns, Tax liability, or audit or other Legal Proceeding. Each Party will
retain all Tax Returns and related records and materials of the Legacy
Corporation and the Company for the Tax periods first ending after the
Closing Date and for all prior Tax periods until the expiration of the
applicable statute of limitations (and, to the extent the other Party
reasonably requests, any extensions thereof) for the Tax periods to which the
Tax Returns and other records and materials relate, and abide by any
applicable record retention agreements entered into with any Governmental
Entity. Thereafter, the Party holding such Tax Returns or related records or
materials may dispose of them _provided_ that such Party shall give the other
Party notice in accordance with _Section 13.5_ prior to doing so, and if the
other Party so requests allow the other Party to take possession or make
copies of such Tax Returns or related records or materials. Each Party shall
make its employees reasonably available on a mutually convenient basis at its
cost to provide explanation of any documents or information so provided.

  



  

9.4. _Transfer Taxes_. All transfer, documentary, sales, use, real
property transfer, recording, stock transfer, stamp, registration and other
such Taxes and fees (including any penalties and interest) incurred in
connection with the Contemplated Transactions shall be paid by Purchaser when
due, and Purchaser shall, at its own expense, file all necessary Tax Returns
and other documentation with respect to all such transfer, documentary,
sales, use, real property transfer, recording, stock transfer, stamp,
registration and other Taxes and fees, and, if required by applicable Law, the
Equityholders shall, and shall cause its Affiliates to, join in the execution
of any such Tax Returns and other documentation.

  



  

9.5. _Tax Advice_. The Legacy Stockholders and the Equityholders
acknowledge and agree that none of Purchaser, its Affiliates
or Representatives has provided any advice with respect to Taxes arising out
of, related to or in connection with the Contemplated Transactions to any of
the Legacy Stockholders, the Equityholders, the Stockholder Representative or
any of their Affiliates or Representatives.

  



    

 | -38-| 
---|---|--- 

 



    



  

ARTICLE X

  

RESTRICTIVE COVENANTS

  



  

10.1. _Confidentiality_. Until the end of the five (5) year period
beginning on the Closing Date (the "Restricted Period"), each of the Legacy
Stockholders and the Equityholders shall, and shall take action to direct
their counsel, accountants, financial advisors and lenders to: (a) keep all
Proprietary Information of the Legacy Corporation, the Company, and Purchaser
and their respective Affiliates confidential and not to disclose or reveal
any such Proprietary Information to any Person other than its Affiliates and
Representatives, including counsel, accountants and financial advisors who
otherwise need to know such Proprietary Information; and (b) not to use such
Proprietary Information for any purpose other than: (i) to the
extent necessary to obtain any of the Consents required hereunder; or (ii) to
enforce such Party's rights and remedies under this Agreement.

  



  

10.2. _Restrictive Covenants_.

  



  

(a) _Non-Solicitation/Non-Acceptance_. As a material inducement to
Purchaser's consummation of the Contemplated Transactions, including
Purchaser's acquisition of the goodwill, the Legacy Corporation and the
Legacy Stockholders shall not, during the Restricted Period, directly or
indirectly, without the prior written consent of Purchaser in each instance in
its sole discretion:

  



  

(i) solicit, accept, call on, divert, take away, influence, induce
or attempt to do any of the foregoing with respect to the customers
or prospective customers of Purchaser or its Affiliates (including, after the
Closing, the Company); or

  



  

(ii) (A) solicit, direct or influence any of the suppliers, vendors,
service providers, insurance carriers, agents, personnel and others having
business relations with the Legacy Corporation or the Company as of the
Closing Date, (B) hire or attempt to hire any of the employees or independent
contractors of the Legacy Corporation or the Company on the Closing
Date subsequently employed or engaged by the Company, Purchaser or any of
their Affiliates or (C) attempt to influence or induce any such employee or
independent contractor to terminate or modify any Contract, arrangement or
relationship with the Company, Purchaser or any of their Affiliates.

  



  

(b) _Non-Competition_. As a material inducement to Purchaser's
consummation of the Contemplated Transactions, including
Purchaser's acquisition of the goodwill, the Legacy Corporation and the
Legacy Stockholders shall not, during the Restricted Period, directly or
indirectly, do any of the following without the prior written consent of
Purchaser in each instance in its sole discretion:

  



  

(i) participate or engage in, or offer any services related to, any
lines of business in the Territory which use any product to diagnose, treat
or cure any Indication (collectively, the "Restricted Business"); _provided,
however_ , that nothing contained herein shall prevent the Legacy Corporation
or either of the Legacy Stockholders from performing services for the
Company, Purchaser or any of its Affiliates; or

  



    

 | -39-| 
---|---|--- 

 



    



  

(ii) become an owner, equityholder, member, lender, partner, co-
venturer, director, manager, officer, employee, agent or consultant, directly
or indirectly, in any Person that engages in the Restricted Business;
_provided_ , that the Legacy Corporation and/or either of the Legacy
Stockholders may own, as a passive investor, and not as part of a group with
any other Person, not more than five percent (5%) of the outstanding
Securities of any class of any publicly traded Securities of such Person.

  



  

(c) Notwithstanding the foregoing, nothing herein shall limit
Hakonarson's ability to perform research and engage in the clinical
practice of medicine at CHOP (or any of its affiliates) or any other academic
institution or research institute.

  



  

10.3. _Specific Enforcement_.

  



  

(a) Each of the Legacy Stockholders and the Equityholders
acknowledge that any breach or threatened breach by it of any provision
of the Restrictive Covenants will cause continuing and irreparable injury to
Purchaser and its Affiliates for which monetary damages would not be an
adequate remedy. Accordingly, Purchaser shall be entitled to injunctive relief
from any court of competent jurisdiction, including specific performance,
with respect to any such breach or threatened breach. In
connection therewith, no Equityholder shall, in any Legal Proceeding to so
enforce any provisions of this _Article X_ assert the claim or defense that
an adequate remedy at Law exists or that the injunctive relief is not an
appropriate form of relief under the circumstances.

  



  

(b) The rights and remedies of Purchaser set forth in this _Section
10.3_ are in addition to any other rights or remedies to which Purchaser may
be entitled, whether existing under this Agreement, at Law or in equity, all
of which shall be cumulative. Furthermore, notwithstanding anything to the
contrary in this Agreement, the obligations for set-off and the limitations
in _Article VIII_ shall not apply to any Losses resulting from a breach of the
obligations set forth in this _Article X_.

  



  

(c) The periods of time set forth in this _Article X_ shall not
include, and shall be deemed extended by, any time required for litigation to
enforce the relevant covenant periods. The term "time required for litigation"
as used in this _Section 10.3(c)_ shall mean the period of time from the
earlier of any Seller's first breach of the provisions of _Section 10.1_ or
_10.2_ or service of process upon any such Seller with respect to a Legal
Proceeding instituted by Purchaser through the expiration of all appeals
related to such Legal Proceeding.

  



  

10.4. _Disclosure_. Each of the Sellers acknowledges that Purchaser may
disclose the existence of this Agreement and the Restrictive Covenants to any
Person with, through or on behalf of which the Sellers may, directly or
indirectly, breach or threaten to breach any of the provisions of _Sections
10.1_ or _10.2_.

  



    

 | -40-| 
---|---|--- 

 



    



  

10.5. _Interpretation_. It is the desire and intent of the Parties that
the provisions of this _Article X_ shall be enforceable to the fullest extent
permissible under Law and public policy. Accordingly, if any provision of this
_Article X_ shall be determined to be invalid, unenforceable or illegal for
any reason, then the validity and enforceability of all of the remaining
provisions of this _Article X_ shall not be affected thereby. If any
particular provision of this _Article X_ shall be adjudicated to be invalid
or unenforceable, then such provision shall be deemed amended to delete
therefrom the portion thus adjudicated to be invalid or unenforceable, such
amendment to apply only to the operation of such provision in the
particular jurisdiction in which such adjudication is made; _provided_ ,
that, if any provision contained in this _Article X_  shall be adjudicated to
be invalid or unenforceable because such provision is held to be excessively
broad as to duration, geographic scope, activity or subject, then such
provision shall be deemed amended by limiting and reducing it so as to
be valid and enforceable to the maximum extent compatible with the Laws and
public policy of such jurisdiction, such amendment only to apply with respect
to the operation of such provision in the applicable jurisdiction in which the
adjudication is made.

  



  

10.6. _Acknowledgment_. Each of the Legacy Stockholders and the
Equityholders acknowledges that it has carefully read and considered the
provisions of this _Article X_. Each Legacy Stockholder and Equityholder
believes that he or it has received and will receive sufficient consideration
and other benefits to justify the restrictions in this _Article X_. Each
Legacy Stockholder and Equityholder also acknowledges and understands that
these restrictions are reasonably necessary to protect interests of Purchaser
and its Affiliates and none of the Legacy Stockholders and the Equityholders
believe that such restrictions will prevent them from conducting businesses
that are not excluded from the Restricted Business during the periods covered
by the Restrictive Covenants.

  



  

ARTICLE XI

  

REGISTRATION RIGHTS

  



  

11.1. _Registration_. As soon as reasonably practicable, but in no
event later than ninety (90) days after the Offering Date or the Phase III
Date, as applicable, Purchaser shall prepare and file with the SEC, a
Registration Statement covering the resale of all, or such portion as
permitted by SEC Guidance (provided that, Purchaser shall use commercially
reasonable efforts to advocate with the SEC for the registration of the
maximum number of the Registrable Securities permitted by SEC Guidance), of
the Registrable Securities received on the applicable Offering Date or Phase
III Date and use commercially reasonable efforts to cause a Registration
Statement to be declared effective (including, without limitation, the
execution of any required undertaking to file post-effective amendments) as
promptly as possible. The Registration Statement shall be on Form S-3 (except
if Purchaser fails to meet one or more of the registrant requirements
specified in General Instruction I.A. on Form S-3, such registration shall be
on another appropriate form in accordance herewith).

  



  

11.2. _Expenses of Registration_. Purchaser shall pay all fees and
expenses incurred in connection with any registration,
qualification, exemption or compliance by Purchaser in the performance of its
obligations pursuant to this _Article XI_ , whether or not any Registrable
Securities are sold pursuant to a Registration Statement, and including all
registration and filing fees, exchange listing fees, and the fees and
expenses of counsel and accountants for Purchaser.

  



  

11.3. _Obligations of Purchaser_. In the case of registration,
qualification, exemption or compliance effected by Purchaser pursuant to
this Agreement, Purchaser will, upon request of the Stockholder
Representative, inform the Stockholder Representative as to the status of
such registration, qualification, exemption and compliance. Purchaser shall,
at its expense and in addition to its obligations under _Section 11.1_ , as
expeditiously as reasonably possible:

  



    

 | -41-| 
---|---|--- 

 



    



  

(a) except for such times as Purchaser is permitted hereunder to
suspend the use of the prospectus forming part of the Registration Statement,
use its commercially reasonable efforts to keep such registration, and any
required qualification, exemption or compliance under state securities laws
effective until the date all Purchaser Common Stock issued as Milestone
Consideration and held by Purchaser stockholders may be sold during any
ninety (90) day period under Rule 144 and any contractual agreements with
Purchaser. The period of time during which Purchaser is required hereunder to
keep the Registration Statement effective is referred to herein as the
"Registration Period";

  



  

(b) advise the Stockholder Representative promptly (and, in any
event, within five (5) business days):

  



  

(i) when the Registration Statement or any amendment thereto has
been filed with the SEC and when the Registration Statement or any post-
effective amendment thereto has become effective;

  



  

(ii) of the receipt by Purchaser of any notification from the SEC of
any stop order suspending the effectiveness of the Registration Statement or
the initiation of any proceedings for such purpose;

  



  

(iii) of the receipt by Purchaser of any notification with respect to
the suspension of the qualification of the Registrable Securities included
therein for sale in any jurisdiction or the initiation or threatening of any
proceeding for such purpose; and

  



  

(iv) of the occurrence of any event that requires the making of any
changes in the Registration Statement or the prospectus so that, as of such
date, the statements therein are not misleading and do not omit to state a
material fact required to be stated therein or necessary to make the
statements therein (in the case of the prospectus, in the light of the
circumstances under which they were made) not misleading;

  



  

(c) use its commercially reasonable efforts to obtain the withdrawal
of any order suspending the effectiveness of any Registration Statement as
soon as reasonably practicable;

  



  

(d) if the Stockholder Representative so requests in writing,
promptly furnish to the Stockholder Representative, without charge, at least
one copy of such Registration Statement and any post-effective amendment
thereto, including financial statements and schedules, and, if explicitly
requested, all exhibits in the form filed with the SEC;

  



  

(e) during the Registration Period, promptly deliver to the
Stockholder Representative, without charge, at least one copy of
the prospectus included in such Registration Statement and any amendment or
supplement thereto and as many additional copies as the Stockholder
Representative may reasonably request; and Purchaser consents to the use,
consistent with the provisions hereof, of the prospectus or any amendment or
supplement thereto by the Stockholder Representative in connection with
the offering and sale of the Registrable Securities covered by the prospectus
or any amendment or supplement thereto;

  



    

 | -42-| 
---|---|--- 

 



    



  

(f) during the Registration Period, if the Stockholder
Representative so requests in writing, deliver to the Stockholder
Representative, without charge, (i) one copy of the following documents,
other than those documents available via EDGAR (and excluding, in each case,
exhibits thereto): (A) its annual report to its stockholders, if any (which
annual report will contain financial statements audited in accordance with
GAAP by a firm of certified public accountants of recognized standing), (B) if
not included in substance in its annual report to stockholders, its annual
report on Form 10-K (or similar form), (C) its definitive proxy statement
with respect to its annual meeting of stockholders, (D) each of its quarterly
reports to its stockholders, and, if not included in substance in its
quarterly reports to stockholders, its quarterly report on Form 10-Q (or
similar form), and (E) a copy of the Registration Statement; and (ii) if
explicitly requested, any exhibits filed with respect to the foregoing;

  



  

(g) upon the occurrence of any event contemplated by _Section
11.3(b)(iv)_ above, except for such times as Purchaser is permitted hereunder
to suspend the use of the prospectus forming part of the Registration
Statement, Purchaser will use its commercially reasonable efforts to as soon
as reasonably practicable prepare a post-effective amendment to the
Registration Statement or a supplement to the related prospectus, or file any
other required document so that, as thereafter delivered to the Stockholder
Representative, the prospectus will not include any untrue statement of a
material fact or omit to state any material fact necessary to make the
statements therein, in the light of the circumstances under which they were
made, not misleading;

  



  

(h) comply in all material respects with all applicable rules and
regulations of the SEC which could affect the sale of the
Registrable Securities;

  



  

(i) use its commercially reasonable efforts to cause all Registrable
Securities to be listed on each securities exchange or market, if any, on
which equity securities issued by Purchaser have been listed;

  



  

(j) use its commercially reasonable efforts to take all other steps
necessary to effect the registration of the Registrable Securities
contemplated hereby and to enable the Stockholder Representative to sell
Registrable Securities under Rule 144; and

  



  

(k) permit counsel for the Stockholder Representative to review the
Registration Statement and all amendments and supplements thereto, within two
(2) business days prior to the filing thereof with the SEC;

  



  

provided that, in the case of _Section 11.3(k)_ above, Purchaser will not be
required to delay the filing of the Registration Statement or any amendment or
supplement thereto to incorporate any comments to the Registration Statement
or any amendment or supplement thereto by or on behalf of the Stockholder
Representative if such comments would require a delay in the filing of such
Registration Statement, amendment or supplement, as the case may be.

  



    

 | -43-| 
---|---|--- 

 



    



  

11.4. _Furnishing Information_. It shall be a condition precedent to
the obligations of Purchaser to take any action pursuant to _Section 11.1_
that the Legacy Corporation and/or the Legacy Stockholders shall furnish to
Purchaser such information regarding themselves, the Registrable Securities
held by them and the intended method of disposition of such securities as
shall be legally required under the Securities Act or otherwise required by
the SEC to effect the registration of their Registrable Securities.

  



  

11.5. _Indemnification; Contribution_.

  



  

(a) Purchaser shall indemnify and hold harmless each Equityholder
(including the employees, agents, representatives, officers and directors of
the Equityholder, if applicable, and its Affiliates) and each Person who
controls such Equityholder (within the meaning of the Securities Act and the
Exchange Act) (each a "Registration Holder Indemnitee") from and against any
and all Losses, claims, damages, Liabilities and expenses (including
reasonable costs of investigation and reasonable legal fees) arising out of
or based upon (i) any untrue, or allegedly untrue, statement of a material
fact contained in any Registration Statement, prospectus or preliminary
prospectus or notification or offering circular prepared by Purchaser in
connection with the registration and/or offering of the Registrable Securities
(as amended or supplemented if Purchaser shall have furnished any amendments
or supplements thereto) or arising out of or based upon any omission or
alleged omission to state therein a material fact required to be stated
therein or necessary to make the statements therein not misleading, except
insofar as the same are caused by or contained in any information concerning
such Equityholder furnished in writing to Purchaser by such Equityholder
expressly for use in such document or (ii) any violation or alleged violation
by Purchaser (or any of its agents or Affiliates) of the Securities Act, the
Exchange Act, any state securities law, or any rule or regulation promulgated
under the Securities Act, the Exchange Act, or any state securities law.

  



  

(b) Each Equityholder and Legacy Stockholder, severally and not
jointly, shall indemnify and hold harmless Purchaser, and its directors,
officers, employees and each Person who controls Purchaser (within the meaning
of the Securities Act and the Exchange Act) from and against any and all
Losses, claims, damages, Liabilities and expenses (including reasonable costs
of investigation) arising out of or based upon any untrue, or allegedly
untrue, statement of a material fact contained in any Registration Statement,
prospectus or preliminary prospectus or notification or offering circular
prepared by Purchaser in connection with the registration and/or offering of
the Registrable Securities (as amended or supplemented if Purchaser
shall have furnished any amendments or supplements thereto) or arising out of
or based upon any omission or alleged omission to state therein a material
fact required to be stated therein or necessary to make the statements therein
not misleading, if such statement or omission was made in reliance upon and
in conformity with any information concerning such Equityholder or Legacy
Stockholder or the Company furnished in writing to Purchaser by such
Equityholder or Legacy Stockholder or the Company specifically for use in the
preparation of such document.

  



    

 | -44-| 
---|---|--- 

 



    



  

(c) Each Person entitled to indemnification hereunder (the
"Registration Indemnified Party") agrees to give prompt written notice to the
indemnifying party (the "Registration Indemnifying Party") after the receipt
by the Registration Indemnified Party of any written notice of the
commencement of any action, suit, proceeding or investigation or threat
thereof made in writing for which the Registration Indemnified Party intends
to claim indemnification or contribution pursuant to this Agreement;
_provided_ , _however_ , that the failure to so notify the Registration
Indemnifying Party shall not relieve the Registration Indemnifying Party of
any liability that it may have to the Registration Indemnified Party
hereunder unless, and only to the extent that, such failure results in the
Registration Indemnifying Party's forfeiture of substantive rights or
defenses. If notice of commencement of any such action is given to the
Registration Indemnifying Party as above provided, the Registration
Indemnifying Party shall be entitled to participate in and, to the extent it
may wish, jointly with any other Registration Indemnifying Party similarly
notified, to assume the defense of such action at its own expense, with
counsel chosen by it and reasonably satisfactory to such Registration
Indemnified Party. The Registration Indemnified Party shall have the right to
employ separate counsel in any such action and participate in the defense
thereof, but the fees and expenses of such counsel (other than reasonable
costs of investigation) shall be paid by the Registration Indemnified Party
unless (i) the Registration Indemnifying Party agrees to pay the same, (ii)
the Registration Indemnifying Party fails to assume the defense of such
action with counsel reasonably satisfactory to the Registration Indemnified
Party in its reasonable judgment or (iii) the named parties to any such action
(including any impleaded parties) have been advised by such counsel that
either (x) representation of such Registration Indemnified Party and the
Registration Indemnifying Party by the same counsel would be inappropriate
under applicable standards of professional conduct or (y) there may be one or
more legal defenses available to it which are different from or additional to
those available to the Registration Indemnifying Party. In either of such
cases, the Registration Indemnifying Party shall not have the right to assume
the defense of such action on behalf of such Registration Indemnified Party.
No Registration Indemnifying Party shall be liable for any settlement entered
into without its written consent (other than in the case where the
Registration Indemnifying Party is unconditionally released from liability and
its rights are not adversely effected), which consent shall not be
unreasonably withheld.

  



  

(d) If the indemnification provided for in this _Section 11.5_ from
the Registration Indemnifying Party pursuant to applicable Law is unavailable
to a Registration Indemnified Party hereunder in respect of any Losses,
claims, damages, Liabilities or expenses referred to therein, then the
Registration Indemnifying Party, in lieu of indemnifying such Registration
Indemnified Party, shall contribute to the amount paid or payable by such
Registration Indemnified Party as a result of such Losses, claims, damages,
Liabilities or expenses in such proportion as is appropriate to reflect the
relative fault of the Registration Indemnifying Party and Registration
Indemnified Party in connection with the actions which resulted in
such Losses, claims, damages, Liabilities or expenses, as well as any other
relevant equitable considerations. The relative faults of such Registration
Indemnifying Party and Registration Indemnified Party shall be determined by
reference to, among other things, whether any action in question, including
any untrue or alleged untrue statement of a material fact or omission
or alleged omission to state a material fact, has been made by, or relates to
information supplied by, such Registration Indemnifying Party or Registration
Indemnified Party, and the parties' relative intent, knowledge, access
to information and opportunity to correct or prevent such action. The amount
paid or payable by a party as a result of the Losses, claims, damages,
Liabilities and expenses referred to above shall be deemed to include, subject
to the limitations set forth in _Sections 11.5(a)_ , _(b)_ and _(c)_ , any
legal or other fees, charges or expenses reasonably incurred by such party in
connection with any investigation or proceeding. The parties hereto agree that
it would not be just and equitable if contribution pursuant to this _Section
11.5(d)_ were determined by pro rata allocation or by any other method of
allocation which does not take account of the equitable considerations
referred to in the immediately preceding paragraph. No Person guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the
Securities Act) shall be entitled to contribution from any Person.

  



    

 | -45-| 
---|---|--- 

 



    



  

ARTICLE XII

  

STOCKHOLDER REPRESENTATIVE

  



  

12.1. _Appointment of the Stockholder Representative; Duties; and Power
of Attorney_.

  



  

(a) Harper is hereby appointed to serve as the Stockholder
Representative and attorney-in-fact of the Legacy Corporation and the
Legacy Stockholders with full power and authority to act (including by
executing, delivering and filing documents, agreements and instruments) in
the name of, for and on behalf of the Legacy Corporation and the Legacy
Stockholders with respect to all matters arising in connection with this
Agreement and the Contemplated Transactions, including the power and authority
to make all decisions relating to:

  



  

(i) the settlement of the post-Closing adjustments (payments) and
the amounts of the Milestone Payments and Earnout Payments, and adjustments
pursuant to _Sections 2.5_ and _2.6_ of this Agreement;

  



  

(ii) the prosecution, defense and/or settlement of any claims for
which any Purchaser Indemnitee or the Equityholder Indemnitee may claim to be
entitled to indemnification pursuant to _Article VIII_ of this Agreement; and

  



  

(iii) all decisions in connection with any amendment to this
Agreement;

  



  

 _provided, however_ , that the Stockholder Representative will have no
obligation to act except as __ expressly provided herein. All decisions and
actions by the Stockholder Representative shall be binding upon the Legacy
Corporation and each of the Legacy Stockholders and neither the Legacy
Corporation nor either Legacy Stockholder shall have the right to object to,
dissent from, protest or otherwise contest the same. In the event of the
death, incapacity, dissolution, insolvency or resignation of the Stockholder
Representative, the Legacy Stockholders shall promptly appoint a substitute
Stockholder Representative which shall be reasonably acceptable to Purchaser;
_provided, however_ , in no event shall the Stockholder Representative resign
without the Legacy Stockholders having first appointed a substitute
Stockholder Representative who shall assume such duties immediately upon the
resignation of the Stockholder Representative.

  



  

(b) The power of attorney granted in this _Article XI_ and all
authority hereby conferred is granted and shall be irrevocable and shall not
be terminated by any act of the Legacy Corporation or either Legacy
Stockholder or by operation of Law. The Legacy Corporation and each Legacy
Stockholder hereby confirms each and every action to be taken by the
Stockholder Representative pursuant to this power of attorney as if it were
its own and waives any right to make any claim against the Stockholder
Representative that may arise, directly or indirectly, as a result of the
Stockholder Representative's actions by virtue of this power of attorney.

  



    

 | -46-| 
---|---|--- 

 



    



  

  



  

  

(c) For clarity, the Stockholder Representative shall not be
considered the representative or agent of CHOP and CHOP shall have sole
authority to make decisions of CHOP pursuant to this Agreement.

  



  

12.2. _Reliance_.

  



  

(a) Any notice or communication delivered by Purchaser to the
Stockholder Representative shall, as between Purchaser, on the one hand, and
the Legacy Corporation and the Legacy Stockholders, on the other hand, be
deemed to have been delivered to all of the Legacy Corporation and the Legacy
Stockholders. Purchaser shall be entitled to rely exclusively upon any
communication or writings given or executed by the Stockholder Representative
in connection with any claims for indemnification and shall not be liable in
any manner whatsoever for any action taken or not taken in reliance upon the
actions taken or not taken or communications or writings given or executed by
the Stockholder Representative. Purchaser shall be entitled to disregard any
notices or communications given or made by the Legacy Corporation or the
Legacy Stockholders in connection with any claims for indemnification unless
given or made through the Stockholder Representative.

  



  

(b) The Stockholder Representative shall be entitled to engage such
Representatives as the Stockholder Representative shall deem necessary in
connection with the Stockholder Representative's exercise of its power and
authority and performance of its duties and obligations under this Agreement
and, in the absence of bad faith on the part of the Stockholder
Representative, shall be entitled to rely conclusively upon the opinions and
advice of any of such Representatives.

  



  

12.3. _Limitation of Liability; Indemnification_.

  



  

(a) Neither the Stockholder Representative nor any of his
Affiliates, as the case may be, will have any Liability to the Legacy
Corporation or either Stockholder or to any other Person with respect to
actions taken or omitted to be taken by the Stockholder
Representative, except that the foregoing shall not relieve the Stockholder
Representative of any Liability with respect to any action which is finally
determined by a court of competent jurisdiction to constitute gross
negligence, bad faith or willful misconduct on the part of the Stockholder
Representative.

  



  

(b) The Legacy Corporation hereby agrees to indemnify and hold
harmless the Stockholder Representative and his Affiliates (the "Stockholder
Representative Parties"), from any Losses that an Stockholder Representative
Party may suffer or incur in connection with the performance of the
Stockholder Representative's duties and obligations in connection with this
Agreement, except to the extent such actions are finally determined by a court
of competent jurisdiction to constitute gross negligence, bad faith or
willful misconduct on the part of such Stockholder Representative.

  



  

12.4. _Fees and Expenses_. The fees, costs and expenses of the
Stockholder Representative incurred following the Closing Date, including any
fees and expenses incurred by it in connection with the retention of any legal
counsel, experts (including expert witnesses), consultants and other
Representatives engaged by it whether involving a claim for indemnification or
otherwise, shall be borne solely by the Legacy Corporation within ten (10)
Business Days after a written request therefore is made by the Stockholder
Representative.

  



  

   

 | -47-| 
---|---|--- 

 



    



  

ARTICLE XIII

  

MISCELLANEOUS

  



  

13.1. _Severability_. Any provision, including any phrase, sentence,
clause, Section or subsection, of this Agreement (other than those contained
in  _Article X_ of this Agreement, in which case, _Section 10.5_ shall govern
with respect to the invalidity, unenforceability, or illegality of any such
provision) that is prohibited or unenforceable in any jurisdiction shall, as
to such jurisdiction, be ineffective to the extent of such prohibition or
unenforceability without invalidating the remaining provisions of this
Agreement or such provision, and any such prohibition or unenforceability in
any jurisdiction shall not invalidate or render unenforceable such provision
in any other jurisdiction.

  



  

13.2. _Amendment and Waivers_. No amendment, modification or discharge
(other than by payment or performance) of this Agreement shall be valid and
binding unless signed by all Parties. No waiver hereunder, shall be valid or
binding unless set forth in writing and duly executed by the Party against
whom enforcement of the amendment, modification, discharge or waiver is
sought. Any such waiver shall constitute a waiver only with respect to the
specific matter described in such writing and shall in no way impair the
rights of the Party granting such waiver in any other respect or at any other
time. Neither the waiver by any of the Parties of a breach of or a default
under any of the provisions of this Agreement, nor the failure by any of the
Parties, on one (1) or more occasions, to enforce any of the provisions of
this Agreement or to exercise any right or privilege hereunder, shall be
construed as a waiver of any other breach or default of a similar nature, or
as a waiver of any of such provisions, rights or privileges hereunder. No
Party shall take any action, or fail to take any action, in concert with
another Party with the primary bad faith intent of avoiding the payment right
of any other Party under this Agreement or the License Agreement.

  



  

13.3. _Entire Agreement_.

  



  

(a) This Agreement, including the Schedules and Exhibits, and the
other Transaction Documents constitute the entire agreement among the Parties
with respect to the subject matter of this Agreement and supersedes all prior
agreements, understandings, and negotiations, whether written or oral, with
respect to the subject matter of this Agreement.

  



  

(b) In the event of any inconsistency between the statements in the
body of this Agreement and those in the Schedules and Exhibits (other than an
exception expressly set forth as such in the Disclosure Schedule with respect
to a representation or warranty), the statements in the body of this
Agreement will control.

  



  

13.4. _Expenses_. Except as otherwise expressly provided in this
Agreement, all expenses incurred by each of the Parties in connection with or
related to the authorization, preparation and execution of this Agreement and
the closing of the Contemplated Transactions, including all fees and expenses
of Representatives employed by any such Party, shall be borne solely by the
Party which has incurred such expense.

  



    

 | -48-| 
---|---|--- 

 



    



  

13.5. _Notice_. All written notices, demands and requests of any kind
which any Party may be required or may desire to serve upon any other
Party in connection with this Agreement shall be in writing and shall be
delivered only by courier or other means of personal service which provides
written verification of receipt or by registered or certified mail return
receipt requested, or by facsimile; _provided _ that the facsimile is
promptly followed by delivery of hard copy of such notice which provides
written verification or receipt (each, a "Notice"). Any such Notice delivered
by registered or certified mail shall be deposited in the United States mail
with postage thereon fully prepaid, or if by courier then deposited prepaid
with the courier. All Notices shall be addressed to the Parties to be served
as follows:

  



  

If to the Legacy Corporation or the Legacy Stockholders, then to the
Stockholder Representative at:

  



  

Philip Harper

  

1877 Covered Bridge Road

  

Malvern, PA 19355

  

Fax No.: 610.647.5095

  



  

with a copy to (which shall not constitute notice):

  



  

Fox Rothschild LLP

  

747 Constitution Drive, Suite 100

  

P.O. Box 673

  

Exton, Pennsylvania 19341

  

Attention: Michael S. Harrington, Esq.

  

Fax No.: 610.458.7337

  



  

If to CHOP, then to:

  



  

The Children\'s Hospital of Philadelphia

  

34th Street and Civic Center Boulevard

  

Philadelphia, PA 19104

  

Attention: Steven Biener, Deputy General Counsel

  

Fax No.: 267.426.6128

  



  

with a copy to (which shall not constitute notice):

  



  

Morgan, Lewis and Bockius LLP

  

502 Carnegie Center

  

Princeton, NJ 08540-6241

  

Attention: Steven M. Cohen

  

Fax No.: 877.432.9652

  



  

If to Purchaser or the Company after the Closing:

  



  

Medgenics, Inc.

  

435 Devon Park Drive, Building 700

  

Wayne, PA 19087

  

Attention: Scott Applebaum, Esquire

  

Fax No.: 610.717.3390

  



  

   

 | -49-| 
---|---|--- 

 



    



  

With a copy to (which shall not constitute notice):

  



  

Pepper Hamilton LLP

  

3000 Two Logan Square

  

18th and Arch Streets

  

Philadelphia, Pennsylvania 19103

  

Attention: Brian M. Katz, Esquire

  

Fax No.: 215.981.4750

  



  

Service of any such Notice so made shall be deemed complete on the day of
actual delivery thereof as shown by the addressee's registry or certification
receipt or other evidence of receipt, or refusal of delivery. Any Party may
from time to time by notice in writing served upon the other as aforesaid
designate a different mailing address or a different or additional person to
which all such notices or demands hereafter are to be addressed.

  



  

13.6. _Governing Law and Jurisdiction_. This Agreement shall be governed
by, and construed in accordance with, the Laws of the State of
Delaware applicable to contracts executed in and to be performed in that
state without giving effect to any choice or conflict of law provision or
rule that would cause the application of the Law of any jurisdiction other
than the State of Delaware. All actions and proceedings arising out of or
relating to this Agreement shall be heard and determined exclusively in any
Delaware state or federal court;  _provided_ , that venue in any action
initiated by Purchaser for specific performance of any Legacy Stockholder's
or Equityholder's obligations and undertakings set forth in _Sections 10.1_
(Confidentiality) and _10.2_ (Restrictive Covenants) may, at Purchaser's
option, be at any court having jurisdiction over such action. EACH PARTY
IRREVOCABLY CONSENTS TO AND SUBMITS TO (A) THE EXCLUSIVE JURISDICTION OF ANY
STATE OR FEDERAL COURT SITTING IN THE ABOVE-NAMED VENUES, AND (B)
IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT BY WAY OF MOTION, DEFENSE, OR
OTHERWISE, IN ANY LEGAL PROCEEDING, ANY CLAIM THAT IT IS NOT
SUBJECT PERSONALLY TO THE JURISDICTION OF THE ABOVE-NAMED COURTS, THAT ITS
PROPERTY IS EXEMPT OR IMMUNE FROM ATTACHMENT OR EXECUTION, THAT THE LEGAL
PROCEEDING IS BROUGHT IN AN INCONVENIENT FORUM, THAT THE VENUE OF THE LEGAL
PROCEEDING IS IMPROPER, OR THAT THIS AGREEMENT OR THE CONTEMPLATED
TRANSACTIONS MAY NOT BE ENFORCED IN OR BY ANY OF THE ABOVE-NAMED COURTS.

  



  

13.7. _Waiver of Jury Trial_. EACH OF THE PARTIES HEREBY IRREVOCABLY
WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR
COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR
RELATING TO THIS AGREEMENT OR THE CONTEMPLATED TRANSACTIONS OR THE ACTIONS OF
THE PARTIES IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT OF
THIS AGREEMENT.

  



    

 | -50-| 
---|---|--- 

 



    



  

13.8. _Assignment; Binding Effect; No Third Party Rights_. None of the
Parties shall have the right to assign this Agreement without the
prior written consent of the other Parties. Notwithstanding the foregoing,
(a) Purchaser may assign its rights and obligations under this Agreement to
any Affiliate of Purchaser; and (b) any or all of the rights and interests of
Purchaser under this Agreement (i) may be assigned to any purchaser of
substantially all of the assets of Purchaser or any of its Affiliates, (ii)
may be assigned as a matter of Law to the surviving entity in any merger,
consolidation, equity interest exchange or reorganization involving Purchaser
or any of its Affiliates, and (iii) may be assigned as collateral security to
any lender or lenders (including any agent for any such lender or lenders) or
to any assignee or assignees of such lender, lenders or agent; _provided that_
in the case of _subclause (i)_ , Purchaser each shall remain responsible for
its obligations set forth in this Agreement, and, in the case of _subclause
(i)_ or _subclause (ii)_ , Purchaser shall make proper provision so that the
successors and assigns shall assume the obligations set forth in this
Agreement. Subject to the preceding sentences, this Agreement shall be
binding upon and inure to the benefit of each of the Parties and their
respective heirs, successors and permitted assigns. Nothing expressed or
referred to in this Agreement will be construed to give any Person other than
the parties hereto any legal or equitable right, remedy or claim under or
with respect to this Agreement or any provision of this Agreement.

  



  

13.9. _Counterparts; Execution by Electronic Means_. This Agreement may be
executed in several counterparts, each of which shall be deemed an
original and all of which shall together constitute one (1) and the same
instrument. The reproduction of signatures by means of facsimile device or
other electronic means shall be treated as though such reproductions are
executed originals, and each Party covenants and agrees to provide the other
Party with a copy of this Agreement bearing original signatures within five
(5) Business Days following transmittal by facsimile or other electronic
means.

  



  

ARTICLE XIV

  

INTERPRETATION; DEFINITIONS

  



  

14.1. _Rules of Construction_. The words "hereby," "herein," "hereof;"
"hereunder" and words of similar import refer to this Agreement as a whole
(including any Exhibits and Schedules hereto) and not merely to the
specific section, paragraph or clause in which such word appears. All
references herein to Articles, Sections, Exhibits and Schedules shall be
deemed references to Articles and Sections of, and Exhibits and Schedules to,
this Agreement unless the context shall otherwise require. The words
"include," "includes" and "including" shall be deemed to be followed by the
phrase "without limitation." The definitions given for terms in this _Article
XIV_ and elsewhere in this Agreement shall apply equally to both the singular
and plural forms of the terms defined. Whenever the context may require,
any pronoun shall include the corresponding masculine, feminine and neuter
forms. Except as otherwise expressly provided herein, all references to
"dollars," "$" or "$" shall be deemed references to the lawful money of
the United States. The use of "or" is not intended to be exclusive unless
expressly indicated otherwise.

  



  

   

 | -51-| 
---|---|--- 

 



    



  

14.2. _Certain Terms_.

  



  

     

(a) Capitalized terms not defined elsewhere herein shall have the
following meanings ascribed to them below:

  



  

"Affiliate" means, at the time of determination: (i) any Person that directly
or indirectly through one (1) or more intermediaries controls, is controlled
by or under common control with the Person specified; (ii) any director,
manager (to the extent the Person is a limited liability company), officer or
Subsidiary of the Person specified; and (iii) any spouse, parent, child,
sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-
in-law or sister-in-law of the Person specified. The term
"control" (including, with correlative meaning, the terms "controlled by" and
"under common control with"), as used with respect to any Person, shall mean
the possession, directly or indirectly, of the power to elect a majority of
the board of directors (or other governing body) or to direct or cause the
direction of the management and policies of such Person, whether through the
ownership of voting Securities, by Contract or otherwise. In any event and
without limiting the generality of the foregoing, any Person owning 10% or
more of the voting Securities of another Person shall be deemed to control
that Person.

  



  

"Annual Net Sales" means the combined Net Sales that occur within each Annual
Period.

  



  

"Books and Records" means, with respect to a Person, all records, documents,
lists and files relating to such Person, its assets and properties, and its
business, including executed originals (or copies of executed originals when
executed originals are not available) of all Tax Returns, Contracts, purchase
orders, sales orders, price lists, lists of accounts, customers,
suppliers, employees, contractors, consultants and other personnel, shipping
records, all product, business and marketing plans, sales and product
brochures, and catalogs and other sales literature and materials, historical
sales data and all books, ledgers, files, financial statements and other
financial and accounting records (and related work papers and correspondence
from accountants), minute books, deeds, title policies, computer files,
programs and retrieved programs, environmental studies and plans and
business records, in each case, whether in hard copy, electronic form or
otherwise.

  



  

"Business" means any and all uses of the Product to diagnose, treat or cure
any disease in humans including any conditions involving the central nervous
system, such as Attention Deficit Hyperactivity Disorder, 22q11 deletion or
duplication syndrome, anxiety, schizophrenia, Tourette's Syndrome, other
behavioral disorders and other cognition-related disorders.

  



  

"Business Day" means any day that is not a Saturday, a Sunday or other day on
which banks are required or authorized by law to be closed in Philadelphia,
Pennsylvania.

  



  

"CHOP Patent Rights" has the meaning set forth in the CHOP License Agreement.

  



  

"Claim" means any written or oral demand, claim, complaint, suit, action,
cause of action, investigation, proceeding or notice by any Person alleging
actual or potential Liability for any Loss, or for any Default under any Law,
Contract, Permit, Employee Benefit Plan or other instrument or agreement,
including any written or oral demand, claim, complaint, suit, action, cause of
action, investigation, proceeding or notice which may be subject to errors
and omissions (or similar) insurance or otherwise relate to the professional
competence of the Company's employees.

  



  

   

 | -52-| 
---|---|--- 

 



    



  

"Code" means the Internal Revenue Code of 1986 and the rules and regulations
promulgated thereunder, as amended and supplemented from time to time, or any
successors thereto.

  



  

"Commercialize" means activities constituting marketing, promoting,
distributing, offering for sale and selling the Product.

  



  

"Commercially Reasonable Efforts" means the carrying out of activities in a
sustained and diligent manner and using efforts and resources that are
comparable to the efforts and resources commonly used by a company with
similar resources as the Purchaser, for products or services of similar
market potential at a similar stage of development or product life, based on
conditions then prevailing and taking account of competition, technological
relevance or obsolescence, changes in regulatory status and law and changes
in reimbursement rates, policies and procedures.

  



  

"Company Patent Rights" means (a) the Patent Rights listed in _Section_
_4.10(a)_ of the Disclosure Schedule; (b) any priority documents to which the
Patent Rights of subpart (a) claim priority; (c) any continuations
(including continuations-in-part solely to the extent of claims entirely
supported in the specification and entitled to the priority date of the
parent application), continued prosecution applications, substitutions,
divisions, extensions and term restorations, registrations, confirmations,
reexaminations, renewals or reissues of subpart (a) and (b) above; (d)
any corresponding foreign Patent Rights to the foregoing; (e) any patents
issuing on the foregoing; and (f) any existing or future Intellectual
Property owned or controlled by the Company, whether or not listed in _Section
4.10(a)_ of the Disclosure Schedule.

  



  

"Computer Software" means all computer software (including source and object
code), owned or licensed, whether for general business usage ( _e.g._ ,
accounting, word processing, graphics, spreadsheet analysis, etc.) or
specific, unique-to-the-business usage ( _e.g._ , order processing,
manufacturing, process control, design, shipping, etc.), all computer
operating security or programming software, owned or licensed, and all
documentation relating to any of the foregoing, excluding COTS Software.

  



  

"Consent" means any consent, approval, authorization, waiver, grant,
franchise, concession, certificate, exemption, Order,
registration, declaration, filing, report, or notice or exemption with or to
any Person.

  



  

"Consideration Shares" means Purchaser Common Shares, deliverable to the
Equityholders in accordance with their respective Pro Rata Share and the
Equityholder Instructions, based on Milestone Payments or Earnout Payments.

  



  

"Contemplated Transactions" means the sale and purchase of the LLC Equity
Interests hereunder and all of the transactions ancillary thereto which are
referred to in this Agreement.

  



    

 | -53-| 
---|---|--- 

 



    



  

"Contract" means, with respect to any Person, any contract, Lease, agreement,
instrument, undertaking or other commitment, whether written or oral, to
which such Person is, or such Person's properties, operations, business or
assets are, bound.

  



  

"Copyrights" means registered copyrights, copyright applications, mask works
and unregistered copyrights.

  



  

"COTS Software" means software that is readily obtainable by the Company
under "shrink wrap," "click wrap" other "click through" or standard form
licensing agreement without material cost or expense.

  



  

"DEA" means the U.S. Drug Enforcement Administration.

  



  

"Default" means, with respect to a Contract, Order, Law, Employee Benefit
Plan, Organizational Document or other instrument or agreement, (i) a
violation, breach or default, (ii) the occurrence of an event that (with or
without the passage of time or the giving of notice or both) would constitute
a violation, breach or default, or (iii) the occurrence of an event, that
(with or without the passage of time or the giving of notice or both) would
give rise to a right of damages, specific performance, termination,
renegotiation or acceleration (including the acceleration of payment).

  



  

"Develop" means pre-clinical, clinical, CMC and regulatory activities
directed to obtaining the FDA's approval of a NDA of the Product.

  



  

"Employee Benefit Plan" means each "employee benefit plan" (as described in
Section 3(3) of ERISA), and any other written or unwritten deferred
compensation, pension, profit sharing, stock option, stock purchase, phantom
stock, restricted stock or other equity-based award, change of control,
severance or termination pay, savings, group insurance or retirement plan,
agreement, arrangement or policy, and all vacation pay, severance pay,
incentive compensation, commission, consulting, bonus and other
employee benefit or fringe benefit plans, policies or arrangements sponsored,
maintained by, contributed to or required to be contributed to by the Company
or any ERISA Affiliate or with respect to which the Company or any ERISA
Affiliate has any current or contingent Liability.

  



  

"Employees" means all of the following: (i) all persons who are active
employees of the Company on the Closing Date, including such employees who on
the Closing Date are on vacation, on a regularly scheduled day off from work,
or on temporary leave for purposes of jury duty or annual two (2) week
national service/military duty; (ii) employees of the Company who on the
Closing Date are on approved non-medical leaves of absence and for whom one
hundred eighty (180) calendar days or less have elapsed since their last day
of active employment; and (iii) employees of the Company who are on
disability or medical leave and for whom one hundred eighty (180) calendar
days or less have elapsed since their last day of active employment.

  



  

"Encumbrance" means, with respect to any asset, any security interest, lien,
encumbrance, pledge, mortgage, charge, conditional or installment sales
Contract, title retention Contract, transferability restriction, community
property or other spousal or partner interest or other burden of any nature
whatsoever attached to or adversely affecting such asset.

  



  

    

 | -54-| 
---|---|--- 

 



    



  

"Environmental Laws" means all Laws relating to pollution or protection of
the environment (including ambient air, surface water, groundwater, land, or
surface or subsurface strata) including Laws relating to emissions,
discharges, releases or threatened releases of pollutants, contaminants,
chemicals, petroleum, or industrial, toxic or hazardous substances or wastes
into the environment and Laws relating to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of any
of the foregoing including the Comprehensive Environmental Response,
Compensation and Liability Act, 42 U.S.C.  9601 _et. seq_. ("CERCLA"), the
Resource Conservation and Recovery Act, 42 U.S.C.  6901 _et. seq_., and the
rules and regulations promulgated under any of the foregoing, all as amended
and supplemented from time to time, and together with any successors thereto.

  



  

"Equity Interests" means the Legacy Equity Interests and the LLC Equity
Interests.

  



  

"ERISA" means the Employment Retirement Income Security Act of 1974 and the
rules and regulations promulgated thereunder, as amended and supplemented
from time to time, or any successors thereto.

  



  

"ERISA Affiliate" means any Person that is included with the Company in a
controlled group or affiliated service group under Sections 414(b), (c), (m)
or (o) of the Code.

  



  

[ *** ].

  



  

"FDA" means the United States Food and Drug Administration, or a successor
agency in the United States with responsibilities comparable to those of the
United States Food and Drug Administration.

  



  

"FDA Regulatory Filings" means all applications, submissions, reports or
other documents, submitted or required to submitted to the FDA, including but
not limited to NDAs, amendments or supplements to any such applications,
annual reports, safety reports, including adverse event reports,
establishment registrations, and listing of drugs reports.

  



  

"FDC Act" means the Federal Food, Drug and Cosmetic Act, as amended.

  



  

"First Commercial Sale" means, on a country-by-country basis, the first
commercial transfer or disposition for value of Product, Improved Product, or
NCE, as applicable, in such country to a Third Party by the Company, or any of
its Affiliates or sublicensees.

  



  

"GAAP" means generally accepted accounting principles in the United States.

  



  

  



  

  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



    

 | -55-| 
---|---|--- 

 



    



  

"Governmental Entity" means any court, tribunal, arbitrator, authority,
agency, commission, official or other instrumentality of the government of
the United States or of any foreign country, any state or any political
subdivision of any such government (whether state, provincial, county, city,
municipal or otherwise).

  



  

"Harper Indebtedness" means all amounts owed to Harper pursuant to that
certain Promissory Note issued by the Company to Harper and dated January 1,
2014.

  



  

"Hazardous Materials" means all explosive or regulated radioactive materials
or substances, hazardous or toxic substances, reactive, corrosive,
carcinogenic, flammable or hazardous pollutant or other substance, hazardous
wastes or chemicals, petroleum or petroleum distillates, natural gas or
synthetic gas, asbestos or asbestos containing materials and all other
materials or chemicals regulated pursuant to any Environmental Laws,
including any "hazardous substance" or "hazardous waste" as defined in
Environmental Laws, materials listed in 49 C.F.R. 172.101, materials defined
as hazardous pursuant to  101(14) of CERCLA, special nuclear or by product
material, as defined by the Atomic Energy Act of 1954, 42 U.S.C.A. 3011 et
seq. and the rules and regulations promulgated thereunder.

  



  

"Improved Product" means [ *** ].

  



  

"Indebtedness" means, with respect to a Person, any obligations of such
Person: (i) for borrowed money, including related fees and expenses; (ii)
evidenced by notes, bonds, debentures or similar instruments; (iii) for the
deferred purchase price of goods or services (other than trade payables or
accruals incurred in the ordinary course of business consistent with past
practices); (iv) all obligations under terms that are or should be, in
accordance with GAAP, as consistently applied by the Legacy Corporation in
accordance with past practices, recorded as capital leases; (v) Liabilities
in respect of unfunded vested benefits under any Employee Benefit Plan; or
(vi) in the nature of guarantees of the obligations described in _clauses (i)_
through _(v)_ above of any other Person.

  



  

"Indication" means (a) ADHD, (b) [ *** ], (c) chromosome 22q11.2
deletion or duplication, (d) [ *** ], (e) [ *** ], (f) [ *** ], (g) [
*** ], and (h) [ *** ].

   



  

"Intellectual Property" means, collectively, (i) all inventions (whether
patentable or unpatentable, whether or not reduced to practice, and whether
or not filed with the U.S. Patent and Trademark Office or a non-U.S. patent
office), all improvements thereto, and all Patents, and all foreign
counterparts thereof; (ii) all Trademarks, fictitious names, brand names,
brand marks, and corporate names, together with all translations,
adaptations, derivations, and combinations thereof, and all applications,
registrations, and renewals in connection therewith; (iii) all copyrightable
works, all Copyrights, and all applications, registrations, and renewals in
connection therewith; (iv) all mask works and all applications, registrations,
and renewals in connection therewith; (v) all trade secrets and confidential
business information (including ideas, research and development, know-how,
formulas, compositions, manufacturing and production processes and
techniques; technical data, designs, drawings, specifications, customer and
supplier lists, pricing and cost information, methods, schematics,
technology, discoveries and inventions; any biological, chemical,
biochemical, toxicological, pharmacological and metabolic material and
information relating thereto, formulation, clinical, analytical and stability
information and data; and business and marketing plans and proposals); (vi)
all Computer Software; (vii) all other proprietary rights; (viii) all copies
and tangible embodiments of any of the foregoing (in whatever form of medium);
(ix) any and all rights to sue for Claims and remedies against past, present
and future infringement, dilution or misappropriations of any or all of
the foregoing, and rights for priority and protection of interests therein
under the Laws of any jurisdiction; and (x) goodwill associated with any of
the foregoing.

  



  

  



  

  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



    

 | -56-| 
---|---|--- 

 



    

  



  

"Knowledge" or "to the Knowledge of" and any other similar phrase or
variation thereof means (i) in the case of any Legacy Stockholder, the actual
knowledge of such Legacy Stockholder, (ii) in the case of CHOP, the actual
knowledge of Bryan Wolff, Steve Biener, Andrew Hardy and Stephanie Laste, and
(iii) in the case of either the Legacy Corporation or the Company, the actual
knowledge and the knowledge, following such inquiries and investigations as
would be deemed appropriate by a reasonable businessperson engaged in a
business similar to the Business in the prudent management of his or her
business affairs, of Philip Harper and Hakon Hakonarson.

  



  

"Law" means, with respect to any Person, any applicable law, statute, treaty,
ordinance, rule, regulation, Order, pronouncement having the effect of law,
or other requirement of any Governmental Entity, including the Foreign Corrupt
Practices Act of 1977, and those covering safety, health, transportation,
bribery, securities regulation, insurance, record keeping, zoning, employment,
Tax, anti-discrimination, antitrust, wage and hour and price and wage control
matters, to which, in each of the foregoing cases, such Person is, or any of
such Person's properties, operations, business or assets are, bound or
subject.

  



  

"Lease" means any lease, agreement (whether verbal or written) or tenancy for
property or assets, together with all subleases, amendments, extensions,
addenda, assignments, waivers and all other rights of use and/or occupancy,
and Contracts and documents relating to any of the foregoing.

  



  

"Legacy Pro Rata Amount" means, with respect to each Legacy Stockholder, a
percentage set forth in _Exhibit A_ , which may be updated by the Legacy
Stockholders, in writing, with up to five (5) Business Days' prior notice.

  



  

"Legal Proceeding" means any audit, Claim or legal, administrative or other
similar proceeding by or before any Governmental Entity (including any self-
regulating organization) or arbitration or alternative dispute resolution
panel.

  



  

"Liabilities" means, without limitation, any direct or indirect liability,
Indebtedness, guaranty, endorsement, Claim, loss, damage, deficiency, cost,
expense, obligation or responsibility, fixed or unfixed, known or unknown,
asserted or unasserted, choate or inchoate, liquidated or unliquidated,
secured or unsecured.

  



    

 | -57-| 
---|---|--- 

 



    



  

"Listed Chemical" means any List I Chemical, List II Chemical, and Schedule
Listed Chemical Product as those terms are defined under the
Controlled Substances Act or regulations implemented by the DEA.

  



  

"Loss" or "Losses" means, with respect to any fact, event or circumstance,
including any Loss Event, any and all Liabilities, Encumbrances, penalties,
fines, settlements, or Claims, including reasonable attorneys', experts' and
accountants' fees, expenses and disbursements, consequential damages and
court costs in connection with any of the foregoing (including any costs of
defense incurred by an Indemnified Party in the event it is required or
entitled to defend a Third Party Claim under  _Section 8.4(b)(i))_ , incurred
by a Person in connection with such fact, event or circumstance, including any
such Loss Event (including any of the foregoing arising out of events, facts
or circumstances that have occurred on or prior to the Closing Date, even
though the Claim in connection with such events, facts or circumstances may
not be filed or come to light until after the Closing Date); _provided,
however_ , that except in the case of any Third Party Claims, Losses shall not
include any damages based on punitive or special damages.

  



  

"Loss Event" means any fact, event or circumstance which has resulted in or is
reasonably likely to result in a Loss or a Third Party Claim.

  



  

"Material Adverse Effect" means, with respect to any event or circumstance,
an effect caused thereby or resulting change therefrom that is or could be
materially adverse as to, or in respect of, the condition (financial or
otherwise), business, operations, results of operations, prospects, affairs,
assets, capitalization, licenses, permits, rights or privileges (whether
contractual or otherwise) of a specified Person or Persons when taken as a
whole, including, any serious adverse events reported in connection with the
ongoing Phase 1b study of the Product.

  



  

"NCE" means [ *** ].

  



  

"NDA" means a New Drug Application or a Biologics License Application, as
applicable, as defined in the FDC Act or United States Public Health Services
Act, as each may be amended from time to time, or any rules, regulations and
requirements promulgated thereunder (including all additions, supplements,
extensions, and modifications thereto) or any similar foreign application.

  



  

"Net Sales" means the gross amount invoiced or otherwise billed by the
Company or its Affiliates or sublicensees (the "Selling Party") for sales of
Products, Improved Products, or NCEs, as applicable, to a Third Party
purchaser from and after the Closing Date, less the following to the extent
reasonable and customary (collectively, "Net Sales Deductions"):

  



  

(a) [ *** ];

  



  



  

  

***Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



    

 | -58-| 
---|---|--- 

 



    



  

(b) [ *** ];

  



  

(c) [ *** ];

  



  

(d) [ *** ]; and

  



  

(e) [ *** ];

  



  

provided that all of the foregoing deductions shall be calculated in
accordance with then-current GAAP or international financial reporting
standards, consistently applied during the applicable calculation period
throughout the Selling Party's organization. To the extent that Net Sales
Deductions are based on estimates, such estimates will be adjusted to actual
on a periodic basis. Notwithstanding the foregoing, the supply of the
Products, Improved Products, or NCEs for (i) samples, (ii) charitable
donations or compassionate use, or (iii) any clinical study materials used in
any clinical study shall not be included within the computation of Net
Sales; provided that such supply is provided at no cost.

  



  

A sale of Products, Improved Products, or NCEs is deemed to occur in
accordance with GAAP or international reporting standards, consistently
applied during the applicable calculation period throughout the Selling
Party's organization.

  



  

For sake of clarity and avoidance of doubt, the transfer of Products,
Improved Products, or NCEs by a Selling Party to another Affiliate of such
Selling Party or to a licensee or sublicensee of such Selling Party for
resale shall not be considered a sale; in such cases, Net Sales shall be
determined based on the amount invoiced or otherwise billed by such Affiliate
or licensee or sublicensee to an independent Third Party, less the Net Sales
Deductions allowed under this Section.

  



  

[ *** ].

  



  

"Order" means any judgment, order, writ, decree, injunction, award, ruling or
other determination whatsoever of any Governmental Entity or any other entity
or body (including any arbitration or similar panel) whose finding, ruling or
holding is legally binding or is enforceable as a matter of right (in any
case, whether preliminary or final).

  



  

"Organizational Documents" means, with respect to Person that is an entity,
the articles or certificate of incorporation or formation, bylaws, operating
agreement, certificate of partnership or other governing or constituent
documents of such Person.

  



  

"Patent Rights" means any of the following, whether existing now or in the
future anywhere in the world: issued patent, including inventor's
certificates, substitutions, extensions, confirmations, reissues, re-
examination, renewal or any like governmental grant for protection of
inventions, and any pending application for any of the foregoing.

  



  

  



  

  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



  

    

 | -59-| 
---|---|--- 

 



    



  

"Patents" means all letters patent and pending applications for patents of
the United States and all countries foreign thereto, and all similar
instruments, including any and all substitutions, regional patents,
certificates of invention and utility models, rights of license or otherwise
to or under letters patent, certificates of intention and utility models which
have been opened for public inspection and all reissues, renewals,
reexaminations, divisions, continuations, continuations-in-part, extensions
thereof, inventors' certificates, supplementary protection certificate
(SPCs), and patent term extensions (PTEs) or the like.

  



  

"Permit" means, with respect to any Person, any license, permit,
authorization, approval, certificates of authority, registration,
qualification, easement, rights of way or similar consent or certificate
granted or issued to such Person.

  



  

"Permitted Encumbrance" means: (i) any Encumbrance for Taxes not yet due and
payable; and (ii) any statutory Encumbrance arising in the ordinary course of
business by operation of Law with respect to a Liability that is not yet due
and payable as of the Closing Date.

  



  

"Person" means any natural person, corporation, general partnership, limited
partnership, limited liability company, proprietorship, joint venture, trust,
association, union, entity, or other form of business organization or any
Governmental Entity whatsoever.

  



  

"Phase III Clinical Trial" means a human clinical trial of a Product in an
indicated patient population that is designed to establish that such Product
is safe and efficacious for its intended use and to determine the benefit/risk
relationship, warnings, precautions, and adverse reactions that are
associated with such Product, which trial is intended to support marketing
approval of such Product, including all tests and studies that are required
by the FDA from time to time, pursuant to Law or otherwise, including the
trials referred to in 21 C.F.R. 312.21(c), as amended, [ *** ].

  



  

"Primary Indication" means an indication related to the treatment of
Attention Deficit Hyperactivity Disorder or 22q11 deletion or duplication
syndrome.

  



  

"Pro Rata Share" means, with respect to each Equityholder, a percentage set
forth in _Exhibit A_ , which may be updated by the Stockholder Representative
and CHOP, in writing, with up to five (5) Business Days' prior notice.

  



  

"Product" means [ *** ].

  



  

  

  



  

  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



  

    

 | -60-| 
---|---|--- 

 



    



  

"Proprietary Information" means at any date, any information of a Person,
that is not already generally available to the public (unless such
information has entered the public domain and become available to the public
through fault on the part of the Party to be charged hereunder), which
constitute trade secrets, personally identifiable financial information, or
personal health information under governing law, including: (i) financial
information, including information set forth in internal records, files and
ledgers, or incorporated in profit and loss statements, fiscal reports and
business plans; (ii) all financial data, pricing terms, information memoranda
and due diligence reports relating thereto; (iii) technology and e-commerce
strategies, business plans and implementations, inventions, algorithms,
computer hardware, software and applications (including but not limited to any
Computer Software); (iv) all internal memoranda and other office records,
including electronic and data processing files and records; (v) regulatory
data packages including pediatric data package exclusivity extensions or the
like; and (vi) any other information constituting a trade secret under the
governing trade secrets law.

  



  

"Purchaser Common Shares" means shares of Purchaser Common Stock.

  



  

"Purchaser Common Stock" means the common stock, par value $0.0001 per share,
of Purchaser.

  



  

"Purchaser Stock Price" means the lower of (a) the closing price of Purchaser
Common Stock as reported by the NYSE MKT exchange on the Business Day
immediately prior to the issuance of such Purchaser Common Stock, and (b) an
amount equal to the volume weighted average price for Purchaser Common Stock
as reported by the NYSE MKT for the ten (10) Trading Days immediately prior to
the date of the occurrence of the applicable Milestone Event.

  



  

"Real Property" means any real estate or interest therein, together with all
buildings, improvements, fixtures, easements, options to acquire real estate
or interest therein, rights to unpaid insurance proceeds in respect of losses
related to real estate, rights to unpaid condemnation awards and all other
rights in or appurtenant thereto.

  



  

"Register," "Registered," and "Registration" refer to a registration effected
by preparing and filing a Registration Statement in compliance with the
Securities Act, and the declaration or ordering of effectiveness of such
Registration Statement or document by the SEC.

  



  

"Registered Intellectual Property" means Patents, patent rights,
registrations for and applications to register, Trademarks, domain names, and
Copyrights.

  



  

"Registrable Securities" means the Purchaser Common Stock issuable as
Milestone Consideration or other securities issued as (or issuable upon the
conversion or exercise of any warrant, right or other security which is issued
as) a dividend or other distribution with respect to, or in exchange for or
in replacement of, the Purchaser Common Stock by way of stock dividend, stock
split or in connection with a combination of shares, recapitalization or
other reorganization or otherwise. Notwithstanding the foregoing, as to
any particular Purchaser Common Stock or other securities described above,
once issued they shall cease to be Registrable Securities when (1) a
registration statement with respect to the sale of such securities shall have
become effective under the Securities Act and such securities shall have been
disposed of in accordance with such registration statement, (2) they shall
have been distributed pursuant to Rule 144 (or any successor provision) under
the Securities Act, or (3) such securities may be sold without
volume restrictions pursuant to Rule 144, as determined by the counsel to
Purchaser pursuant to a written opinion letter to such effect, addressed and
acceptable to Purchaser's transfer agent.

  



    

 | -61-| 
---|---|--- 

 



    

  



  

"Registration Holder Indemnitee" is defined in _Section 11.5(a)_.

  



  

"Registration Indemnified Party" is defined in _Section 11.5(c)_.

  



  

"Registration Indemnifying Party" is defined in _Section 11.5(c)_.

  



  

"Registration Period" is defined in _Section 11.3(a)_.

  



  

"Registration Statement" means a Registration Statement filed pursuant to the
Securities Act.

  



  

"Regulatory Approval" means the approval of the applicable Regulatory
Authority necessary for the testing, commercial manufacture, distribution,
marketing, promotion, offer for sale, use, import, export and sale of a
Product in a regulatory jurisdiction in the Territory, including, where
required, separate pricing and/or reimbursement approvals.

  



  

"Regulatory Authority" means any applicable supranational, national,
regional, state or local regulatory agency, department, bureau, commission,
council or other government entity involved in granting of Regulatory Approval
for a Product in a jurisdiction within the Territory, including, without
limitation, the FDA.

  



  

"Related Party Agreement" means a Contract with any current or former
equityholder, director, manager or officer of the Legacy Corporation, the
Company or any of their respective Affiliates (other than the CHOP License
Agreement).

  



  

"Relevant Group" means any affiliated, combined, consolidated, unitary or
similar group.

  



  

"Reporting Period" means each twelve-month period ending December 31.

  



  

"Representatives" means, as to any Person, such Person's accountants,
counsel, consultants (including actuarial, environmental and
industry consultants), officers, directors, managers, employees, agents and
other advisors and representatives.

  



  

"Restrictive Covenants" means the covenants of the Legacy Stockholders and
Equityholders contained in _Article X_.

  



  

"SEC Guidance" means (i) any publicly available written guidance, or rule of
general applicability of the SEC staff, or (ii) written
comments, requirements or requests of the SEC staff to Purchaser in
connection with the review of a Registration Statement.

  



  

"Securities" means, with respect to a Person that is an entity, any shares of
capital stock, membership interests, options, warrants, notes, bonds or other
equity or debt securities of such Person which have ever been offered or sold
by such Person.

  



    

 | -62-| 
---|---|--- 

 



    



  

"Securities Act" means the Securities Act of 1933, as amended.

  



  

"Stockholder Representative" means Harper.

  



  

"Subsidiary" means any entity with respect to which a specified Person (or a
subsidiary thereof) owns a majority of the voting Securities or otherwise has
the power to vote or direct the voting of sufficient Securities to elect a
majority of the directors or managers.

  



  

"Tax Returns" means any return, declaration, report, Claim, or information
return or statement relating to Taxes, including any schedule or attachment
thereto, and including any amendment thereof.

  



  

"Taxes" means all federal, state, local, or foreign net or gross income,
gross receipts, net proceeds, sales, use, ad valorem, value added, franchise,
bank shares, withholding, payroll, employment, excise, property, deed, stamp,
alternative or add-on minimum, environmental, profits, windfall profits,
transaction, license, lease, service, use, occupation, severance, energy,
unemployment, social security, worker's compensation, capital, premium,
surplus lines, unclaimed property, or other taxes, assessments, customs,
duties, fees, levies, or other governmental charges of any nature whatever,
whether disputed or not, together with any interest, penalties, additions to
tax, or additional amounts with respect thereto.

  



  

"Term" means the Milestone Periods and the Earnout Periods.

  



  

"Territory" means worldwide, excluding Japan.

  



  

"Third Party" means any Person other than Purchaser, the Legacy Corporation,
the Company, the Legacy Stockholders, the Equityholders, the
Stockholder Representative, or an Affiliate of any of the foregoing.

  



  

"Trademarks" means registered and unregistered trademarks and service marks,
trademark and service mark applications, domain names, logos, trade names,
and trade dress.

  



  

"Transaction Documents" means, collectively, (a) this Agreement; (b) and all
other Contracts, instruments and certificates contemplated hereunder to be
delivered by any Party at or prior to the Closing.

  



  

"Transaction Expenses" means all of the costs, fees and expenses incurred by
a Party in connection with the investigating, pursuing, negotiating and
completing the Contemplated Transactions.

  



  

"Valid Claim" means a claim of (a) an issued and unexpired patent in CHOP
Patent Rights or Company Patent Rights, which claim has not been revoked or
held unenforceable, unpatentable or invalid by a decision of a court or other
governmental agency of competent jurisdiction, which is not appealable or has
not been appealed within the time allowed for appeal, and which has not been
abandoned, disclaimed, denied or admitted to be invalid or unenforceable
through reissue, re-examination or disclaimer or otherwise; or (b) a
patent application for a patent included within the CHOP Patent Rights or
Company Patent Rights, which is pending, which is being prosecuted in good
faith, and which claim has not been finally cancelled, withdrawn or abandoned.

  



  

   

 | -63-| 
---|---|--- 

 



    



  

(b) Each of the following terms is defined in the Section of this
Agreement set forth opposite such term in the table below:

  



     TERM  |   | SECTION 
---|---|--- 
   AGREEMENT  |   | PREAMBLE 
   ANNUAL PERIOD  |   | SECTION 2.3(a)(v) 
   AUDITED PARTY  |   | SECTION 2.5(g)(ii) 
   BANKRUPTCY AND EQUITY EXCEPTIONS  |   | SECTION 3.1 
   BASE PURCHASE PRICE  |   | SECTION 2.1 
   CHOP  |   | PREAMBLE 
   CHOP LICENSE AGREEMENT  |   | BACKGROUND 
   CLOSING  |   | SECTION 6.1 
   CLOSING DATE  |   | SECTION 6.1 
   COMPANY  |   | PREAMBLE 
   CONSIDERATION  |   | SECTION 2.1 
   DISAGREEING PARTY  |   | SECTION 2.5(g) 
   DISCLOSURE SCHEDULE  |   | Article III 
   DISPUTED AMOUNT  |   | SECTION 8.4(c) 
   EARNOUT CONSIDERATION  |   | SECTION 2.4 
   EARNOUT PAYMENT  |   | SECTION 2.4 
   EARNOUT PERIOD  |   | SECTION 2.4 
   EQUITYHOLDER INDEMNITEES  |   | SECTION 8.3 
   EQUITYHOLDER INSTRUCTIONS  |   | SECTION 2.1 
   EQUITYHOLDERS  |   | BACKGROUND 
   EXCHANGE ACT  |   | SECTION 5.6 
   FINAL REPORTS  |   | SECTION 2.5(g)(iii) 
   FUNDAMENTAL REPRESENTATIONS  |   | SECTION 8.1(a)(ii) 
   HAKONARSON  |   | PREAMBLE 
   HARPER  |   | PREAMBLE 
   INDEMNIFIED PARTY  |   | SECTION 8.4(a) 
   INDEMNIFYING PARTY  |   | SECTION 8.4(a) 
   INDEMNITY NOTICE  |   | SECTION 8.4(a) 
   LEGACY CORPORATION  |   | PREAMBLE 
   LEGACY EQUITY INTERESTS  |   | BACKGROUND 
   LEGACY STOCKHOLDERS  |   | BACKGROUND 
   MATERIAL CONTRACT  |   | SECTION 4.11(a) 
   M/E DISPUTED ITEMS  |   | SECTION 2.5(g) 
   M/E NOTICE OF DISAGREEMENT  |   | SECTION 2.5(g) 
   M/E UNRESOLVED CHANGES  |   | SECTION 2.5(g) 
   MILESTONE CONSIDERATION  |   | SECTION 2.3(a) 
   MILESTONE EVENT  |   | SECTION 2.3(a) 
   



  

   

 | -64-| 
---|---|--- 

 



    



  

       TERM  |   | SECTION 
---|---|--- 
   MILESTONE PAYMENT  |   | SECTION 2.3(a) 
   MILESTONE PERIOD  |   | SECTION 2.3(a) 
   NCE  |   | SECTION 2.3(a)(iv) 
   NEGOTIATION PERIOD  |   | SECTION 7.8 
   NOTICE  |   | SECTION 13.5 
   OFFER  |   | SECTION 7.8 
   OFFERING DATE  |   | SECTION 2.3(a)(i) 
   OVERALL CAP  |   | SECTION 8.5(a) 
   PAYMENT STREAM  |   | SECTION 7.8 
   PAYMENT STREAM BUYER  |   | SECTION 7.8 
   PAYMENT STREAM SELLER  |   | SECTION 7.8 
   PARTY OR PARTIES  |   | PREAMBLE 
   [ *** ]  |   | [ *** ] 
   PRIVACY LAWS  |   | SECTION 4.10(d) 
   PRIVACY POLICIES  |   | SECTION 4.10(d) 
   PRODUCT REPORTS  |   | SECTION 2.5(b) 
   PROPERTY  |   | SECTION 4.8 
   PURCHASER  |   | PREAMBLE 
   PURCHASER INDEMNITEES  |   | SECTION 8.2 
   PURCHASER SEC DOCUMENTS  |   | SECTION 5.6 
   REGISTRATION HOLDER INDEMNITEE  |   | SECTION 11.5(a) 
   REGISTRATION INDEMNIFIED PARTY  |   | SECTION 11.5(c) 
   REGISTRATION INDEMNIFYING PARTY  |   | SECTION 11.5(c) 
   REGISTRATION PERIOD  |   | SECTION 11.3(a) 
   REORGANIZATION  |   | BACKGROUND 
   REPRESENTATION CAP  |   | SECTION 8.5(a) 
   RESTRICTED BUSINESS  |   | SECTION 10.2(b)(i) 
   RESTRICTED PERIOD  |   | SECTION 10.1 
   SARBANES-OXLEY ACT  |   | SECTION 5.6 
   SEC  |   | SECTION 5.6 
   SELLERS  |   | Article III 
   SETTLEMENT ARBITRATOR  |   | SECTION 2.5(g)(ii) 
   SURVIVAL DATE  |   | SECTION 8.1(b) 
   THIRD PARTY CLAIM  |   | SECTION 8.4(b) 
   THIRD PARTY CLAIM NOTICE  |   | SECTION 8.4(b)(i) 
   THRESHOLD AMOUNT  |   | SECTION 8.5(a) 
  



  

[SIGNATURE PAGES FOLLOW]

  



  

  



  

  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



  

    

 | -65-| 
---|---|--- 

 



    



  

IN WITNESS WHEREOF, the Parties have executed this Equity Interest Purchase
Agreement as of the date first written above.

  



  

       | MEDGENICS, INC. 
---|--- 
     |   | 
     | By:  | /s/ Michael Cola 
     | Print Name: Michael Cola 
     | Title: Chief Executive Officer 
     | 
     | NEUROFIX THERAPEUTICS, INC. 
     |   | 
     | By:  | /s/ Philip Harper 
     | Print Name: Philip Harper 
     | Title: President and CEO 
     | 
     | NEUROFIX, LLC 
     |   | 
     | By:  | /s/ Philip Harper 
     | Print Name: Philip Harper 
     | Title: Manager 
     | 
     | /s/ Philip Harper 
     | Philip Harper 
     | 
     | /s/ Hakon Hakonarson 
     | Hakon Hakonarson 
     | 
     | THE CHILDREN'S HOSPITAL OF 
     | PHILADELPHIA 
     |   | 
     | By:  | /s/ Madeline Bell 
     | Print Name: Madeline Bell 
     | Title: President and CEO 
    



  

 _\- Signature page to Equity Interest Purchase Agreement -_

  



    

 | | 
---|---|--- 

 



    



  

 _EXHIBIT A_

  



  

Allocation; Pro Rata Share

  



     Equityholder|   | Pro  Rata Share| 
---|---|---|--- 
   |   | | 
   The Legacy Corporation|   | | 80%| 
   |   | | | 
   CHOP|   | | 20%| 
    



  

  

Allocation; Legacy Pro Rata Amount

  



     Legacy Stockholder|   | Legacy Pro Rata Amount| 
---|---|---|--- 
   |   | | 
   Harper|   | | 50%| 
   |   | | | 
   Hakonarson|   | | 50%| 
   



    

 | | 
---|---|--- 

 



    



  

Exhibit A

  



  

Portions of this exhibit have been omitted and filed separately with the
Secretary of the Securities and Exchange Commission (the "Commission")
pursuant to an application for confidential treatment filed with the
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended. Such portions are marked as indicated below.

  



  

LICENSE AGREEMENT

  



  

BY AND BETWEEN

  



  

THE CHILDREN'S HOSPITAL OF PHILADELPHIA

  



  

AND

  



  

NEUROFIX, LLC

  



    

 | | 
---|---|--- 

 



    



  

TABLE OF CONTENTS

  



       |   | Page 
---|---|--- 
     |   | 
   ARTICLE 1  | DEFINITIONS   | 2 
     |   | 
   ARTICLE 2  | LICENSES AND OTHER RIGHTS   | 8 
   2.1  | Grant of License to Licensee   | 8 
   2.2  | Future CHOP IP  | 8 
   2.3  | Limitations on License and Option   | 9 
   2.4  | Grant of Sublicense by Licensee   | 9 
   2.5  | No Implied License   | 11 
   2.6  | No Development or Commercialization  Outside the Field   | 11 
   2.7  | Research License to CHOP   | 11 
   2.8  | [ *** ]  | 11 
     |   | 
   ARTICLE 3  | DILIGENCE   | 12 
   3.1  | Development Plan   | 12 
   3.2  | Diligence Events   | 12 
   3.3  | Progress Reports   | 13 
     |   | 
   ARTICLE 4  | FINANCIAL PROVISIONS  | 14 
   4.1  | Equity Issuance   | 14 
   4.2  | Milestone Payments  | 14 
   4.3  | Royalties   | 15 
   4.4  | Annual Maintenance Fees   | 15 
   4.5  | CHOP Sublicense Income  | 16 
   4.6  | Mode of Payment and Currency   | 16 
   4.7  | Royalty and CHOP Sublicense Income Reports    | 17 
   4.8  | Late Payments   | 17 
   4.9  | Default Payment   | 17 
   4.10  | Accounting  | 17 
   4.11  | Books and Records   | 17 
   4.12  | Audits  | 18 
   4.13  | Taxes   | 18 
  



  

  



  

  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



  

    

 | -i-| 
---|---|--- 

 



    



  

TABLE OF CONTENTS

  

(continued)

  



  

       |   | Page 
---|---|--- 
     |   | 
   ARTICLE 5  | INTELLECTUAL PROPERTY  | 18 
   5.1  | Patent Filing Prosecution and Maintenance  | 19 
   5.2  | Patent Costs  | 20 
   5.3  | Infringement  | 20 
   5.4  | Invalidity or Unenforceability Defenses  or Actions  | 22 
   5.5  | Litigation Costs and Expenses  | 23 
   5.6  | Patent Marking  | 23 
   5.7  | Confidentiality  | 23 
     |   | 
   ARTICLE 6  | REPRESENTATIONS, WARRANTIES AND COVENANTS  | 24 
   6.1  | Mutual Representations and Warranties  | 24 
   6.2  | CHOP Representations and Warranties  | 24 
   6.3  | Disclaimer of Representations and Warranties  | 24 
   6.4  | Covenants of Licensee  | 25 
     |   | 
   ARTICLE 7  | INDEMNIFICATION; INSURANCE AND LIMITATION  OF LIABILITY 
| 25 
   7.1  | Indemnification by Licensee  | 25 
   7.2  | Insurance  | 26 
   7.3  | LIMITATION OF LIABILITY  | 27 
     |   | 
   ARTICLE 8  | TERM AND TERMINATION  | 27 
   8.1  | Term  | 27 
   8.2  | Termination by Licensee for Convenience  | 28 
   8.3  | Termination by CHOP for Cause  | 28 
   8.4  | Effects of Termination  | 29 
     |   | 
   ARTICLE 9  | ADDITIONAL PROVISIONS  | 31 
   9.1  | Relationship of the Parties  | 31 
   9.2  | Third Party Beneficiary  | 31 
   9.3  | Use of Names  | 31 
   9.4  | No Discrimination  | 31 
   9.5  | Successors and Assignment  | 31 
   9.6  | Further Actions  | 32 
   9.7  | Entire Agreement of the Parties; Amendments  | 32 
   9.8  | Governing Law  | 32 
   9.9  | Dispute Resolution  | 32 
    

  



    

 | -ii-| 
---|---|--- 

 



    



  

TABLE OF CONTENTS

  

 (continued)

  



  

       |   | Page 
---|---|--- 
     |   | 
   9.10  | Notices and Deliveries  | 32 
   9.11  | Waiver  | 33 
   9.12  | Severability  | 33 
   9.13  | Interpretation  | 33 
   9.14  | Counterparts  | 33 
    

  



  

     Schedule 1.1  | Diligence Events and Achievement Dates 
---|--- 
   Schedule 1.4  | CHOP Patent Rights 
   Schedule 2.3.2  | Third Party Rights 
   Appendix A  | Purchase Agreement Appendix B Equity Issuance Agreement 
   Appendix C  | The Children's Hospital of Philadelphia-Patent and
Intellectual Property Policy Effective Date July 1, 2009 
    

  



    

 | -iii-| 
---|---|--- 

 



    



  

LICENSE AGREEMENT

  



  

This License Agreement (this "Agreement") is dated as of September 9, 2015
(the "Effective Date") by and between The Children's Hospital of
Philadelphia, a non-profit entity organized and existing under the laws of
the Commonwealth of Pennsylvania ("CHOP"), and neuroFix, LLC, a limited
liability company organized under the laws of the State of Delaware
("Licensee"). CHOP and Licensee may be referred to herein as a "Party" or,
collectively, as "Parties".

  



  

RECITALS:

  



  

WHEREAS, CHOP owns and controls certain innovative technology related to (a)
the Association of Rare Recurrent Genetic Variations to Attention-Deficit,
Hyperactivity Disorder ("ADHD") and Methods of Use Thereof for the Diagnosis
and Treatment of the same ("ADHD Technology") as disclosed in CHOP Invention
Disclosure No. [ *** ] (the "ADHD Disclosures") that was developed in the
course of research at CHOP by [ *** ] (the "ADHD Inventors"); (b) [ *** ];
(c) the diagnosis and treatment of [ *** ]; and (d) [ *** ], the
"Technology") [ *** ], the "Disclosures") [ *** ] the "Inventors");

  



  

WHEREAS, CHOP and Licensee entered into an Option Agreement effective May 7,
2013 covering a portion of the Technology;

  



  

WHEREAS, Licensee wishes to exercise its option and license from CHOP the
Technology and CHOP's intellectual property rights in the Technology, to
develop, manufacture and commercialize such Technology, all on the terms and
conditions of this Agreement;

  



  

WHEREAS, CHOP desires to license to Licensee the Technology and CHOP's
intellectual property rights in the Technology, in a manner that will benefit
the public and best facilitate the distribution of useful products and the
utilization of new technology, consistent with CHOP's missions and goals, all
on the terms and conditions of this Agreement;

  



  

NOW, THEREFORE, in consideration of the various promises and undertakings set
forth herein, the Parties agree as follows:

  



  

ARTICLE 1

  



  

DEFINITIONS

  



  

Unless otherwise specifically provided herein, the following terms shall have
the following meanings:

  



   | 1.1| "Achievement  Date" means, with respect to a Diligence Event,
the corresponding date such  Diligence Event is to be achieved as provided in
_Schedule 1.1_ attached hereto  subject to modification pursuant to Section
3.2.3 below.  
---|---|--- 
  



   | 1.2| "Affiliate"  means a Person that controls, is controlled by or
is under common control with a Party,  but only for so long as such control
exists. For the purposes of this Section 1.2, the  word "control" (including,
with correlative meaning, the terms "controlled  by" or "under the common
control with") means the actual power, either  directly or indirectly through
one or more intermediaries, to direct the management and  policies of such
Person or entity, whether by the ownership of more than fifty percent  (50%)
of the voting stock or interests of such entity, or by contract or
otherwise.  
---|---|--- 
  



  

  



  

  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



    

 | | 
---|---|--- 

 



    

  



     1.3  | "CHOP Know-How"  means all information, know-how and
knowledge relating to the development, manufacture and use of the Technology
disclosed  in the CHOP Patent Rights or the Disclosure and all other
information, know-how and knowledge Controlled by CHOP as of the  Effective
Date or at any time thereafter during the Term that relates to the Technology
or Compound, was Derived from the  Inventors and is reasonably necessary or
useful for the development, manufacture, commercialization or use of the
Product  in the Field, but excluding inventions covered by claims of CHOP
Patent Rights. 
---|--- 
     | 
   1.4  | "CHOP Patent Rights"  means (a) the Patent Rights listed in
_Schedule 1.4_ , (b) any priority documents to which the Patent Rights of
subpart  (a) claim priority, (c) any continuations (including continuations-
in-part solely to the extent of claims entirely supported  in the
specification and entitled to the priority date of the parent application),
continued prosecution applications, substitutions,  divisions, extensions and
term restorations, registrations, confirmations, reexaminations, renewals or
reissues of subpart  (a) above, (d) any Patent Rights created pursuant to
Section 5.1.1 or 5.1.2 of this License, (e) any corresponding foreign  Patent
Rights to the foregoing and (f) any patents issuing on the foregoing. CHOP
Patent Rights also include any Patent Rights  covering NFC-1 Trial IP
determined to be owned by CHOP. 
     | 
   1.5  | "Commercially Reasonable  Efforts" means the carrying out of
activities in a sustained and diligent manner and using efforts and
resources  that are comparable to the efforts and resources commonly used by
a company with similar resources as Medgenics, for products  or services of
similar market potential at a similar stage of development or product life,
based on conditions then prevailing  and taking account of competition,
technological relevance or obsolescence, changes in regulatory status and law
and changes  in reimbursement rates, policies and procedures. 
     | 
   1.6  | "Compound" means  [ *** ]. 
     | 
   1.7  | "Compound Know-How"  means any information related to the
Compound disclosed in the CHOP Patent Rights, but excluding inventions covered
by claims  of CHOP Patent Rights. 
     | 
   1.8  | "Confidential Information"  of a Party means (a) information
relating to the intellectual property, research, business, operations or
products of a Party  or any of its Affiliates, including any know-how, that
was or is disclosed by such Party to the other Party prior to or during  the
Term of this Agreement, or that otherwise becomes known to the other Party by
virtue of this Agreement, and (b) the terms  of this Agreement. 
     | 
   1.9  | "Controlled" means, with respect to intellectual  property
rights, that a Party or one of its Affiliates owns or has a license or
sublicense to such intellectual property rights  and has the ability to
provide to, grant a license or sublicense to, or assign its right, title and
interest in and to, such  intellectual property rights as provided for in
this Agreement without violating the terms of any agreement or other
arrangement  with any Third Party. 
   



  

  



  

 *** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



    

 | 2| 
---|---|--- 

 



    



     1.10  | "Derived" means,  in whole or in part, obtained, developed,
created, designed, derived or resulting from, based upon, enabled by,
containing,  incorporating, using or otherwise generated from. 
---|--- 
     | 
   1.11  | "Diligence Event"  means each of the events that Licensee is
expected to accomplish in the development of a Product as provided in
_Schedule  1.1_ attached hereto, as may be amended pursuant to Section 3.2.3. 
     | 
   1.12  | "Drug Approval Application"  means a New Drug Application or a
Biologics License Application for an Indication, as applicable, as defined in
the United  States Federal Food, Drug, and Cosmetic Act or United States
Public Health Services Act, as each may be amended from time  to time, or any
rules, regulations and requirements promulgated thereunder (including all
additions, supplements, extensions,  and modifications thereto) or any
similar foreign application. 
     | 
   1.13  | "FDA" means the  United States Food and Drug Administration,
and any successor or replacement agency. 
     | 
   1.14  | "Field" means  any commercial activities related to the methods
or therapies disclosed in the CHOP Patent Rights or CHOP Know-How, where 
such activities are for the diagnosis or treatment of an Indication. 
     | 
   1.15  | "First Commercial Sale"  means, on a country-by-country basis,
the first commercial transfer or disposition for value of Product in such
country to  a Third Party by Licensee, or any of its Affiliates or
Sublicensees. 
     | 
   1.16  | "Future CHOP IP"  means all discoveries and inventions relating
to diagnosis or treatment of a disease or disorder identified by [ *** ] in 
the Field or relating to other neurological or neurodevelopmental diseases and
disorders, including without limitations neurodegenerative  and
neuropsychiatric disorders, in each case that satisfy all of the following:
(a) are Controlled by CHOP, free from any  obligations to any Third Parties
(other than the United States Government, provided that any rights granted to
Future CHOP  IP hereunder will be subject to the rights of the United States
Government) and (b) are invented as a result of, or arising  out of the
research conducted at CHOP by Dr. Hakon Hakonarson or those under his control. 
     | 
   1.17  | "GAAP" means United  States generally accepted accounting
principles applied on a consistent basis. 
     | 
   1.18  | "Governmental Approval"  means, with respect to a Product in a
country or region, all approvals, licenses, registrations and authorizations
of the  relevant Governmental Body, if applicable, required for the
commercialization of such Product in such country. 
  



  



  

  

  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



    

 | 3| 
---|---|--- 

 



    



     1.19  | "Governmental Body" means any: (a) nation,  principality,
state, commonwealth, province, territory, county, municipality, district or
other jurisdiction of any nature;  (b) federal, provincial, state, local,
municipal, foreign or other government; (c) governmental or quasi-governmental
authority  of any nature (including any governmental division, subdivision,
department, agency, bureau, branch, office, commission, council,  board,
instrumentality, officer, official, representative, organization, unit, body
or entity and any court or other tribunal);  (d) multi-national or
supranational organization or body; or (e) individual, entity, or body
exercising, or entitled to exercise,  any executive, legislative, judicial,
administrative, regulatory, police, military or taxing authority or power of
any nature.  
---|--- 
     | 
   1.20  |

"Indication" means (a) ADHD, (b) [ *** ], (c) chromosome 22q11.2 deletion or
duplication, (d) [ *** ], (e) [ *** ], (f) [ *** ], (g) [ *** ], and (h) [ ***
].

    
     | 
   1.21  | "Law" or "Laws" means all  applicable laws, statutes, rules,
regulations, ordinances and other pronouncements having the binding effect of
law of any  Governmental Body. 
     | 
   1.22  | "Major Market" means the United States, the  United Kingdom,
France, Germany, Italy, Spain and Japan. 
     | 
   1.23  | "Medgenics" means Medgenics, Inc., a Delaware  corporation or
one of its Affiliates. 
     | 
   1.24  | "Net Sales" means the gross amount invoiced  or otherwise
billed by Licensee or its Affiliates or Sublicensees (the "Selling Party") for
sales of Product  to a Third Party purchaser from and after the Effective
Date, less the following to the extent reasonable and customary
(collectively,  "Net Sales Deductions"): 
  



  

(a) [ *** ];

  



  

(b) [ *** ];

  



  

(c) [ *** ];

  



  

(d) [ *** ]; and

  



  

(e) [ *** ];

  



  

provided that all of the foregoing deductions shall be calculated in
accordance with then-current GAAP or international financial reporting
standards, consistently applied during the applicable calculation period
throughout the Selling Party's organization. To the extent that Net
Sales Deductions are based on estimates, such estimates will be adjusted to
actual on a periodic basis. Notwithstanding the foregoing, the supply of the
Product for (i) samples, (ii) charitable donations or compassionate use, or
(iii) any clinical study materials used in any clinical study shall not be
included within the computation of Net Sales; provided that such supply is
provided at no cost.

  



  

A sale of a Product is deemed to occur in accordance with GAAP or
international reporting standards, consistently applied during the applicable
calculation period throughout the Selling Party's organization.

  



  

For sake of clarity and avoidance of doubt, the transfer of a Product by a
Selling Party to another Affiliate of such Selling Party or to a licensee or
sublicensee of such Selling Party for resale shall not be considered a sale;
in such cases, Net Sales shall be determined based on the amount invoiced or
otherwise billed by such Affiliate or licensee or sublicensee to an
independent Third Party, less the Net Sales Deductions allowed under this
Section.

   



  

[ *** ].

  



  

  



  

  

  

 *** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



  

    

 | 4| 
---|---|--- 

 



    

  

  



     1.25  | "NFC-1 Trial IP"  means all intellectual property arising
from the Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-
Blind, Placebo-Controlled  Dose Escalation Study of NFC-1 in Adolescents With
Attention-Deficit Hyperactivity Disorder (NFC1-GREAT) to the extent that  it
is owned by CHOP. 
---|--- 
     | 
   1.26  | "Patent Rights"  means any of the following, whether existing
now or in the future anywhere in the world: issued patent, including
inventor's  certificates, substitutions, extensions, confirmations, reissues,
re-examination, renewal or any like governmental grant for  protection of
inventions, and any pending application for any of the foregoing. 
     | 
   1.27  | "Person" means  any natural person, corporation, firm, business
trust, joint venture, association, organization, company, partnership or
other  business entity, or any government or agency or political subdivision
thereof. 
     | 
   1.28  | "Phase II" means  a human clinical trial of a Product, the
principal purpose of which is a determination of safety and efficacy in the
target  patient population, which is prospectively designed to generate
sufficient data that may permit commencement of pivotal clinical  trials,
including the trials referred to in 21 C.F.R. 312.21(b), as amended. 
     | 
   1.29  | "Phase III" means  a human clinical trial of a Product in an
indicated patient population that is designed to establish that such Product
is  safe and efficacious for its intended use and to determine the
benefit/risk relationship, warnings, precautions, and adverse  reactions that
are associated with such Product, which trial is intended to support marketing
approval of such Product, including  all tests and studies that are required
by the FDA from time to time, pursuant to Law or otherwise, including the
trials referred  to in 21 C.F.R. 312.21(c), as amended. 
     | 
   1.30  |

"Product" means  any (a) process, service or method that is (i) covered by or
Derived from CHOP Know-How, (ii) covered by a Valid Claim  or (iii) whose use
or practice would, absent the License, constitute an infringement, inducement
of infringement or contributory  infringement of any Valid Claim ("Method");
(b) article, composition, apparatus, substance, chemical  or any other
material that is (i) covered by or Derived from the CHOP Know-How, (ii)
covered by a Valid Claim or (iii)  whose manufacture, import, use offer for
sale or sale would, absent the License, constitute an infringement,
inducement  of infringement or contributory infringement of any Valid Claim;
or (c) service, article, composition, apparatus, chemical,  substance or any
other material made, used or sold by or utilizing or practicing a Method. 

  



  

     1.31  | "Purchase Agreement"  means the Equity Interest Purchase
Agreement by and among Medgenics, Licensee, CHOP and the other parties
thereto, a copy  of which is attached hereto as _Appendix A_. 
---|--- 
     | 
   1.32  | Reserved. 
  



    

 | 5| 
---|---|--- 

 



    



     1.33  | "Royalty Term"  means, with respect to each Product and
each country or other jurisdiction in the Territory, the period beginning on
the Effective  Date and ending on the later to occur of (a) the expiration,
invalidation or abandonment of the last CHOP Patent Rights that  include a
Valid Claim and (b) January 1, 2025. 
---|--- 
     | 
   1.34  | "Sale" means any  transaction for which consideration is
received or expected by Licensee, its Affiliates or Sublicensees for sale,
use, lease,  transfer or other disposition of a Product to or for the benefit
of a Third Party. For clarity, sale, use, lease, transfer  or other
disposition of a Product by Licensee or any of its Affiliates or Sublicensees
to another of these entities for resale  by such entity to a Third Party
shall not be deemed a Sale unless such Product is not ultimately resold. 
     | 
   1.35  | "Sublicensee"  means a Person (including any Affiliate) to
which a Sublicense is granted pursuant to the terms of Section 2.4. 
     | 
   1.36  | "Sublicense Documents"  means any and all agreements,
amendments or written understandings entered into with a Sublicensee
(including any of its Affiliates)  that are directly or indirectly related to
a Sublicense, CHOP Patent Rights, CHOP Know How or Product. For clarity, a
development  agreement or distribution agreement for a Product is a
Sublicense Document. 
     | 
   1.37  | "Sublicense Income"  means income received by Licensee or its
Affiliates in consideration for a Sublicense or other agreement providing the
right  to negotiate or obtain a Sublicense. Sublicense Income includes income
received from a Sublicensee in the form of license  issue fees, milestone
payments and the like but specifically excludes (a) royalties on the sale or
distribution of Product,  including royalties paid as a percentage of Net
Sales, and (b) payments received for funding research and development
services  pursuant to a written research and development agreement between
Licensee (or one of its Affiliates) and Sublicensee up to  the fair market
value of such services. 
     | 
   1.38  | "Tax" means all  taxes, duties, fees, premiums, assessments,
imposts, levies, rates, withholdings, dues, government contributions and
other  charges of any kind whatsoever, whether direct or indirect, together
with all interest, penalties, fines, additions to tax  or other additional
amounts, imposed by any Governmental Body. 
     | 
   1.39  | "Third Party"  means any Person other than CHOP, Licensee or
any of their respective Affiliates. 
     | 
   1.40  | "Third Party Royalties"  means any royalties Licensee has paid
to one or more Third Parties pursuant to one or more licenses to issued Patent
Rights  entered into by Licensee that is required to avoid infringement of
such issued Patent Rights in the manufacture, use, import  or sale of any
Product. 
     | 
   1.41  | "United States"  or "US" means the United States of America,
its territories and possessions. 
  



  

     1.42  | "USD" or "$"  means the lawful currency of the United
States of America. 
---|--- 
     | 
   1.43  | "Valid Claim"  means a claim of (a) an issued and unexpired
patent in CHOP Patent Rights which claim has not been revoked or held
unenforceable  or invalid by a decision of a court or governmental agency of
competent jurisdiction from which no further appeal can be taken  or has been
taken within the time allowed for appeal, and has not been abandoned,
disclaimed, denied or admitted to be invalid  or unenforceable through
reissue or disclaimer; or (b) a pending patent application that is included in
CHOP Patent Rights  which was filed and is being prosecuted in good faith,
and has not been abandoned or finally disallowed without the possibility  of
appeal. 
  

  



  

   

 | 6| 
---|---|--- 

 



    



     1.44  | Other Terms. The definition  of each of the following terms
is set forth in the section of the Agreement indicated below: 
---|--- 
  



     Defined  Term  |   | Section 
---|---|--- 
   ADHD  |   | Recitals 
   Adjustment Equity  |   | 4.1.2 
   Advance Payment  |   | 5.2.2 
   Agreement  |   | Preamble 
   Annual Maintenance Fee  |   | 4.4 
   [ *** ]  |   | 2.8 
   [ *** ]  |   | 5.1.2 
   Bankruptcy Action  |   | 8.3.4 
   CHOP  |   | Preamble 
   CHOP Indemnitees  |   | 7.1.1 
   CHOP Sublicense Income  |   | 4.5 
   Claimed Amount Due  |   | 8.3.5 
   Development Plan  |   | 3.1 
   Disclosure  |   | Recitals 
   Effective Date  |   | Preamble 
   Event Explanation  |   | 3.2.2 
   Equity Interest  |   | 4.1.1 
   Event Plan  |   | 3.2.2 
   Exclusive License  |   | 2.1.1 
   Financial Report  |   | 4.7 
   Founders  |   | 4.1.2 
   Infringement Notice  |   | 5.3.1 
   Inventor(s)  |   | Recitals 
   License  |   | 2.1.2 
   Licensee  |   | Preamble 
   Method  |   | 1.30 
   Milestone  |   | 4.2 
   Milestone Payment  |   | 4.2 
   [ *** ]  |   | 5.1.1 
    Non-Exclusive License  |   | 2.1.2 
   Option  |   | 2.2 
   Parties  |   | Preamble 
   Party  |   | Preamble 
   Patent Costs  |   | 5.2.1 
   Patent Termination Notice  |   | 5.2.2 
   Progress Report  |   | 3.3.1 
   Royalty  |   | 4.3.1 
   Sublicense  |   | 2.4.1 
   Sublicense Payment Percentage  |   | 4.5.1 
   Technology  |   | Recitals 
   Term  |   | 8.1 
  



  

  



  

  

  

  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



  

   

 | 7| 
---|---|--- 

 



    

  



  

ARTICLE 2

  



  

LICENSES AND OTHER RIGHTS

  



   | 2.1| Grant of License to Licensee.  
---|---|--- 
  



   | 2.1.1| Subject to the terms and conditions of this Agreement, CHOP 
hereby grants to Licensee an exclusive, worldwide, royalty-bearing right and
license  (with the right to sublicense as provided in, and subject to, the
provisions of Section  2.4) under CHOP Patent Rights and Compound Know-How to
make, have made, use, sell, offer  for sale, import and otherwise
commercially exploit Products in the Field during the  Term (the "Exclusive
License"). 
---|---|--- 
  



   | 2.1.2| Subject to the terms and conditions of this Agreement, CHOP 
hereby grants to Licensee a non-exclusive, worldwide, royalty-bearing right
and license  (with the right to sublicense as provided in, and subject to,
the provisions of Section  2.4) under CHOP Know-How (other than Compound
Know-How) to make, have made, use, sell,  offer for sale, import and
otherwise commercially exploit Products in the Field during  the Term (the
"Non-Exclusive License" and, together with the Exclusive  License, the
"License"). 
---|---|--- 
  



   | 2.2| Future CHOP IP. Subject to the terms and conditions of this 
Agreement, CHOP hereby grants to Licensee an exclusive option during the
Term  to negotiate an exclusive license to Future CHOP IP (the "Option"). 
Licensee may elect to exercise the option for a particular Future CHOP IP by
giving written  notice to CHOP no later than six (6) months after CHOP's
Office of Technology Transfer  provides a copy of the invention disclosure
for such Future CHOP IP to Licensee. CHOP  shall inform Licensee of any
Future CHOP IP within four (4) weeks of receipt by the CHOP  Office of
Technology Transfer of relevant disclosure and CHOP Office of Technology
Transfer  shall follow up such initial invention disclosure with notice of
any relevant Third Party  rights. Upon exercise of the option by Licensee
with respect to a particular Future CHOP  IP, the Parties shall negotiate in
good faith a license agreement for such Future CHOP  IP on terms comparable
to the terms of this Agreement and the Purchase Agreement (with  adjustments
for any differences in value between such Future CHOP IP and the
intellectual  property licensed hereunder) for a period ending on the later
of (a) three (3) months  after the date that the Licensee exercises its
option over such Future CHOP IP or (b)  six (6) months after CHOP's Office of
Technology Transfer provides a copy of the  invention disclosure for such
Future CHOP IP. The license agreement negotiation period  may be extended for
an additional three (3) months upon mutual written agreement of the  Parties,
after which and assuming the Parties do not enter into license or other
agreement,  all rights of Licensee relating to such Future CHOP IP under this
Agreement shall terminate. 
---|---|--- 
  



  

   | 2.3| Limitations on License and Option.  Notwithstanding anything to
the contrary in this Agreement: 
---|---|--- 
  



   | 2.3.1| CHOP retains the right under  CHOP Patent Rights and CHOP
Know-How for each of the following: (a) to conduct teaching,  educational,
research and patient care activities itself, (b) to conduct collaborations 
with and extend such rights to the following Persons for the purposes of
performing such  collaborations: not-for-profit, governmental, educational or
non-commercial Third Parties  and (c) for all purposes outside of the Field. 
---|---|--- 
  

  



   

    

 | 8| 
---|---|--- 

 



    

  



   | 2.3.2| The rights granted by CHOP to Licensee under this Agreement 
(including under Sections 2.1 and 2.2) are subject in all respects to the
obligations  of CHOP, if any, existing as of the Effective Date or imposed by
Law, including (a) any  rights and interests of any Government Agency
including all applicable provisions of  any license to the United States
Government executed by CHOP and any overriding obligations  to the United
States Government under 35 U.S.C. 200-212, as amended, applicable 
governmental implementing regulations, and any U.S. Government sponsored
research agreement  or other guidelines, including that products that result
from intellectual property funded  by the United States Government that are
sold in the United States be substantially manufactured  in the United
States, (b) human subject consents and other institutional review board-
related  limitations and (c) the Third Party rights as set forth on _Schedule
2.3.2_. The  rights granted by CHOP to Licensee under Section 2.2 shall be
subject in all respects  to the obligations of CHOP, if any, existing at the
time the applicable invention disclosure  is received by CHOP. 
---|---|--- 
  



   | 2.4| Grant of Sublicense by Licensee.  
---|---|--- 
  



   | 2.4.1| CHOP grants to Licensee the right to grant sublicenses, in 
whole or in part, under the License (each, a "Sublicense") subject  to the
terms and conditions of this Agreement and specifically this Section 2.4. 
---|---|--- 
  



   | 2.4.2| All Sublicenses will be (a) issued in writing, (b) to the 
extent applicable, include all of the rights of CHOP and require the
performance of obligations  due to CHOP (and, if applicable, the U.S.
Government under 35 U.S.C. 200-212)  contained in this Agreement, (c)
subject to the provisions of Section 2.3 and (d) shall  include no less than
the following terms and conditions: 
---|---|--- 
  



   | (a)| Reasonable  record keeping, audit and reporting obligations
sufficient to enable Licensee and CHOP  to reasonably verify the payments due
to Licensee and CHOP under such Sublicense and  to reasonably monitor such
Sublicensee's progress in developing and/or commercializing  Product,
provided that such obligations (including reporting and auditing
requirements)  shall be no less stringent that those provided in this
Agreement for Licensee.  
---|---|--- 
  



   | (b)| A  provision prohibiting Sublicensee from sublicensing its
rights under the Sublicense.  
---|---|--- 
  



  

   | (c)| Infringement  and enforcement provisions that do not conflict
with the restrictions and procedural  requirements imposed on Licensee and do
not provide greater rights to Sublicensee than  as provided in Sections 5.3
and 5.4.  
---|---|--- 
  



   | (d)| Confidentiality  provisions with respect to confidential
information of CHOP consistent with the restrictions  on Licensee in Section
5.7 of this Agreement.  
---|---|--- 
  



   | (e)| Covenants  by Sublicensee that are equivalent to those made by
Licensee in Section 6.4.  
---|---|--- 
  



   | (f)| A  requirement of indemnification of CHOP that is equivalent to
the indemnification of CHOP  Indemnities by Licensee under Section 7.1 of
this Agreement and providing that the CHOP  Indemnities are third party
beneficiaries of the Sublicense for purposes of such indemnification.  
---|---|--- 
  



    

 | 9| 
---|---|--- 

 



    



   | (g)| A  requirement of obtaining and maintaining insurance by
Sublicensee that is equivalent  to the insurance requirements of Licensee
under Section 7.2 of this Agreement, including  coverage under such insurance
of CHOP as provided in Section 7.2.  
---|---|--- 
  



   | (h)| A  provision providing that CHOP may assume the Sublicense
pursuant to Section 8.4.6 if  this Agreement is terminated.  
---|---|--- 
  



   | (i)| Restriction  on use of CHOP's names etc. consistent with Section
9.3 of this Agreement.  
---|---|--- 
  



   | (j)| A  requirement of antidiscrimination no less stringent than that
provided in Section 9.4  of this Agreement.  
---|---|--- 
  



   | (k)| requirement  that CHOP is a third party beneficiary of such
Sublicense.  
---|---|--- 
  



  

Should any sublicense attempted to be granted fail to include all of the
terms and conditions set forth in this Section 2.4.2, or is otherwise issued
lacking accordance with the terms and conditions set forth in this Section
2.4, Licensee shall promptly attempt to rectify by entering into a new
Sublicense Document meeting the necessary requirements. Any Sublicense that
does not include all of the terms and conditions set forth in this Section
2.4.2 or which is not issued in accordance with the terms and conditions set
forth in this Section 2.4, shall be considered null and void with no further
notice from CHOP.

  



   | 2.4.3| Within thirty (30) days after the execution of a Sublicense 
Document, Licensee shall provide a complete and accurate copy of such
Sublicense Document  to CHOP. Following receipt of such Sublicense Document,
CHOP shall promptly notify Licensee  of any alleged breach in Section 2.4.2. 
---|---|--- 
  



   | 2.4.4| When the public health and safety so require, in the
reasonable  opinion of CHOP, acting in good faith, and after written notice
to Licensee providing  Licensee a sixty (60) day opportunity to respond, CHOP
shall have the right to require  Licensee to grant Sublicenses to responsible
applicants, on reasonable terms in accordance  with this Agreement, unless
Licensee can reasonably demonstrate that the granting of  the Sublicense
would not materially improve or address the public health and safety issue. 
CHOP shall not require the granting of a Sublicense unless the responsible
applicant  has first negotiated in good faith with Licensee. 
---|---|--- 
  



  

   | 2.4.5| Licensee's granting of a Sublicense shall not relieve 
Licensee of any of its obligations under this Agreement. Licensee shall be
liable to  CHOP for any act or omission of an Affiliate or other Sublicensee
of Licensee that would  be a breach of this Agreement if performed or omitted
by Licensee, and Licensee shall  be deemed in breach of this Agreement as a
result of such act or omission. 
---|---|--- 
  



   | 2.5| No Implied License. Each Party acknowledges that the rights  and
licenses granted in this Agreement are limited to the scope expressly
granted.  Accordingly, except for the rights expressly granted under this
Agreement, no right,  title, or interest of any nature whatsoever is granted
whether by implication, estoppel,  reliance, or otherwise, by either Party to
the other Party. All rights with respect to  any know-how, patent or other
intellectual property right rights that are not specifically  granted herein
are reserved to the owner thereof. 
---|---|--- 
  



  

    

 | 10| 
---|---|--- 

 



    

  



   | 2.6| No Development or Commercialization Outside the Field.
Notwithstanding  anything to the contrary in this Agreement, Licensee shall
not, and shall ensure  that no Affiliates, either directly or through Third
Parties, develop or commercialize  any Product outside the Field, except to
the extent Licensee or its Affiliates have entered  into and maintain a
license agreement with CHOP on mutually agreeable economic and other  terms
governing such development or commercialization outside of the Field. 
---|---|--- 
  



   | 2.7| Research License to CHOP. Licensee hereby grants to CHOP,  a
non-exclusive, worldwide, fully paid up, royalty-free license under all
intellectual  property rights Controlled by Licensee to make and use the
Products for educational and  non-commercial research purposes. CHOP may
sublicense its rights under this Section 2.7  for its non-commercial
collaborations with and use by other not-for-profit, governmental,  non-
commercial scientific and educational entities. For the avoidance of doubt,
the granting  of such sublicenses by CHOP shall not require approval of
Licensee, provided that CHOP  shall notify Licensee of the existence of each
such sublicense. If CHOP requests that  Licensee provide it with reasonable
quantities of Products for educational and non-commercial  research purposes,
then the Parties shall discuss, in good faith, working collaboratively  to
provide such materials to CHOP for such purposes. In connection with such
supply,  upon request by Licensee, CHOP and Licensee shall enter into a
customary materials transfer  agreement with reasonable terms. 
---|---|--- 
  



   | 2.8| [ *** ]. 
---|---|--- 
  



  

  

ARTICLE 3

  

DILIGENCE

  



   | 3.1| Development Plan. 
---|---|--- 
  



   | 3.1.1| Within ninety (90) days of the Effective Date, Licensee shall 
submit to CHOP a development plan for the development and commercialization of
Products  for the first Indication in the United States, including timelines
for achievement of  activities thereunder consistent with the Diligence
Events (as revised or amended pursuant  to this Section, the "Development
Plan"). CHOP shall have a right  to consider and comment on the Development
Plan. While approval by CHOP is not required,  Licensee shall consider
comments by CHOP in good faith. 
---|---|--- 
  



   | 3.1.2| Licensee shall use Commercially Reasonable Efforts to perform 
the activities set forth in the Development Plan and to develop, market and
commercialize  Product in the United States identified in the Development
Plan. 
---|---|--- 
  



  

  



  

  

  

  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



  

    

 | 11| 
---|---|--- 

 



    



   | 3.2| Diligence Events. 
---|---|--- 
  



   | 3.2.1| Licensee shall use Commercially  Reasonable Efforts to achieve
each Diligence Event by the corresponding Achievement Date. 
---|---|--- 
  



   | 3.2.2| If Licensee believes that, despite using Commercially
Reasonable  Efforts, it will not achieve a Diligence Event by the
corresponding Achievement Date,  it may notify CHOP in writing in advance of
the relevant deadline. Licensee shall include  with such notice (a) a
reasonable explanation of the reasons for such failure ("Event  Explanation")
and (b) a reasonable, detailed, written plan for promptly achieving  a
reasonable extension in the applicable Achievement Date and/or amendment to
the applicable  Diligence Event ("Event Plan"). 
---|---|--- 
  



   | 3.2.3| If Licensee timely provides CHOP  with an Event Explanation
and Event Plan pursuant to Section 3.2.2 then: 
---|---|--- 
  



   | (a)| if  both the Event Explanation and Event Plan are reasonably
acceptable to CHOP, _Schedule  1.1_ shall be automatically amended to
incorporate the extended Achievement Date and/or  amended Diligence Event set
forth in the Event Plan; or  
---|---|--- 
  



   | (b)| if  either or both of the Event Explanation and Event Plan are
not reasonably acceptable  to CHOP, then CHOP shall provide notice to
Licensee explaining why the Event Explanation  or Event Plan is not
acceptable and Licensee shall have until the existing Achievement  Date to
provide CHOP with an updated Event Explanation and Event Plan that are
reasonably  acceptable to CHOP. If Licensee timely provides CHOP with an
updated Event Explanation  and Event Plan that are reasonably acceptable to
CHOP, _Schedule 1.1_ shall be automatically  amended to incorporate the
extended Achievement Date and/or amended Diligence Event set  forth in the
updated Event Plan.  
---|---|--- 
  



  

      | 3.2.4| If Licensee fails to timely provide CHOP with both an
Event  Explanation and Event Plan reasonably acceptable to CHOP pursuant to
Section 3.2.2, then  Licensee shall have until the existing Achievement Date
to achieve the applicable Diligence  Event. If Licensee fails to achieve a
Diligence Event by the Achievement Date, as may  be amended pursuant to
Section 3.2.3 and Licensee is no longer using Commercially Reasonable 
Efforts to do so, then CHOP shall have the termination right as set forth in
Section  8.3.1(b) with respect to all Indications other than any Indication
for which the Diligence  Event has been achieved. 
---|---|--- 
  



   | 3.3| Progress Reports. 
---|---|--- 
  



   | 3.3.1| Licensee, within ninety (90) days after the end of each
calendar  year basis, shall submit to CHOP a progress report for the
preceding calendar year (each,  a "Progress Report") covering Licensee's (and
any Affiliates'  and Sublicensees') activities related to the development of
all Products for each  Indication and the obtaining of Governmental Approvals
necessary for commercialization  of Products for each Indication. 
---|---|--- 
  



  

   

 | 12| 
---|---|--- 

 



    



   | 3.3.2| Each Progress Report must include  all of the following for
each Indication: 
---|---|--- 
  



   | (a)| Summary  of work completed, including comparison against the
prior year's Development Plan  Progress Report ;  
---|---|--- 
  



   | (b)| Status  of applications for Governmental Approvals, if
applicable;  
---|---|--- 
  



   | (c)| Key  scientific discoveries;  
---|---|--- 
  



   | (d)| Current  schedule of anticipated events or milestones, including
anticipated timeline for achievement  of Diligence Events;  
---|---|--- 
  



   | (e)| Commercialization  plans for Products, if applicable;  
---|---|--- 
  



   | (f)| An  updated listing of any and all Sublicenses granted by
Licensee; and  
---|---|--- 
  



   | (g)| The  names and addresses of all Sublicensees, and a current and
valid phone number and e-mail  address for a principal point of contact at
each such Sublicensee who is responsible  for administering the
Sublicensee.  
---|---|--- 
  



   | 3.3.3| Licensee shall report to CHOP the date of First Commercial 
Sale of Product in each country within sixty (60) days of its occurrence.
Following the  First Commercial Sale for a Product in a given country,
Licensee shall use Commercially  Reasonable Efforts to make such Licensed
Product reasonably accessible to the public  in such country. 
---|---|--- 
  



  

ARTICLE 4

  

 FINANCIAL PROVISIONS

  



   | 4.1| Equity Issuance. As partial  consideration for the License: 
---|---|--- 
  



   | 4.1.1| Licensee shall, contemporaneous with the execution of this 
Agreement and subject to the terms of the Equity Issuance Agreement in
substantially  the form attached hereto as _Appendix B_ , issue to CHOP an
ownership interest in  Licensee ("Equity Interest") that is equal to twenty
percent (20%)  of all securities of Licensee outstanding on a fully diluted
basis as of the Effective  Date, assuming the exercise, conversion and
exchange of all outstanding securities of  Licensee and that Licensee is cash
free and debt free on date of issue of the Equity  Interest. If the
securities of Licensee are certificated, Licensee shall also, within  ten
(10) days of the Effective Date, deliver a stock certificate in the name of
CHOP  reflecting the Equity Interest. 
---|---|--- 
  



  

   | 4.1.2| If any securities of Licensee other than ownership interests 
that have already been issued as of the Effective Date have been or will be
issued to  the founders of Licensee (i.e., Mr. Harper or Dr. Hakonarson
collectively the "Founders")  as a group, in proportion to the original
allocation of securities to the Founders, or  without cash consideration
(other than nominal cash consideration), Licensee shall provide  to CHOP
twenty percent (20%) of such securities contemporaneous with the provision
of  such securities to the Founders ("Adjustment Equity"). For clarity, 
Adjustment Equity shall be issued at no additional consideration from CHOP and
Licensee  shall, if its securities are certificated, deliver a certificate in
the name of CHOP  reflecting the Adjustment Equity within thirty (30) days of
issuance of Adjustment Equity. 
---|---|--- 
 

  



  

   

 | 13| 
---|---|--- 

 



    

     

  

  



   | 4.1.3| If (a) any securities of Licensee other than ownership
interests  that have already been issued to the Founders as of the Effective
Date have been or will  be issued to the Founders for cash consideration
(other than nominal cash consideration)  or (b) Licensee wishes to conduct an
equity financing or a financing in which the offered  securities are
convertible into equity, then, in both cases (a) and (b), CHOP shall have 
the right to participate pari passu with the Founders in order to maintain its
twenty  percent (20%) ownership interest in Licensee. 
---|---|--- 
  



   | 4.1.4| The obligations of Licensee contained  in Sections 4.1.2 and
4.1.3 shall terminate and be of no effect upon the Closing (as  such term is
defined in the Purchase Agreement) of the transactions contemplated by the 
Purchase Agreement. 
---|---|--- 
  



   | 4.2| Milestone Payments. As additional consideration for the 
License, Licensee will pay CHOP the milestone payments (each, a "Milestone 
Payment") provided in the table below upon achievement of the corresponding 
milestone in the table below for the first Product for each Indication (each,
a "Milestone").  Licensee shall promptly notify CHOP in writing of the
achievement of any such Milestone  and Licensee shall pay CHOP in full the
corresponding Milestone Payment within thirty  (30) days of such achievement.
For clarity, each Milestone Payment is payable multiple  times (i.e., once
for each Indication). The Milestone Payments are non-refundable, and  are not
an advance against royalties due to CHOP or any other amounts due to CHOP. 
---|---|--- 
  



  

       |   | Milestone 
---|---|--- 
   Milestone  |   | Payment 
   [ *** ]  |   | $[  *** ] 
   [ *** ]  |   | $[  *** ] 
    



  

  

   | 4.3| Royalties. 
---|---|--- 
  



   | 4.3.1| As further consideration for the License, during the Royalty 
Term, Licensee shall pay to CHOP a non-refundable, non-creditable royalty as
set forth  in the table below (subject to the adjustment set forth in Section
6.4.1) on all Net  Sales of Product ("Royalty"). 
---|---|--- 
  



       |   | Percent of 
---|---|--- 
   Time  Period  |   | Net  Sales 
   [ *** ]  |   | [ *** ]% 
   [ *** ]  |   | [ *** ]% 
   [ *** ]  |   | [ *** ]% 
  



   | 4.3.2| [ *** ]:  
---|---|--- 
  



   | (a)| [ *** ];  and  
---|---|--- 
  



   | (b)| [ *** ].  
---|---|--- 
  



  

  



  

  

  

 *** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



  

   

 | 14| 
---|---|--- 

 



    



   | 4.3.3| Licensee must pay Royalties owed to CHOP on a calendar
quarter  basis within two months of the end of each calendar quarter (i.e.,
paid by Feb. 28, May  31, August 31 and Nov. 30 of each year). 
---|---|--- 
  



   | 4.4| Annual Maintenance Fees. Licensee shall pay to CHOP the  annual
maintenance fees ("Annual Maintenance Fees") set forth below  by each due
date in the table below for which such fee applies. The Annual Maintenance 
Fees paid for a calendar year shall be creditable against Royalties or
Milestone Payments  due in such calendar year. 
---|---|--- 
  



       |   | Annual 
---|---|--- 
   Due  Date  |   | Maintenance  Fee 
   [ *** ]  |   | $[ *** ] 
   [ *** ]  |   | $[ *** ] 
   [ *** ]  |   | $[ *** ] 
  



   | 4.5| CHOP Sublicense  Income.  
---|---|--- 
  



   | 4.5.1| Licensee will pay to CHOP [ *** ] (" Sublicense  Payment
Percentage") of Sublicense Income  within 30 days of receipt by Licensee,
subject to the following  adjustments, if applicable ("CHOP Sublicense
Income"). If a  Sublicense Document includes the grant to Sublicensee  of
rights to Licensee-owned Patent Rights in addition to  CHOP Patent Rights
and/or CHOP Know-How, the Sublicense Payment Percentage  shall: (a) remain [
*** ] if such Sublicense  document is executed before the third anniversary 
of the Effective Date, (b) be [ *** ] if such Sublicense  document is
executed on or after the third anniversary  of the Effective Date but before
the sixth anniversary of the Effective Date and (c)  be [ *** ] if such
Sublicense document is executed on or after the sixth anniversary  of the
Effective Date. 
---|---|--- 
  



  

   | 4.5.2| To the extent required by the Agreement between Licensee  and
Nippon Shinyaku Co., Ltd ("Nippon Shinyaku") dated November 13,  2013,
Licensee may grant a Sublicense to Nippon Shinyaku in the territory of Japan
that  does not require the payment of royalties or fees and, in such case,
sales by Nippon  Shinyaku in Japan shall not be included for purposes of the
calculation of Royalties  owed to CHOP hereunder, no Sublicense Income shall
be collected by Licensee, and, accordingly,  no CHOP Sublicense Income shall
be payable to CHOP. 
---|---|--- 
 



  

  



  

  

  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



  

    

 | 15| 
---|---|--- 

 



    

  

  



   | 4.6| Mode of Payment and Currency. All payments to CHOP hereunder 
must be made in USD in the requisite amount to "The Children's Hospital  of
Philadelphia Research Institute" by one of the following delivery methods
(subject  to updates pursuant to Section 9.10): 
---|---|--- 
  



     _By  ACH/Wire to:_   |   | _By  Check (lockbox) to:_ 
---|---|--- 
   Wells Fargo Bank, N.A.  |   | The Children's Hospital of
Philadelphia  Research 
   ABA #031201467  |   | Institute 
   (domestic wires)  |   | Lock Box #1457 
   SWIFT CODE: PNBPUS33  |   | P.O. Box 8500 
   (international wires only)  |   | Philadelphia, PA 19178-1457 
   Account Number: 2000049262603  |   | Attention: Director of Research
Finance 
   Payment must include the necessary  amount  |   | Reference: CHOP OTT
Technology 0494 
   to cover any bank charges incurred  |   | 
  



  

If payment is made by ACH/Wire, notice of payment including confirmation of
wire transfer must be provided to:

  



  

The Children's Hospital of Philadelphia Research Institute

  

Colket Translational Research Building

  

3501 Civic Center Blvd, Suite 2200

  

Philadelphia, PA 19104-4319

  

Attention: Director of Research Finance

  

Reference: CHOP OTT Technology 0494

  



  

All Royalties and other payments payable shall be calculated first in the
currency of the jurisdiction in which payment was made, and if not in the
United States, then converted into USD. The exchange rate for such conversion
shall be the average of the rate quoted in The Wall Street Journal, Eastern
Edition for the last business day of each month in the calendar quarter for
such Royalty or other payment made.

  



   | 4.7| Royalty and CHOP Sublicense Income Reports. Within sixty  (60)
days after the end of each calendar quarter (i.e. Feb. 28, May 31, August  31
and Nov. 30), Licensee shall deliver to CHOP a report ("Financial Report") 
setting out all details necessary to calculate the Royalty and CHOP Sublicense
Income  due under this Article 4 for such calendar quarter, including: 
---|---|--- 
  



  

  

      | 4.7.1| Number of each Product Sold by  Licensee, its Affiliates
and Sublicensees in each country, the corresponding name of  each such
Product; 
---|---|--- 
  



   | 4.7.2| Gross sales and Net Sales of  each Product made by Licensee,
its Affiliates and Sublicensees; 
---|---|--- 
  



   | 4.7.3| Royalties; 
---|---|--- 
  



   | 4.7.4| Sublicense Income and the calculation  of CHOP Sublicense
Income; 
---|---|--- 
  



   | 4.7.5| The method and currency exchange  rates (if any) used to
calculate the Royalties and CHOP Sublicense Income; 
---|---|--- 
  



   | 4.7.6| A specification of all deductions  and their dollar value that
were taken to calculate Net Sales; and 
---|---|--- 
  



    

  

   

 | 16| 
---|---|--- 

 



    



   | 4.7.7| A list of all countries in which  Product is being
manufactured. 
---|---|--- 
  



   | 4.8| Late Payments. In addition to any other remedies available  to
CHOP, including the right to terminate this Agreement, any failure by
Licensee  to make a payment within thirty (30) days after the date when due
shall obligate Licensee  to pay computed interest, the interest period
commencing on the due date and ending on  the actual payment date, to CHOP at
a rate per annum equal to the average of the United  States Prime Rate as
published by the Wall Street Journal, Eastern Edition, plus an additional 
one percent (1.0%) per month calculated for the period of the delinquent
payment, or  the highest rate allowed by Law, whichever is lower. The
interest rate shall be adjusted  with changes to the reference rate published
by the Wall Street Journal, Eastern Edition,  and interest shall be
calculated daily and compounded monthly in arrears. 
---|---|--- 
  



   | 4.9| Default Payment. In the event of default in payment of any 
payment owing to CHOP under the terms of this Agreement, and if it becomes
necessary  for CHOP to undertake legal action to collect said payment,
Licensee shall pay reasonable,  documented legal fees and costs incurred in
connection therewith. 
---|---|--- 
  



   | 4.10| Accounting. Licensee shall calculate all amounts, and perform
other accounting procedures required, under this Agreement and applicable to
it in accordance with GAAP.  
---|---|--- 
  



   | 4.11| Books and Records. Licensee will keep accurate books and
records of all Products developed, manufactured, used or sold and all
Sublicenses, collaboration agreements and joint venture agreements entered
into by Licensee that involved CHOP Patent Rights and/or CHOP Know-How.
Licensee will preserve these books and records for at least six (6) years
from the date of the Financial Report to which they pertain. Upon
reasonable notice, the books and records will be open to examination by
representatives or agents of CHOP during regular office hours to determine
their accuracy and assess Licensee's compliance with the terms of this
Agreement, provided that Licensee shall not have an obligation to provide
access more than once in any given twelve (12) month period, other than for
cause.  
---|---|--- 
  



  

   | 4.12| Audits.  
---|---|--- 
  



   | 4.12.1| Licensee agrees to conduct an independent audit of
the relevant records of Licensee pertaining to the calculation of any
Royalties and CHOP Sublicense Income due to CHOP under this Agreement at
least every two years if annual sales of the Licensed Product or Licensed
Processes are over fifty million dollars ($50,000,000). Such audit shall
address, at a minimum, the amount of gross sales by or on behalf of Licensee
during the audit period, the amount of Sublicense Income, the amount of funds
owed to CHOP under this Agreement, and whether the amount owed has been paid
to CHOP and is reflected in the records of the Licensee. A report by the
auditor shall be submitted promptly to CHOP on completion. Licensee shall pay
for the entire cost of such audit.  
---|---|--- 
  

  



  

   

 | 17| 
---|---|--- 

 



    



  

       | 4.12.2  | In addition to the right of CHOP to examine the
books and records as provided in Section 4.9 and the periodic audit required
in Section 4.12.1, CHOP, at its own cost, through an independent auditor
reasonably acceptable to Licensee (and who has executed an appropriate
confidentiality agreement reasonably acceptable to Licensee that requires the
auditor to keep any information learned by it confidential except as needed to
report its audit conclusions to CHOP), may inspect and audit the relevant
records of Licensee pertaining to the calculation of any Royalties and CHOP
Sublicense Income due to CHOP under this Agreement. Licensee shall provide
such auditors with access to the records during reasonable business hours.
Such access need not be given to any such set of records more often than once
each year. CHOP shall provide Licensee with written notice of its election to
inspect and audit the records related to the royalty due hereunder not less
than thirty (30) days prior to the proposed date of review of Licensee's
records by CHOP's auditors. Should the auditor find any underpayment of
Royalties or CHOP Sublicense Income by Licensee, Licensee shall (a) promptly
pay CHOP the amount of such underpayment, and shall reimburse CHOP for the
cost of the audit, should such underpayment equal or exceed five percent (5%)
of Royalties or CHOP Sublicense Income paid during the time period audited,
and (b) provide such auditors with an audit right exercisable within six (6)
months after Licensor receives the audit report. If the auditor finds
overpayment by Licensee, then Licensee shall have the right to deduct the
overpayment from any future royalties due to CHOP by Licensee or, if no such
future royalties are payable, then CHOP shall refund the overpayment to
Licensee within thirty (30) days after Licensor receives the audit report.
Licensee may designate competitively sensitive information which such auditor
may see and review but which it may not disclose to Licensor; provided,
however, that such designation shall not restrict the auditor's investigation
or conclusions. 
---|---|--- 
  



   | 4.13| Taxes. All payments made by Licensee under the Agreement shall
be made free and clear of and without any deduction for or on account of any
Taxes.  
---|---|--- 
  



  

ARTICLE 5

  

INTELLECTUAL PROPERTY

  



   | 5.1| Patent Filing Prosecution and Maintenance.  
---|---|--- 
  



   | 5.1.1| CHOP Patent Rights, [ *** ].  Licensee shall be engaged [ ***
] as client, and CHOP shall be engaged by [ *** ] as an accommodated
party, each in accordance with an engagement letter reasonably satisfactory
to CHOP and Licensee. Licensee shall control all actions and decisions with
respect to the filing, prosecution and maintenance of such CHOP Patent Rights;
provided that Licensee may not take any actions that may adversely impact
such CHOP Patent Rights without CHOP's prior written approval and CHOP may
take any actions that are necessary to preserve rights if Licensee has failed
to do so in a timely fashion. In addition, Licensee will consider any
reasonable comments or suggestions by CHOP with respect to the filing,
prosecution and maintenance of such CHOP Patent Rights. Licensee will copy,
and will instruct [ *** ] to copy, CHOP on all correspondence related to such
CHOP Patent Rights (including all copies of patent applications, office
action, response to office action, request for terminal disclaimer, and
request for reissue or reexamination of any patent or patent application) and
to interact with CHOP in regards to the preparation, filing, prosecution and
maintenance of such CHOP Patent Rights. Licensee has the right to take any
action to preserve rights whether or not CHOP has commented, and will not
allow any such CHOP Patent Rights for which Licensee is licensed and is
underwriting the costs to lapse or become abandoned without providing at
least thirty (30) days prior written notice to CHOP and CHOP's
written authorization under this Agreement, except for filing of
continuations, divisionals, or the like that substitute for the
lapsed application. Control of CHOP Patent Rights (including the right to
control all actions and decisions with respect to the filing, prosecution and
maintenance) will revert to CHOP upon termination of this Agreement or upon
any decision by Licensee to terminate or abandon any CHOP Patent Rights in
accordance with Section 5.2.2 or otherwise. 
---|---|--- 
  

  



  

  



  

  

  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



  

   

 | 18| 
---|---|--- 

 



    

  



   | 5.1.2| CHOP Patent Rights [ *** ]. CHOP shall control all actions 
and decisions with respect to the filing, prosecution and maintenance of such
CHOP Patent  Rights and will consider any reasonable comments or suggestions
by Licensee with respect  to such. CHOP will instruct [ *** ] to copy
Licensee on all correspondence related to  such CHOP Patent Rights (including
all copies of patent applications, office action,  response to office action,
request for terminal disclaimer, and request for reissue or  reexamination of
any patent or patent application) and to interact with Licensee in regards 
to the preparation, filing, prosecution and maintenance of such CHOP Patent
Rights. CHOP  has the right to take action to preserve rights whether or not
Licensee has commented,  and will use reasonable efforts to not allow any
such CHOP Patent Rights for which Licensee  is licensed and is underwriting
the costs to lapse or become abandoned without Licensee's  written
authorization under this Agreement, except for filing of continuations,
divisionals,  or the like that substitute for the lapsed application. For
clarity, CHOP shall have  no requirement to file, prosecute, or maintain such
CHOP Patent Rights if Licensee is  not current with the Patent Cost
obligations as set forth in this Agreement. 
---|---|--- 
  



   | 5.1.3| Disagreements regarding the filing, prosecution, and
maintenance  of CHOP Patent Rights will be resolved by the Parties in favor
of preserving rights and  breadth of claim coverage. If there is a dispute
between the Parties relating to the  actions and decisions with respect to
the filing, prosecution and maintenance of CHOP  Patent Rights that cannot be
resolved based on the foregoing principle, then the dispute  shall first be
referred to the chief scientific officers of the Parties, who shall confer 
in good faith on the resolution of the issue. Any final decision mutually
agreed to by  the chief scientific officers shall be conclusive and binding
on the Parties. If the  chief scientific officers are not able to agree on
the resolution of any such issue within thirty (30) days after such issue was
first referred to them (or such shorter time period as may be required due to
filing, prosecution or maintenance deadlines), then, such dispute shall be
handled in accordance with Section 9.9; provided that while any such dispute
is ongoing, all actions will continue to be taken in favor of preserving
rights and breadth of claim coverage. 
---|---|--- 
  



  

   | 5.2| Patent Costs. 
---|---|--- 
  



   | 5.2.1| Within thirty (30) days of the Effective Date, Licensee will 
reimburse CHOP for all out-of-pocket costs incurred prior to the Effective
Date for the  filing, prosecution and maintenance of CHOP Patent Rights,
including all accrued attorney  fees, expenses, official and filing fees
("Patent Costs"). As of July  10, 2015, Patent Costs are approximately
$85,000 US dollars. 
---|---|--- 
  



   | 5.2.2| Licensee will bear all Patent Costs incurring during the Term.
Licensee shall pay [ ***  ] directly, and will reimburse CHOP for all costs
associated with [ *** ] preparation and prosecution of CHOP Patent  Rights,
as applicable, for any such Patent Costs within thirty (30) days of receipt of
each invoice.  
---|---|--- 
  



  

  



  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



  

    

 | 19| 
---|---|--- 

 



    

  



   | 5.2.3| Licensee may terminate its rights in, and obligations with 
respect to any or all of CHOP Patent Rights by providing written notice to
CHOP ("Patent  Termination Notice"). Termination of Licensee's rights in and
obligation  with respect to such Patent Rights will be effective six (6)
months after receipt of  such Patent Termination Notice by CHOP. In the event
of termination of less than the  full CHOP Patent Rights, the non-terminated
Rights remain subject to all terms of License.  CHOP will use reasonable
efforts to curtail Patent Costs chargeable to Licensee under  this Agreement
after the receipt of the Patent Termination Notice is received. CHOP may 
prosecute and maintain such Patent Rights at its sole discretion and expense,
and such  Patent Rights will thereafter not be subject to this Agreement,
including the License,  and Licensee will have no further rights or license
to them. 
---|---|--- 
  



   | 5.3| Infringement. 
---|---|--- 
  



   | 5.3.1| If either Party believes that an infringement by a Third 
Party with respect to any CHOP Patent Right in the Field is occurring or may
potentially  occur, the knowledgeable Party will provide the other Party with
(a) written notice of  such infringement or potential infringement and (b)
evidence of such infringement or  potential infringement (the "Infringement
Notice"). During the period  in which, and in the jurisdiction where,
Licensee has exclusive rights under this Agreement,  neither CHOP or Licensee
will notify such a Third Party (including the infringer) of  infringement or
put such Third Party on notice of the existence of CHOP Patent Rights 
without first obtaining the written consent of the other Party. Both CHOP and
Licensee  will use their diligent efforts to cooperate with each other to
terminate such infringement  without litigation. 
---|---|--- 
  



  

   | 5.3.2| If infringing activity of potential commercial significance
has  not been abated within ninety (90) days following the date the
Infringement Notice for  such activity was provided, then Licensee may
institute suit for patent infringement  against the infringer in the Field.
CHOP may voluntarily join such suit at Licensee's  reasonable expense, but
may not thereafter commence suit against the infringer for the  acts of
infringement that are the subject of Licensee's suit or any judgment
rendered  in such suit. Licensee may not join CHOP in a suit initiated by
Licensee without CHOP's  prior written consent. If in a suit initiated by
Licensee, CHOP is involuntarily joined  other than by Licensee, then Licensee
and CHOP may choose mutually agreeable co-counsel,  and Licensee will pay any
costs incurred by CHOP arising out of such suit, including  any legal fees of
co-counsel. If CHOP and Licensee choose to employ co-counsel, CHOP  and
Licensee each may engage separate counsel in addition to co-counsel, at the
engaging  Party's expense. Licensee shall be free to enter into a settlement,
consent judgment  or other voluntary disposition, provided that any
settlement, consent judgment or other  voluntary disposition that (a) limits
the scope, validity or enforcement of CHOP Patent  Rights or (b) admits fault
or wrongdoing on the part of Licensee or CHOP must be approved  in advance by
CHOP in writing. Licensee's request for such approval shall include  complete
copies of final settlement documents, a detailed summary of such settlement, 
and any other information material to such settlement. CHOP shall provide
Licensee notice  of its approval or denial within thirty (30) days of any
request for such approval by  Licensee, provided that, in the event CHOP
wishes to deny such approval, such notice  shall include a detailed written
description of CHOP's reasonable objections to  the proposed settlement,
consent judgment, or other voluntary disposition. 
---|---|--- 
 



  

    

 | 20| 
---|---|--- 

 



    

  



   | 5.3.3| If, within one hundred and twenty (120) days following the
date  the Infringement Notice was provided, infringing activity of potential
commercial significance  has not been abated and if Licensee has not brought
suit against the infringer, then  CHOP may, following consultation with and
good faith consideration of any Licensee comments,  and only if Licensee
fails to provide a reasonable basis for its decision, institute  suit for
patent infringement against the infringer. If CHOP institutes such suit,
then  Licensee may not join such suit without the prior written consent of
CHOP and may not  thereafter commence suit against the infringer for the acts
of infringement that are  the subject of CHOP's suit or any judgment rendered
in such suit. 
---|---|--- 
  



   | 5.3.4| Notwithstanding Sections 5.3.2 and 5.3.3, in the event that
any  CHOP Patent Rights are infringed by a Third Party (a) prior to the First
Commercial Sale  of a Product in the United States or (b) if any of the
infringed CHOP Patent Rights are  also licensed by CHOP to a Third Party,
prior to any enforcement action being taken by  either Party regarding such
infringement, the Parties shall discuss, and will mutually  agree, in
writing, as to how to handle such infringement by such Third Party. 
---|---|--- 
  



   | 5.3.5| In the event that any CHOP Patent Right in the Field is the
subject  of a Paragraph IV Certification (21 U.S.C.  355(j)(2)(B)(iv)) or
the like, Licensee  and CHOP will convene to mutually consider options for
response. In the event that CHOP  and Licensee cannot come to a mutually
agreeable response, Licensee will have unilateral  rights to determine how
and when respond. 
---|---|--- 
  



   | 5.3.6| Any recovery or settlement received in connection with any
suit  in the Field will first be shared by CHOP and Licensee equally to cover
any litigation  costs of co-counsel. Any remaining recoveries shall be
allocated as follows: 
---|---|--- 
  



  

   | (a)| For any portion of the recovery or settlement where Licensee was
a party in the litigation, other than for amounts attributable and paid as
enhanced damages for willful infringement:  
---|---|--- 
  



   | (i)| for any suit that is initiated by Licensee and in which CHOP was
not a party in the litigation, CHOP shall receive twenty five percent (25%) of
the recovery and Licensee shall receive the remainder; and  
---|---|--- 
  



   | (ii)| for any suit that is initiated by Licensee or CHOP and that the
other Party joins voluntarily (but only to the extent such voluntary joining
is allowed under this Agreement or expressly by the other Party in a separate
agreement) or involuntarily, the non-initiating party's percentage of the
total litigation costs incurred by CHOP and Licensee, but in no event shall
the non-initiating Party receive less than twenty five percent (25%) of such
recovery, while the initiating party shall receive the remainder.  
---|---|--- 
  



   | (b)| For any portion of the recovery or settlement paid as enhanced
damages for willful infringement where Licensee was a party in the
litigation:  
---|---|--- 
  



   | (i)| for any suit that is initiated by Licensee and in which CHOP was
not a party in the litigation, CHOP shall receive thirty percent (30%) and
Licensee shall receive the remainder; and  
---|---|--- 
  



  

    

 | 21| 
---|---|--- 

 



    



   | (ii)| for any suit that is initiated by Licensee or CHOP and the
other Party voluntarily but only to the extent such voluntary joining is
allowed under this Agreement or expressly by the other Party in a separate
agreement) or involuntarily, CHOP shall receive fifty percent (50%) and
Licensee shall receive the remainder.  
---|---|--- 
  



   | (c)| For any portion of the recovery or settlement received in
connection with any suit that is initiated by CHOP and in which Licensee was
not a party in the litigation, any recovery in excess of litigation costs
will belong to CHOP.  
---|---|--- 
  



   | 5.4| Invalidity or Unenforceability Defenses  or Actions. 
---|---|--- 
  



   | 5.4.1| Each Party shall promptly notify  the other Party in writing
of any alleged or threatened assertion of invalidity or unenforceability  of
any of the CHOP Patent Rights by a Third Party of which such Party becomes
aware. 
---|---|--- 
  



   | 5.4.2| Licensee shall have the first right, but not the obligation, 
to defend and control the defense of the validity and enforceability of the
patents in  CHOP Patent Rights at its own expense. CHOP may participate in
any such claim, suit,  or proceeding with counsel of its choice. If Licensee
elects not to defend or control  the defense of the patents in CHOP Patent
Rights in a suit, or otherwise fails to initiate  and maintain the defense of
any such claim, suit, or proceeding, then CHOP may, but shall  not have the
obligation to, conduct and control the defense of any such claim, suit,  or
proceeding. 
---|---|--- 
  



  

   | 5.5| Litigation Costs and Expenses. If CHOP is a party to any  suit
or action under Sections 5.3 or 5.4, Licensee shall reimburse CHOP for all 
reasonable costs, expenses, and fees (including reasonable attorneys' fees),
which  CHOP incurs as a result of becoming a party to such suit or other
action, including any  and all costs, expenses and fees (including attorneys'
fees), except if CHOP and  Licensee engage separate counsel in addition to
co-counsel according to Section 5.4.2.  Licensee shall reimburse any and all
such costs, expenses and fees within thirty (30)  days after receiving an
invoice from CHOP. 
---|---|--- 
  



   | 5.6| Patent Marking. Licensee shall place in a conspicuous location 
on any Product (or its packaging where appropriate and practicable) made or
sold  under this Agreement a patent notice in accordance with the Laws
concerning the marking  of patented articles where such Product is made or
sold, as applicable. 
---|---|--- 
  



   | 5.7| Confidentiality. 
---|---|--- 
  



   | 5.7.1| Each Party agrees that, for the Term and for five (5) years 
thereafter, such Party shall (a) use the same degree of care to maintain the
secrecy  of the Confidential Information of the other Party that it uses to
maintain the secrecy  of its Confidential Information of like kind but in no
case less than a reasonable degree  of care, (b) use the Confidential
Information only to accomplish the purpose of this  Agreement or for audit or
management purposes and (c) ensure that any employees, customers, 
distributors are bound to it by similar obligations of confidence and to make
sure such  disclosure only as required to accomplish the purposes of this
Agreement. 
---|---|--- 
  



   | 5.7.2| Neither Party will have any confidentiality  obligations with
respect to Confidential Information belonging to the other Party that: 
---|---|--- 
  



  

    

 | 22| 
---|---|--- 

 



    

  

  



   | (a)| is or becomes generally available to the public other than as a
result of disclosure by the recipient;  
---|---|--- 
  



   | (b)| is already known by or in the possession of the recipient at the
time of disclosure by the disclosing Party;  
---|---|--- 
  



   | (c)| is independently developed by recipient without use of or
reference to the disclosing Party's Confidential Information; or  
---|---|--- 
  



   | (d)| is obtained by recipient from a Third Party that
lawfully obtained it and has not breached any obligations of
confidentiality.  
---|---|--- 
  



   | 5.7.3| A Party may disclose the Confidential Information of the 
other Party to the extent required by Law or court order; provided, however,
that the  recipient promptly provides to the disclosing Party prior written
notice of such disclosure  and provides reasonable assistance in obtaining an
order or other remedy protecting the  Confidential Information from public
disclosure. 
---|---|--- 
  



  

ARTICLE 6

  

REPRESENTATIONS, WARRANTIES AND COVENANTS

  



   | 6.1| Mutual Representations and Warranties.  Each Party represents
and warrants to the other Party that, as of the Effective  Date: 
---|---|--- 
  



   | 6.1.1| such Party is duly organized  and validly existing under the
Laws of the jurisdiction of its incorporation or organization; 
---|---|--- 
  



   | 6.1.2| such Party has taken all action  necessary to authorize the
execution and delivery of this Agreement and the performance  of its
obligations under this Agreement; 
---|---|--- 
  



   | 6.1.3| this Agreement is a legal and valid obligation of such Party, 
binding upon such Party and enforceable against such Party in accordance with
the terms  of this Agreement, except as enforcement may be limited by
applicable bankruptcy, fraudulent  conveyance, insolvency, reorganization,
moratorium and other laws relating to or affecting  creditors' rights
generally and by general equitable principles; and 
---|---|--- 
  



   | 6.1.4| such Party has all right, power  and authority to enter into
this Agreement, to perform its obligations under this Agreement. 
---|---|--- 
  



   | 6.2| CHOP Representations and Warranties.  CHOP represents and
warrants that, subject to Schedule 2.3.2: 
---|---|--- 
  



   | 6.2.1| CHOP owns or Controls the CHOP  Patent Rights; 
---|---|--- 
  



   | 6.2.2| Hakon Hakonarson is "Hospital Personnel" as per  the
definition in CHOP's Patent and Intellectual Property Policy dated July 1, 
2009 ("CHOP IP Policy"; copy at _Appendix C_ ); 
---|---|--- 
  



   | 6.2.3| CHOP has the right to grant the  licenses set forth in this
Agreement; 
---|---|--- 
  



   | 6.2.4| CHOP's entry into and performance  of this Agreement shall not
violate or conflict with any agreement between CHOP and any  Third Party; and 
---|---|--- 
  



  

   

 | 23| 
---|---|--- 

 



    

  



   | 6.2.5| except for potential rights of the United States Government 
including under 35 U.S.C. 200-212, as amended, the CHOP Patent Rights are 
not subject to the rights of any Third Party that funded the research at CHOP
that resulted  in the creation of the CHOP Patent Rights. 
---|---|--- 
  



   | 6.3| Disclaimer of Representations and  Warranties. 
---|---|--- 
  



   | 6.3.1| Other than the representations  and warranties provided in
Sections 6.1 and 6.2 above, 
---|---|--- 
  



  

CHOP MAKES NO REPRESENTATIONS OR WARRANTIES, WHETHER EXPRESS OR IMPLIED, AND
EXPLICITLY DISCLAIMS ANY REPRESENTATION AND WARRANTY, INCLUDING WITH RESPECT
TO ANY ACCURACY, COMPLETENESS, MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, COMMERCIAL UTILITY, VALIDITY OR NON-INFRINGEMENT FOR THE TECHNOLOGY,
CHOP PATENT RIGHTS, CHOP KNOW HOW, LICENSE AND ANY PRODUCT. LICENSEE ACCEPTS
CHOP PATENT RIGHT AND CHOP KNOW-HOW "AS IS" AND CHOP DOES NOT OFFER ANY
GUARANTEE OF ANY KIND.

  



  

   | 6.3.2| Furthermore, nothing in this  Agreement will be construed as: 
---|---|--- 
  



   | (a)| A representation or warranty by CHOP as to the validity or scope
of any CHOP Patent Right;  
---|---|--- 
  



   | (b)| A representation or warranty that anything made, used, sold or
otherwise disposed of under the License is or will be free from infringement
of patents, copyrights, trademarks or any other forms of intellectual
property rights or tangible property rights of Third Parties;  
---|---|--- 
  



   | (c)| Obligating CHOP to bring or prosecute actions or suits against
Third Parties for patent, copyright or trademark infringement;  
---|---|--- 
  



   | (d)| Conferring by implication, estoppel or otherwise any license or
rights under any Patent Rights of CHOP other than CHOP Patent Rights as
defined herein, and regardless of whether such Patent Rights are dominant or
subordinate to CHOP Patent Rights.  
---|---|--- 
  



   | 6.4| Covenants of Licensee. 
---|---|--- 
  



   | 6.4.1| Licensee and its Affiliates will not, directly or indirectly 
(including where done by a Third Party on behalf of Licensee or its
Affiliates, at the  urging of Licensee or its Affiliates or with the
assistance of the Licensee or its Affiliates)  challenge the validity, scope,
or enforceability of or otherwise oppose any CHOP Patent  Right, provided
that if any CHOP Patent Right is asserted against Licensee or its Affiliate 
for activities authorized under this Agreement, then such Licensee or its
Affiliates  is entitled to all and any defenses available to it including
challenging the validity  or enforceability of such Patent Right. In the
event of breach of this Section 6.4.1,  the royalty rates set forth in the
table in Section 4.3.1 shall immediately double unless  and until a court of
competent jurisdiction finally finds (without the possibility of  appeal) all
CHOP Patent Rights to be invalid or unenforceable. 
---|---|--- 
  



  

   

 | 24| 
---|---|--- 

 



    



   | 6.4.2| Licensee will comply with all Laws that apply to its
activities  or obligations under this Agreement. For example, Licensee will
comply with applicable  United States export laws and regulations. The
transfer of certain technical data and  commodities may require a license
from the applicable agency of the United States government  and/or written
assurances by Licensee that Licensee will not export data or commodities  to
certain foreign countries without prior approval of the agency. 
---|---|--- 
  



   | 6.4.3| Licensee will not grant a security  interest in the License or
this Agreement. 
---|---|--- 
  



   

ARTICLE 7

  

INDEMNIFICATION; INSURANCE AND LIMITATION OF LIABILITY

  



   | 7.1| Indemnification by Licensee. 
---|---|--- 
  



   | 7.1.1| Licensee shall indemnify CHOP and its current and former
directors, governing board members, trustees, officers, faculty,
students, fellows, employees, consultants, contractors and agents and their
respective successors, heirs and assigns (the "CHOP Indemnitees") from and
against any and all liability, damage, loss, demands, cost or expense
(including reasonable attorneys' fees), including bodily injury, risk of
bodily injury, death and property damage to the extent arising out of claims
or suits related to (a) Licensee, Affiliate or Sublicensee or their customers
activities related to Products, Patent Rights, CHOP Patent Rights or CHOP
Know-How, (b) this Agreement or any Sublicense, including (i) the development,
design, testing, use, manufacture, packaging, promotion, import, export,
distribution, lease, sale or other disposition of any Product (including any
product liability claim), (ii) any enforcement action or suit brought by
Licensee against a Third Party for infringement of CHOP Patent Rights, (iii)
any claim by a Third Party that the practice of CHOP Patent Rights or the
design, composition, manufacture, use, sale or other disposition of any
Product infringes or violates any patent, copyright, trade secret, trademark
or other intellectual property right of such Third Party, (iv) any breach of
this Agreement or Laws by Licensee, its Affiliates or Sublicensees, and (c)
Licensee's negligence, omissions or willful misconduct, provided that
Licensee's obligations pursuant to this Section 7.1 shall not apply to
the extent such claims or suits result from the gross negligence or willful
misconduct of CHOP. 
---|---|--- 
  



   | 7.1.2| CHOP shall: (a) promptly notify Licensee as soon as it becomes
aware of a claim or suit for which indemnification may be sought pursuant
hereto; provided that any failure to provide such prompt notice shall not
relieve Licensee of any of its obligations hereunder except and only to the
extent Licensee is prejudiced thereby; (b) reasonably cooperate, and cause the
individual CHOP Indemnitees to reasonably cooperate, with Licensee in the
defense, settlement or compromise of such claim or suit; and (c) permit the
Licensee to control the defense, settlement or compromise of such claim or
suit, including the right to select defense counsel reasonably acceptable to
CHOP. In no event, however, may Licensee compromise or settle any claim or
suit in a manner which (a) admits fault or negligence on the part of CHOP or
any other CHOP Indemnitee; or (b) commits CHOP or any other CHOP Indemnitee to
take, or forbear to take, any action, without the prior written consent of
CHOP. 
---|---|--- 
  



   | 7.1.3| Notwithstanding Section 7.1.2 above, in the event that CHOP
believes in good faith that a bona fide conflict exists between Licensee and
CHOP or any other CHOP Indemnitee with respect to a claim or suit subject to
indemnification hereunder, then CHOP or any other CHOP Indemnitee shall have
the right in defending against any such claim or suit itself, including by
selecting its own counsel, and Licensee will not be required to pay for any
fees and expenses incurred by CHOP. 
---|---|--- 
  



   | 7.2| Insurance. 
---|---|--- 
  



   | 7.2.1| Licensee, at its sole cost and expense, must insure its
activities in connection with the work under this Agreement and obtain, and
keep in force and maintain Commercial Form General Liability Insurance
(contractual liability included) with limits as follows: 
---|---|--- 
  



       | (a)  | Each occurrence  | $[ *** ] 
---|---|---|--- 
     | (b)  | General aggregate  | $[ *** ] 
  



  

  



  

  

  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



    

 | 25| 
---|---|--- 

 



    



  

 _Prior to the commencement of clinical trials, if applicable, involving
Product:_

  



       | (c)  | Clinical Trial coverage   | $[ *** ] 
---|---|---|--- 
  



  

 _Prior to the First Commercial Sale of a Product:_

  



       | (d)  | Product Liability  | $[ *** ] 
---|---|---|--- 
  



  

CHOP may review periodically the adequacy of the minimum amounts of insurance
for each coverage required by this Section 7.2.1, and has the right to require
Licensee to adjust the limits in CHOP reasonable discretion

  



   | 7.2.2| If the above insurance is written on a claims-made form, it
shall continue for three (3) years following termination or expiration of
this Agreement. The insurance shall have a retroactive date of placement prior
to or coinciding with the Effective Date of this Agreement. 
---|---|--- 
  



   | 7.2.3| Licensee expressly understands, however, that the coverages and
limits in Section 7.2.1 do not in any way limit Licensee's liability or
indemnification obligations. Licensee's insurance will: 
---|---|--- 
  



   | (a)| Be issued by an insurance carrier with an A.M. Best rating of "A"
or better; 
---|---|--- 
  



   | (b)| Provide for thirty (30) day advance written notice to CHOP of any
modification; 
---|---|--- 
  



   | (c)| State that CHOP is endorsed as an additional insured with respect
to the coverages in Section 7.2.1; and 
---|---|--- 
  



   | (d)| Include a provision that the coverages will be primary and will
not participate with nor will be excess over any valid and collective
insurance or program of self insurance carried or maintained by CHOP. 
---|---|--- 
  



   | 7.2.4| Licensee must furnish to CHOP with (a) valid certificate of
insurance evidencing compliance with all requirements of this Agreement and
(b) additional insured endorsements for Licensee's applicable policies naming
"The Children's Hospital of Philadelphia" as an additional insured. Licensee
must furnish both documents within thirty (30) days of the Effective
Date, once per year thereafter and at any time there is a modification in
such insurance. 
---|---|--- 
  



   | 7.3| LIMITATION OF LIABILITY. EXCEPT FOR LICENSEE'S INDEMNIFICATION
OBLIGATIONS UNDER SECTION 7.1, IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS
AFFILIATES BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR SPECIAL,
INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING LOSS OF
PROFITS, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR
OTHERWISE ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE TRANSACTIONS
CONTEMPLATED HEREIN OR ANY BREACH HEREOF. 
---|---|--- 
  

  



  

  



  

  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



    

 | 26| 
---|---|--- 

 



    



  

ARTICLE 8

  

TERM AND TERMINATION

  



   | 8.1| Term. The term of this Agreement (the "Term") shall commence on
the Effective Date and, unless terminated sooner as provided below, shall
continue in full force and effect until the expiration of the Royalty Term.
Upon expiration of the Term, the licenses granted to Licensee under Section 2
shall automatically become non-exclusive, perpetual, irrevocable, fully paid-
up and royalty-free and shall remain subject to the provisions of Section 2.3. 
---|---|--- 
  



   | 8.2| Termination by Licensee for Convenience. At any time during the
Term, Licensee may, at its convenience, terminate this Agreement upon
providing at least six (6) months prior written notice to CHOP of such
intention to terminate. 
---|---|--- 
  



   | 8.3| Termination by CHOP for Cause. 
---|---|--- 
  



   | 8.3.1| Termination for Breach of Diligence Obligations. If Licensee
fails to fulfill its obligations under Sections 3.1 or 3.2 (including the
failure to achieve any Diligence Event by the corresponding Achievement Date,
as may be amended pursuant to Section 3.2.3), CHOP may provide written notice
to Licensee of such failure. If Licensee fails to address such failure to the
reasonable satisfaction of CHOP within three (3) months of receiving such
written notice, CHOP may, upon written notice to Licensor, terminate this
Agreement (a) in its entirety or (b) if such failure is with respect to a
given Indication, terminate this Agreement with respect to such Indication.  
---|---|--- 
  



   | 8.3.2| Termination for Other Material Breach. If Licensee materially
breaches any of its material obligations under this Agreement other than
those covered in Section 8.3.1 above, CHOP may give to Licensee a written
notice specifying the nature of the default, requiring it to cure such
breach, and stating its intention to terminate this Agreement. If such breach
is not cured within thirty (30) days of such notice, such termination shall
become effective upon a notice of termination by CHOP thereafter. For
clarity, such breach of a material obligation includes: 
---|---|--- 
  



   | (a)| failure to deliver to CHOP any payment at the time or times that
such payment is due to CHOP under this Agreement; 
---|---|--- 
  



   | (b)| failure to provide reports as set forth in Sections 3.3.1 and
4.7; 
---|---|--- 
  



   | (c)| failure to possess and maintain insurance as set forth in Section
7.2; 
---|---|--- 
  



   | (d)| grant of a sublicense under the CHOP Patent Rights or CHOP Know-
How that is not in accordance with the terms of this Agreement; 
---|---|--- 
  



   | (e)| failure to terminate a Sublicense upon written request of CHOP
where Sublicensee is in breach of the obligations on it pursuant to (i)
Sections 2.4.2(a), 2.4.2(d), 2.4.2(g) and 2.4.2(i) and fails to cure such
breach within thirty (30) days of being notified of such breach and (ii)
Section 2.4.2(e). 
---|---|--- 
  



    

 | 27| 
---|---|--- 

 



    



   | 8.3.3| Termination for Patent Challenge. In addition to all other
remedies available to it, CHOP may terminate this Agreement, upon written
notice, with immediate effect, upon a breach of Section 6.4.1. 
---|---|--- 
  



   | 8.3.4| Termination for Insolvency. CHOP may terminate this Agreement,
upon written notice, with immediate effect if, at any time, Licensee files in
any court or agency pursuant to any statute or regulation of any state,
country or jurisdiction, a petition in bankruptcy or insolvency or for
reorganization or for an arrangement or for the appointment of a receiver or
trustee of Licensee or of its assets, or if Licensee proposes a written
agreement of composition or extension of its debts, or if Licensee is served
with an involuntary petition against it, filed in any insolvency proceeding,
and such petition is not dismissed within ninety (90) days after the filing
thereof, or if Licensee proposes or is a party to any dissolution or
liquidation, or if Licensee makes an assignment for the benefit of its
creditors of all or substantially all its assets (in each case, a
"Bankruptcy Action"). 
---|---|--- 
  



   | 8.3.5| Termination for Breach of Purchase Agreement. If the
transaction for the purchase of Licensee contemplated by the Purchase
Agreement is consummated, and Medgenics, its Affiliates, successors or assigns
fails to pay CHOP an amount due under Article II of the Purchase Agreement by
the applicable due date, CHOP may give Medgenics written notice of such
failure in accordance with the Purchase Agreement (such amount, the "Claimed
Amount Due"). If Medgenics pays the Claimed Amount Due in accordance with the
terms of the Purchase Agreement, CHOP shall have no right to terminate this
Agreement. If Medgenics disputes the Claimed Amount Due pursuant to the terms
of Section 2.5 of the Purchase Agreement, the dispute shall be subject to the
dispute procedures set forth in Section 2.5(g) of the Purchase Agreement. If
the result of such formal dispute resolution process is that Medgenics is
ordered to pay CHOP in a final order from which no appeal can be taken or is
taken within the deadline to take such appeal, then Medgenics shall make the
required payment pursuant to the terms of the Purchase Agreement. If such
required payment is not paid pursuant to the terms of the Purchase Agreement,
then CHOP may deliver notice to Medgenics specifying the nature of the
default and stating its intention to terminate this Agreement. If such
required payment is not made by Medgenics within ninety (90) days of such
notice, such termination of this Agreement shall become effective upon a
notice of termination by CHOP thereafter. 
---|---|--- 
  



   | 8.4| Effects of Termination. 
---|---|--- 
  



   | 8.4.1| Notwithstanding the termination or expiration of this
Agreement, the following provisions shall survive termination or
expiration: Article 1, Section 2.7, Section 4.1, Sections 4.8 - 4.12, Section
5.7, Article 6, Article 7, Sections 8.1 and 8.4, and Article 9. 
---|---|--- 
  



   | 8.4.2| Upon the effective date of termination of this Agreement, all
rights and licenses granted by CHOP hereunder shall terminate and Licensee
shall cease all activities that use or derive from the CHOP Know-How or would
infringe the CHOP Patent Rights. If Licensee violates this Section 8.4.2 and
continues such activities, in addition to all other remedies available to CHOP
under Law or this Agreement, Sections 4.2, 4.3, 4.4, 4.5.1, 4.6, 4.7, and
4.13 shall also survive termination of this Agreement and Licensee shall
continue to pay all Milestone Payments, Royalties and Annual Maintenance Fees
applicable to such ongoing activities following termination. 
---|---|--- 
  



    

 | 28| 
---|---|--- 

 



    



   | 8.4.3| Upon the effective date of the termination of this Agreement
for any reason, either Party may request in writing, and the other Party
either, with respect to Confidential Information to which such first Party
does not retain rights under the surviving provisions of this Agreement: (a)
as soon as reasonably practicable, destroy all copies of such Confidential
Information in the possession of the other Party and confirm such destruction
in writing to the requesting Party; or (b) as soon as reasonably practicable,
deliver to the requesting Party, at the other Party's expense, all copies of
such Confidential Information in the possession of the other Party; provided,
that the other Party shall be permitted to retain one (1) copy of such
Confidential Information for the sole purpose of performing any continuing
obligations hereunder, as required by Law, or for archival purposes.
Notwithstanding the foregoing, such other Party also shall be permitted to
retain such additional copies of or any computer records or files
containing such Confidential Information that have been created solely by
such Party's automatic archiving and back-up procedures, to the extent
created and retained in a manner consistent with such other Party's standard
archiving and back-up procedures, but not for any other use or purpose. 
---|---|--- 
  



   | 8.4.4| Termination of this Agreement shall not relieve the Parties of
any obligation or liability that, at the time of termination, has already
accrued hereunder, or which is attributable to a period prior to the effective
date of such termination. Termination of this Agreement shall not preclude
either Party from pursuing all rights and remedies it may have hereunder or at
Law or in equity with respect to any breach of this Agreement nor prejudice
either Party's right to obtain performance of any obligation. 
---|---|--- 
  



   | 8.4.5| Upon termination of this Agreement for any reason, Licensee
shall promptly pay all amounts owed to CHOP under this Agreement before the
earlier of (a) sixty (60) days from the effective date of termination or (b)
the due date for such payment in accordance with the terms of this Agreement. 
---|---|--- 
  



   | 8.4.6| If this Agreement is terminated for any reason, all outstanding
Sublicenses (including all Sublicense Documents for each Sublicense) not in
default will be, in CHOP's sole discretion either (a) assigned by Licensee to
CHOP or (b) terminated. Each assigned Sublicense will remain in full force
and effect with CHOP as the licensor instead of Licensee, but the duties and
obligations of CHOP under the assigned Sublicenses will not be greater than
the duties of CHOP under this Agreement, and the rights of CHOP under the
assigned Sublicenses will not be less than the rights of CHOP under this
Agreement, including all financial consideration and other rights of CHOP.
CHOP may, at its sole discretion, amend such outstanding Sublicenses to
contain the terms and conditions found in this Agreement. 
---|---|--- 
  



   | 8.4.7| If this Agreement is terminated for any reason, the following
shall apply with regard to Products: 
---|---|--- 
  



   | (a)| Licensee shall assign to CHOP, at Licensee's sole cost and
expense, all rights, title and interest of Licensee in and to (i) all
regulatory approvals and applications therefor and all pricing and
reimbursement approvals pertaining to Products (ii) all trademarks
(including, without limitation, the goodwill associated with such trademarks)
used to brand the Products and (iii) any copyrights to the extent necessary
or useful for marketing or commercialization of the Products. 
---|---|--- 
  



    

 | 29| 
---|---|--- 

 



    



   | (b)| Licensee shall transfer to CHOP, at Licensee's sole cost and
expense, copies of all non-clinical and clinical data and material regulatory
correspondence of Licensee relating to the Products. 
---|---|--- 
  



   | (c)| Licensee agrees to grant, and hereby does grant, to CHOP a
perpetual, irrevocable, worldwide, exclusive (even as to Licensee), fully
paid up, royalty-free and fully transferable and sublicensable license under
all Patent Rights and other intellectual property rights Controlled by
Licensee to the extent necessary or useful to make, use, sell, offer for sale
or import the Products. 
---|---|--- 
  



   | (d)| Licensee shall furnish CHOP with reasonable cooperation to assure
a smooth transition of any clinical or other studies in progress related to
Product, CHOP Patent Rights or CHOP Know-How that CHOP determines to continue. 
---|---|--- 
  



   | (e)| Licensee shall have the right to dispose of all previously made
or partially made Products within a period of one hundred and eighty (180)
days following the effective date of any such termination; provided, however,
that the sale of such Products shall be subject to the terms of this
Agreement including the payment of royalties at the rate and at the time
provided herein and the rendering of reports thereon. 
---|---|--- 
  



  

ARTICLE 9

  

ADDITIONAL PROVISIONS

  



   | 9.1| Relationship of the Parties. Nothing in this Agreement is
intended or shall be deemed, for financial, tax, legal or other purposes, to
constitute a partnership, agency, joint venture or employer-employee
relationship between the Parties. The Parties are independent contractors and
at no time will either Party make commitments or incur any charges or expenses
for or on behalf of the other Party. 
---|---|--- 
  



   | 9.2| Third Party Beneficiary. The Parties agree that each Sublicensee
is a third party beneficiary of this Agreement with respect to Section 8.4.6. 
---|---|--- 
  



   | 9.3| Use of Names. Licensee, its Affiliates and Sublicensees may not
use the name, logo, seal, trademark, or service mark (including any
adaptation of them) of CHOP or any CHOP school, organization, employee,
student or representative, without the prior written consent of CHOP.
Notwithstanding the foregoing, Licensee may use the name of CHOP in a non-
misleading and factual manner solely in (a) executive summaries, business
plans, offering memoranda and other similar documents used by Licensee for
the purpose of raising financing for the operations of Licensee as related to
Product, or entering into commercial contracts with Third Parties, but in
such case only to the extent necessary to inform a reader that the CHOP Patent
Rights has been licensed by Licensee from CHOP, and to inform a reader of the
identity and published credentials of Inventors of the Technology, and (b) any
securities reports required to be filed with the Securities and Exchange
Commission. 
---|---|--- 
  



   | 9.4| No Discrimination. Neither CHOP nor Licensee will discriminate
against any employee or applicant for employment because of race, color, sex,
sexual or affectional preference, age, religion, national or ethnic origin,
handicap, or veteran status 
---|---|--- 
  



    

 | 30| 
---|---|--- 

 



    



   | 9.5| Successors and Assignment. 
---|---|--- 
  



   | 9.5.1| The terms and provisions hereof shall inure to the benefit of,
and be binding upon, the Parties and their respective successors and
permitted assigns. 
---|---|--- 
  



   | 9.5.2| Licensee may not assign or transfer this Agreement or any of
Licensee's rights or obligations created hereunder, by operation of law or
otherwise, without the prior written consent of CHOP. Notwithstanding the
foregoing, no such consent shall be required in connection with an assignment
to a successor, whether in a merger, sale of stock, sale of assets or any
other transaction, of all or substantially all the business of Licensee to
which this Agreement relates; provided that, in the case of successors
other than Medgenics pursuant to the Purchase Agreement, Licensee provides
prompt notice to CHOP of such proposed assignment and evidence reasonably
satisfactory to CHOP that such proposed assignee is able to perform the
obligations of Licensee under this Agreement. Any permitted assignee shall
assume all obligations of Licensee under this Agreement. 
---|---|--- 
  



   | 9.5.3| Any assignment not in accordance with this Section 9.5 shall be
void. 
---|---|--- 
  



   | 9.6| Further Actions. Each Party agrees to execute, acknowledge and
deliver such further instruments and to do all such other acts as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement. 
---|---|--- 
  



   | 9.7| Entire Agreement of the Parties; Amendments. This Agreement, the
Appendices and Schedules hereto, the Equity Issuance Agreement and the
Purchase Agreement constitute and contain the entire understanding and
agreement of the Parties respecting the subject matter hereof and cancel and
supersede any and all prior negotiations, correspondence, understandings and
agreements between the Parties, whether oral or written, regarding such
subject matter including the Option Agreement. No waiver, modification or
amendment of any provision of this Agreement shall be valid or effective
unless made in a writing referencing this Agreement and signed by a duly
authorized officer of each Party. 
---|---|--- 
  



   | 9.8| Governing Law. This Agreement shall be governed by and
interpreted in accordance with the laws of the Commonwealth of Pennsylvania,
excluding application of any conflict of laws principles that would require
application of the law of a jurisdiction outside of the Commonwealth of
Pennsylvania. 
---|---|--- 
  



   | 9.9| Dispute Resolution. If a dispute arises between the Parties
concerning this Agreement, then the Parties will confer, as soon as
practicable, in an attempt to resolve the dispute. If the Parties are unable
to resolve such dispute amicably, then the Parties will submit to the
exclusive jurisdiction of, and venue in, the state and Federal courts located
in the Eastern District of Pennsylvania. 
---|---|--- 
  



   | 9.10| Notices and Deliveries. Any notice, request, approval or consent
required or permitted to be given under this Agreement shall be in writing
and directed to a Party at its address, facsimile number, or e-mail as shown
below or such other address, e-mail, or facsimile number as such Party shall
have last given by notice to the other Party. A notice will be
deemed received: if delivered personally, on the date of delivery; if mailed,
five (5) days after deposit in the United States mail; if sent via courier,
one (1) business day after deposit with the courier service; or if sent via
facsimile or e-mail, upon receipt of confirmation of transmission provided
that a confirming copy of such notice is sent by certified mail, postage
prepaid, return receipt requested. 
---|---|--- 
  



    

 | 31| 
---|---|--- 

 



    



     **__For CHOP__**   | **_ _**   | **__with a copies to_ :_** 
---|---|--- 
     |   | 
   **The Children 's Hospital of Philadelphia**  |   | **Abrahamson
Research Center** 
   **Research Institute**   |   | The Children's Hospital of Philadelphia 
   Officer of Technology Transfer  |   | Office of General Counsel 
   3501 Civic Center Blvd., Suite 2200  |   | 34th and Civic Center Blvd 
   Philadelphia, PA 19104  |   | Philadelphia, PA, 19104 
   Attention: Director, Technology Transfer  |   | Attention: Deputy
General Counsel 
   Fax: (215) 590-5484  |   | 
     |   | 
     |   | **Morgan, Lewis and Bockius LLP** 
     |   | 502 Carnegie Center 
     |   | Princeton, NJ 08540-6241 
     |   | Attention: Steven M. Cohen 
     |   | Fax No.: (877) 432-9652 
     |   | 
   **__For Licensee_ :_**  | **_ _**   | **__with copies to_ :_** 
   **NeuroFix, LLC**   |   | **Fox Rothschild LLP** 
   c/o Philip Harper  |   | 747 Constitution Drive, Suite 100 
   1877 Covered Bridge Road  |   | P.O. Box 673 
   Malvern, PA 19355  |   | Exton PA 19341-0673 
   Fax: (610) 647-5095  |   | Attention: Michael S. Harrington, Esquire 
   Email: philipharper173@gmail.com  |   | Fax: (610) 458-7337 
     |   | Email: mharrington@foxrothschild.com 
     |   | 
   **__with copies to:__**   | **_ _**   | **__and__** 
   **Medgenics, Inc.**   |   | **Pepper Hamilton LLP** 
   435 Devon Park Drive, Building 700  |   | 3000 Two Logan Square 
   Wayne, PA 19087  |   | 18th and Arch Streets 
   Attention: Scott Applebaum, Esquire  |   | Philadelphia, PA 19103 
   Fax No.: (610) 717-3390  |   | Attention: Brian M. Katz, Esquire 
     |   | Fax: (215) 981-4750 
  



   | 9.11| Waiver. A waiver by either Party of any of the terms and
conditions of this Agreement in any instance shall not be deemed or construed
to be a waiver of such term or condition for the future, or of any other term
or condition hereof. All rights, remedies, undertakings, obligations and
agreements contained in this Agreement shall be cumulative and none of them
shall be in limitation of any other remedy, right, undertaking, obligation or
agreement of either Party. 
---|---|--- 
  



   | 9.12| Severability. When possible, each provision of this Agreement
will be interpreted in such manner as to be effective and valid under law,
but if any provision of this Agreement is held to be prohibited by or invalid
under law, such provision will be ineffective only to the extent of such
prohibition or invalidity, without invalidating the remainder of this
Agreement. The Parties shall make a good faith effort to replace the invalid
or unenforceable provision with a valid one which in its economic effect is
most consistent with the invalid or unenforceable provision. 
---|---|--- 
  



    

 | 32| 
---|---|--- 

 



    



   | 9.13| Interpretation. The words "include," "includes" and "including"
shall be deemed to be followed by the phrase "without limitation." All
references herein to Articles, Sections, and Schedules shall be deemed
references to Articles and Sections of, and Schedules to, this Agreement
unless the context shall otherwise require. Except as otherwise expressly
provided herein, all terms of an accounting or financial nature shall be
construed in accordance with GAAP, as in effect from time to time. Unless the
context otherwise requires, countries shall include territories.
References to any specific Law or article, section or other division thereof,
shall be deemed to include the then-current amendments or any replacement Law
thereto. 
---|---|--- 
  



   | 9.14| Counterparts. This Agreement may be executed in counterparts,
each of which will be deemed an original, and all of which together will be
deemed to be one and the same instrument. A facsimile or a portable document
format (PDF) copy of this Agreement, including the signature pages, will be
deemed an original. 
---|---|--- 
  



  

IN WITNESS WHEREOF, duly authorized representatives of the Parties have
executed this Agreement as of the Effective Date.

  



     THE CHILDREN'S HOSPITAL OF  |   | NEUROFIX , LLC 
---|---|--- 
   PHILADELPHIA  |   | 
     |   | 
   By:  | /s/ Madeline Bell  |   | By:  | /s/ Philip R. Harper 
     | Name: Madeline Bell  |   |   | Name: Philip R. Harper 
     | Title: President and CEO  |   |   | Title: President and CEO 
    



  

    

 | 33| 
---|---|--- 

 



    



  

Schedule 1.1

  



  

Diligence Events and Achievement Dates

  



  

ADHD

  



     **Diligence Event**   |   | **Achievement Date** 
---|---|--- 
   Initiation of Phase II in the United States  |   | The 18 month
anniversary of the Effective Date 
   Initiation of Phase III in the United States or a pivotal  |   | The
fourth anniversary of the Effective Date 
   Phase II if the FDA determines Phase III is not required  |   | 
   First Commercial Sale of Product  |   | The sixth anniversary of the
Effective Date 
  



  

SECOND INDICATION

  



     **Diligence Event**   |   | **Achievement Date** 
---|---|--- 
   Initiation of Phase I in the United States  |   | The 18 month
anniversary of the Effective Date 
   If Phase I results are such that Phase II should be initiated:  |   |
The third anniversary of the completion of Phase I 
   Initiation of Phase II in the United States  |   | 
  



    



 



    



  

Schedule 1.4

  



  

CHOP Patent Rights

  



       | **1.**   | [ *** ] 
---|---|--- 
     |   | *  | US Provisional Patent Application Serial Number [ ***
]; 
     |   | *  | US Provisional Patent Application Serial Number [ ***
]; 
     |   | *  | PCT Patent Application Serial Number [ *** ]; 
     |   | *  | Australia Patent Application Serial Number [ *** ]; 
     |   | *  | Canada Patent Application Serial Number [ *** ]; 
     |   | *  | European Patent Application Serial Number [ *** ]; 
     |   | *  | Japan Patent Application Serial Number [ *** ]; 
     |   | *  | US Patent Application Serial Number [ *** ]. 
     |   |   | 
     | **2.**   | [ *** ] 
     |   | *  | US Provisional Patent Application Serial Number [ ***
]; 
     |   | *  | PCT Patent Application Serial Number [ *** ]; 
     |   | *  | US Patent Application Serial Number [ *** ]. 
     |   |   | 
     | **3.**   | [ *** ] 
     |   | *  | Any patent claim that issues from US Patent Application
Serial Number [ *** ]; 
     |   | *  |  

Any US or foreign patent claim that issues from an application that claims
priority to US Patent Application Serial Number [ *** ]. 

  



   | 4.| US provisional patent application based on the invention
disclosure received by CHOP's Office of Technology Transfer on [ *** ],
reference number [ *** ], related to [ *** ], filed in the United
States Patent and Trademark Office on [ *** ]. 
---|---|--- 
  



   | 5.| US provisional patent application based on the invention
disclosure received by CHOP's Office of Technology Transfer on [ *** ],
reference number [ *** ] related to [ *** ], filed in the United
States Patent and Trademark Office on [ *** ]. 
---|---|--- 
  



   | 6.| US provisional patent application based on the invention
disclosure received by CHOP's Office of Technology Transfer on [ *** ],
reference number [ *** ], related to [ *** ], filed in the United
States Patent and Trademark Office on [ *** ]. 
---|---|--- 
  



  



  

  

  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



    



 



    



   | 7.| US provisional patent application based on the invention
disclosure received by CHOP's Office of Technology Transfer on [ *** ],
reference number [ *** ],a related to [ *** ], including [ *** ],
filed in the United States Patent and Trademark Office on [ *** ]. 
---|---|--- 
  



   | 8.| Any additional Patent Rights covering NFC-1 Trial IP, to the
extent that CHOP owns or controls such Patent Rights. 
---|---|--- 
  

  



  



  

  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



    



 



    



  

Schedule 2.3.2

  



  

Third Party Rights

  



  

 _I. Third Party License_

  



  

The following rights have been granted to a Third Party and are expressly
excluded from this Agreement:

  



  

 _Patents_

  

The following CHOP intellectual property is currently exclusively licensed,
worldwide, in all fields of use:

  



   | 1.| The following applications: 
---|---|--- 
  



   | a.| PCT patent application serial no. [ *** ], entitled [
*** ], which claims priority to U.S. provisional patent application serial
no. [ *** ], [ *** ] and U.S. provisional patent application
serial no[ *** ], filed [ *** ]; 
---|---|--- 
  



   | b.| PCT patent application serial no. [ *** ], entitled [
*** ], which claims priority to U.S. provisional patent application serial
no. [ *** ], filed [ *** ]. 
---|---|--- 
  



   | c.| all patent applications and patents that may be based on, or
derived from CHOP OTT ID Number [ *** ] by [ *** ] dated [
*** ], entitled [ *** ] ("CHOP disclosure [ *** ]"), and an
associated schedule of Copy Number Variants, including US application [ ***
]. 
---|---|--- 
  



   | d.| all applications from which such applications and patents claim
priority, all divisions and continuations of these applications, all patents
issuing from such applications, divisions, and continuations, and any
reissues, reexaminations, and extensions of all such patents; 
---|---|--- 
  



   | 2.| All i) continuations-in-part of above; ii) all divisions and
continuations of these continuations-in-part; iii) all patents issuing from
such continuations-in-part, divisions, and continuations; and iv) any
reissues, reexaminations, and extensions of all such patents, including US
Application [ *** ], subject to 4 below; 
---|---|--- 
  



   | 3.| All counterpart foreign applications and patents to the above. 
---|---|--- 
  



   | 4.| The license does not include the claims of 2 or 3 above, to the
extent that such claims are directed to new matter that is not the subject
matter disclosed in 1 above. 
---|---|--- 
  



  

 _Know-How_

  

The following CHOP intellectual property is currently non-
exclusively licensed, worldwide, to the extent necessary or useful to
practice Technologies. "Technologies" mean any service, process, and/or
product which, in the course of manufacture, use, or sale would, in the
absence of a license to the above patent rights, infringe or would induce
infringement of, or constitute contributory infringement of, one or more
claims covering the above that have not been held invalid or unenforceable by
an unappealed or unappealable judgment of a court of competent jurisdiction.

  



   | 1.| discoveries, data, information, processes, methods, techniques,
materials, cell lines, molecules, compounds, technology, results or other
know-how, whether or not patentable, that is necessary or useful for the
manufacture, use, commercial development, or sale of Technologies. 
---|---|--- 
  

  



  



  

  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



    



 



    



  

 _Improvements_

  

In addition to the above licenses, CHOP granted an option to include CHOP\'s
patent rights in any inventions conceived and reduced to practice: (i)
directly relate to and directly involve the subject matter of the above
patent rights and (ii) arise directly from research performed at CHOP by or
under the supervision of, or in the laboratories of, any of the inventors
named in the above patent rights (any such invention an "Improvement"). Such
Improvements may include, for example, surrogate markers of those markers
already described in the above patent rights, but shall expressly not include
(i) new independent markers identified in research performed at CHOP and (ii)
intellectual property conceived and reduced to practice in a certain
Sponsored Research Agreement.

  



  

[ *** ].

  



  



  

  

  

*** Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to this omitted information.

  



    



 



    



  

Appendix A

  



  

Purchase Agreement

  



  

(Please see attached)

  



    



 



    



  

Appendix B

  



  

Equity Issuance Agreement

  



    



 



    



  

MEMBERSHIP INTEREST ISSUANCE AGREEMENT

  



  

THIS MEMBERSHIP INTEREST ISSUANCE AGREEMENT (this " _Agreement_ ") is made on
this 9th day of September, 2015, by and between neuroFix, LLC, a Delaware
limited liability company (" _Company_ "), and The Children's Hospital of
Philadelphia, a Pennsylvania non-profit corporation (" _CHOP_ ").

  



  

WHEREAS, Company, neuroFix Therapeutics, Inc. (" _Parent_ "), CHOP and
Medgenics, Inc., a Delaware corporation (" _Medgenics_ "),
anticipate entering into an Equity Interest Purchase Agreement (the "
_Purchase Agreement_ ") prior to which Parent has agreed to transfer to
Company substantially all of its assets and liabilities, and Company has
agreed to issue to CHOP a 20% membership interest in Company;

  



  

WHEREAS, immediately prior to the "Effective Time" (as defined below), Parent
contributed substantially all of its assets and liabilities to Company
pursuant to that certain Contribution Agreement between Parent and Company
dated as of even date herewith (the " _Contribution Agreement_ "); and

  



  

WHEREAS, as of the Effective Time, Company and CHOP are entering into a
License Agreement, and in connection therewith Company desires to issue to
CHOP, and CHOP desires to receive from Company, a 20% membership interest in
Assignee pursuant to the terms of this Agreement.

  



  

NOW, THEREFORE, in consideration of the mutual promises and agreements made
herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto hereby agree
as follows.

  



  

1. _Issuance of Membership Interest; Capitalization_. Subject to the terms and conditions hereof, as of the Effective Time, Company hereby issues to CHOP, and CHOP hereby agrees to accept from Company, a 20% membership interest in Company (the " _Membership_   _Interest_ "). Immediately following such issuance, Parent shall own an 80% membership interest in Company.

  



  

2. _Effective Time_. The transactions contemplated by this Agreement shall become effective immediately after the consummation of the transactions contemplated by the Contribution Agreement and immediately prior to the closing of the transactions contemplated by the Purchase Agreement (the " _Effective Time_ ").

  



  

3. _No Operating Agreement; Restrictions_. The parties acknowledge and agree that because CHOP will own the Membership Interest for a moment in time prior to the consummation of the transactions contemplated by the Purchase Agreement, no Operating Agreement of Company shall be entered into by Parent and CHOP. Company agrees that it shall not issue any membership interest in Company other than as contemplated by this Agreement. Parent and CHOP agree to not transfer their respective membership interests except to Medgenics in connection with the Purchase Agreement. CHOP acknowledges and agrees that Company is not making any representations or warranties regarding Company's business or otherwise in connection with the issuance set forth herein.

  



    



 



    



  

4. _CHOP Representations_. In connection with the grant of the Membership Interest hereunder, CHOP represents and warrants to Company as follows:

  



  

(a) CHOP is aware of Company's financial condition and has acquired
sufficient information about Company to reach an informed and knowledgeable
decision to acquire the Membership Interest.

  



  

(b) CHOP understands that the Membership Interest have not been
registered under the Securities Act of 1933, as amended.

  



  

(c) CHOP understands that CHOP may suffer tax consequences as a
result of CHOP's acquisition or disposition of the Membership Interest. CHOP
represents that CHOP has consulted any tax and legal advisors that CHOP deems
advisable in connection with the acquisition or disposition of the Membership
Interest and that CHOP is not relying on Company for any tax advice.

  



  

5. _Company Representations_. In connection with the grant of the Membership Interest hereunder, Company represents and warrants to CHOP that Company has no assets or liabilities except for the "Contributed Assets" (as defined in the Contribution Agreement), the "Assumed Liabilities" (as defined in the Contribution Agreement), the Contribution Agreement and this Agreement.

  



  

6. _Miscellaneous_.

  



  

(a) _Assignment; Successors and Assigns_. No party may assign any
of its rights under this Agreement to any third party (whether by
operation of law or otherwise) without the prior written consent of the other
party. Any assignment of this Agreement shall not relieve the assigning party
of its obligations hereunder. This Agreement is binding upon and inures to the
benefit of the parties hereto and their respective successors and permitted
assigns, and survives the execution and delivery hereof.

  



  

(b) _Entire Agreement_. This Agreement, the Purchase Agreement and
the documents delivered pursuant hereto and thereto constitute the
entire agreement of the parties with respect to the subject matter hereof.

  



  

(c) _Notices_. Any notices given in connection with this Agreement
shall be in writing and shall be delivered as set forth in Section 13.5
of the Purchase Agreement.

  



  

(d) _Amendment; Waiver_. This Agreement may be amended or modified
only by an instrument in writing by the parties hereto. Any term or
provision of this Agreement may be waived, or the time for its performance
may be extended, by the party or parties entitled to the benefit thereof. Any
such waiver is validly and sufficiently authorized if, as to any party, it is
authorized in writing by an authorized representative of such party. The
failure of any party hereto to enforce at any time any provision of this
Agreement shall not be construed to be a waiver of such provision, nor in any
way to affect the validity of this Agreement or any part hereof, or the right
of any party thereafter to enforce each and every provision. No waiver of any
breach of this Agreement shall be held to constitute a waiver of any other or
subsequent breach.

  



    



 



    



  

(e) _Partial Invalidity_. Wherever possible, each provision hereof
is to be interpreted in such manner as to be effective and valid
under applicable law, but in case any one or more of the provisions contained
herein is, for any reason, held to be invalid, illegal or unenforceable in
any respect, such provision will be ineffective to the extent, but only to the
extent, of such invalidity, illegality or unenforceability without
invalidating the remainder of such invalid, illegal or unenforceable provision
or provisions or any other provisions hereof, unless such a construction
would be unreasonable.

  



  

(f) _Execution in Counterparts_. This Agreement may be executed in
one or more counterparts, and by the different parties hereto in
separate counterparts, each of which when executed is to be deemed to be an
original but all of which taken together will constitute one and the same
instrument.

  



  

(g) _Governing Law; Jurisdiction_. This Agreement shall be governed
by and construed in accordance with the internal laws (as opposed to
the conflicts of law provisions) of the State of Delaware. The parties hereby
consent to the exclusive jurisdiction and venue of the state courts located
in Delaware and the federal courts of the United States District Court for the
District of Delaware for any claims arising under this Agreement. Under no
circumstances will any party assert any claim or cause of action in any state
or federal court outside of the foregoing.

  



  

[s _ignature page follows_ ]

  



    



 



    



  

IN WITNESS WHEREOF, this Membership Interest Issuance Agreement has been
executed by the parties on the date first written above.

  



       | NEUROFIX, LLC 
---|--- 
     | 
     | By:  | 
     | Name:  | 
     | Title:  | 
     | 
     | THE CHILDREN'S HOSPITAL OF PHILADELPHIA 
     | 
     | By:  | 
     | Name:  | 
     | Title:  | 
  



    



 



    



  

Appendix C

  



  

CHOP IP Policy

  



    



 



    



     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 1 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  



  

 _PURPOSE_

  



  

To provide a policy that governs the treatment of Intellectual Property.

  



  

 _POLICY_

  



  

The Hospital strives to be a world leader in the advancement of health care
for children by integrating excellent patient care, innovative research, and
quality professional education into all of its programs. Although the
Hospital does not undertake these activities principally for the purpose of
developing Intellectual Property, Intellectual Property may result from these
activities. In promulgating this policy, the Hospital seeks to achieve
certain objectives, including: (a) encouraging research and scholarship by
Hospital Personnel; (b) where appropriate, promoting the protection of
Intellectual Property that may arise in the course of Hospital activities; (c)
serving the public interest by making Intellectual Property available to the
public at the earliest appropriate time; (d) encouraging the earliest
possible disclosure of specific Intellectual Property to the Hospital in
order to avoid the unintended forfeiture of rights and to expedite the public
availability of the Intellectual Property; (e) defining the rights and
obligations of Hospital Personnel and of the Hospital with respect to
Intellectual Property; (f) generating funds for scientific investigation,
clinical innovation, and research; and (g) providing an administrative
function that can assist in the administration of this policy, including
evaluating Intellectual Property, appraising and determining the relative
rights and equities of parties involved in the creation of Intellectual
Property, overseeing the filing of Patent and Copyright applications and
related documents, promoting the licensing of Intellectual
Property, assisting in obtaining funds for research that may result in the
creation or further development of Intellectual Property, and otherwise
promoting the fair and uniform application of this policy.

  



  

 _SCOPE_

  



  

This policy applies to all Trustees, directors, officers, members of Board
committees, employees, members of the Medical Staff, and Scientists engaged in
research under the auspices, of The Children\'s Hospital of Philadelphia,
including The Children's Hospital of Philadelphia Research Institute, the
CHOPPA Practice Plans (currently Children's Anesthesiology Associates,
Children's Health Care Associates, Children's Surgical Associates, Radiology
Associates of Children's Hospital, and their New Jersey affiliates), and
entities controlling, controlled by or under common control with The
Children\'s Hospital of Philadelphia, including, without limitation, The
Children\'s Hospital of Philadelphia Foundation (together, the "Hospital"),
and others who conduct research or develop Intellectual Property using
Hospital Facilities, Hospital Funds, and/or other Hospital Resources,
including, without limitation, students, residents, fellows, post-docs,
trainees, technicians, scientists, physicians, nurses, employees,
administrators, occupants of the Hospital laboratories, volunteers of the
Hospital, and all persons whose grants, contracts or other funds are
administered by the Hospital, and/or whose salaries are paid directly, or
indirectly, by the Hospital, including indirectly through a University of
Pennsylvania account (all such persons under referenced Scope, "Hospital
Personnel").

  



    



 



    



     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 2 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  



     **_RELATED POLICIES_**   |   |   |   | 
---|---|---|---|--- 
     |   |   |   | 
   Administrative Policy Manual  |   | _No. A-3-1_   |   | _Conflicts
of Interest_ 
   Administrative Policy Manual  |   | _No. A-3-5_   |   |
_Confidentiality of Patient and Institutional Information_ 
   Administrative Policy Manual  |   | _No. A-3-7_   |   |
_Interactions with Vendors_ 
  



  

 _DEFINITIONS_

  



   | A.| "2000 Policy" has the meaning set forth in Section II. Q. 
---|---|--- 
  



   | B.| "Author" means the creator of a Work, however fixed, including the
creator of a copyrightable Work and/or the creator of Software. 
---|---|--- 
  



   | C.| "Biological Materials" means any and all tissue, fluid, material,
matter or section derived from a biological source, and any part or
derivative arising from or based on any of the foregoing, including, without
limitation, amino acid sequences, antibodies, blood, cells, cell lines,
clones, genetic constructs, germplasm, hybridomas, nucleic and ribonucleic
acid sequences, organic reagents, organisms and recombinant organisms,
peptides, plasma, plasmids, proteins, urine, and vectors). 
---|---|--- 
  



   | D.| "Copyright" means the form of protection, ownership and control of
the intellectual property in a Work that is subject to the copyright laws of
the United States (applicable state law and/or Title 17 of the U.S. Code)
and/or foreign jurisdictions. 
---|---|--- 
  



   | E.| "Confidential Information" means any and all information, in
whatever form (regardless of media or format, including without limitation,
oral, electronic or on paper), whether technical or non-technical in nature
(whether or not patentable), that is or relates to, directly or indirectly,
non-public Hospital business information, non-public research information,
vendor Trade Secrets or other confidential Hospital information, including,
without limitation, Data and Inventions. 
---|---|--- 
  



   | F.| "Data" means any and all data, information and results, in
whatever form (regardless of media or format, including without limitation,
oral, electronic or on paper), whether technical or non-technical (whether or
not patentable), and in each case, any records thereof, including, without
limitation, protected health information (PHI), research protocols
(clinical and non-clinical), research plans, statements of work, technical
specifications, procedures, laboratory notebooks, research
results, materials, processes, techniques, methods, know-how, show-how, and
collections of materials (such as libraries, registries and databases). 
---|---|--- 
  



    



 



    



     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

No. A-3-4 

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 3 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  

  



   | G.| "Effective Disclosure Date" means for purposes of Section II.Q.
the earliest of the following dates (as supported by contemporaneous written
record, fixed in a tangible or intangible form, regardless of media or format,
including without limitation, oral, electronic or on paper): (i) conception,
actual reduction to practice, creation and/or development of
Intellectual Property; (ii) disclosure of Intellectual Property to the IPA in
accordance with Section II.B.; (iii) protection of Intellectual Property
(such as by the filing of a Patent or Copyright); or (iv) third party
licensing or commercialization. 
---|---|--- 
  



   | H.| "Effective Policy Date" has the meaning set forth in Section II.
Q. 
---|---|--- 
  



   | I.| "Gross Income" means all monies received by the Hospital from its
ownership or administration of Intellectual Property of Hospital Personnel,
including royalties, lump sum payments and milestone payments paid in
consideration for the use of Intellectual Property, but excluding sponsored
research or similar payments and payments intended to reimburse the
Hospital for past or future expenses, less any monies that the Hospital is
required to pay to sponsoring organizations, co-owners of the subject
Intellectual Property and others with a claim of right to such monies. 
---|---|--- 
  



   | J.| "Hospital" means The Children\'s Hospital of Philadelphia,
including The Children's Hospital of Philadelphia Research Institute, the
CHOPPA Practice Plans (currently Children's Anesthesiology Associates,
Children's Health Care Associates, Children's Surgical Associates, Radiology
Associates of Children's Hospital, and their New Jersey affiliates), and
entities controlling, controlled by or under common control with The
Children\'s Hospital of Philadelphia, including, without limitation, The
Children\'s Hospital of Philadelphia Foundation. 
---|---|--- 
  



   | K.| ""Hospital Facilities" means any facility owned, leased, licensed
or otherwise in the possession of the Hospital. 
---|---|--- 
  



   | L.| "Hospital Funds" means funds that are owned, held in trust by or
for, or administered by the Hospital, regardless of their origin. Such funds
include, but are not limited to, Hospital operating funds, Board-restricted
funds, investment funds, endowments, amounts received by the Hospital from
contracts or grants, including sub-contracts or sub-grants, amounts
received by the Hospital from contributions, gifts or awards and any income
resulting from any of them. 
---|---|--- 
  



   | M.| "Hospital Personnel" means Trustees, directors, officers, members
of Board committees, employees, members of the Medical Staff, Scientists
engaged in research under the auspices, of the Hospital and others who conduct
research or develop Intellectual Property using Hospital Facilities, Hospital
Funds, and/or other Hospital Resources, including, without
limitation, students, residents, fellows, post-docs, trainees, technicians,
scientists, physicians, nurses, employees, administrators, occupants of the
Hospital laboratories, volunteers of the Hospital, and all persons whose
grants, contracts or other funds are administered by the Hospital, and/or
whose salaries are paid directly, or indirectly, by the Hospital, including
indirectly through a University of Pennsylvania account. 
---|---|--- 
  



    



 



    



     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 4 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  



   | N.| "Hospital Resources" means Hospital Facilities, Hospital Funds,
property or other tangible or intangible assets or resources of the Hospital,
such as Hospital equipment, inventory, Intellectual Property owned by or
licensed to the Hospital, and/or Hospital Personnel during periods when
Hospital Personnel are acting within the scope of their relationship with the
Hospital or are using Hospital Facilities, Hospital Funds, or other Hospital
Resources, including without limitation other Hospital Personnel. 
---|---|--- 
  



   | O.| "Institutional Work" has the meaning set forth in Section I.E.2. 
---|---|--- 
  



   | P.| "Intellectual Property" means any and all creations of the mind,
including, without limitation, (i) Biological Materials, (ii) Confidential
Information, (iii) Data, (iv) Inventions, (v) Patents, (vi) Works, (vii)
Service Marks and Trademarks, and (viii) Trade Secrets, and for each of the
foregoing, any and all rights that may arise or result from Intellectual
Property, including, without limitation, Patent Rights, Copyright, and any
other associated right arising from or under Intellectual Property. 
---|---|--- 
  



   | Q.| "Invention" means (whether or not patentable) any new and useful
idea, invention, know-how, process, show-how, technology, Software or
discovery of any apparatus, composition of matter, design device, formulation,
machine, manufacture, method of making, method (such as diagnostic or
therapeutic), process, new use, new life forms, or any variety of plant, and
for each of the foregoing, any improvement, enhancement, progeny, product,
variant or derivative thereof or resulting therefrom. 
---|---|--- 
  



   | R.| "Inventor" means an individual who, individually or jointly,
conceives of a definite and permanent idea of the complete and operative
Invention such that it is capable of being reduced to practice, or otherwise
inventively contributes to the conception of an Invention, and in any case,
an individual who meets the criteria for inventorship under United States
Patent laws. 
---|---|--- 
  



   | S.| "IPA" means the Institutional Intellectual Property Administrator,
as described more fully in Section IV. 
---|---|--- 
  



   | T.| "IIPAC" means the Internal Intellectual Property Advisory
Committee. 
---|---|--- 
  



   | U.| "Net Income" means Gross Income minus the total of all costs
relating to the protection and commercialization of Intellectual Property,
including without limitation: (i) the preparation, filing and maintenance fees
and costs, legal fees and other costs relating to the protection of
Intellectual Property, including with respect to Patents or Copyrights, (ii)
costs relating to the enforcement and/or defense of Intellectual Property,
including without limitation, costs associated with litigation, disputes,
legal advice and representation, judgments, settlements, fines, and
assessments; (iii) costs relating to the commercialization of Intellectual
Property, including without limitation, production, advertising, marketing,
and marketability search expenses, and (iv) other costs incurred by the
Hospital attributable to Intellectual Property. 
---|---|--- 
  



    



 



    



     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 5 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  

  



   | V.| Patent" includes (i) one or more patents, certificates of
invention, registration or other form of protection for an Invention issued
by any government or governmental agency, domestic and foreign, including,
without limitation, re-exams, reissues, corrections and extensions thereof,
(ii) all related patent applications filed, pending and/or published,
including, without limitation, provisionals, continuations, divisions
continuations-in-part, re-examinations, any Patent Cooperation Treaty (PCT)
application filed or to be filed and all national stage applications filed
therefrom, (iii) and for each of (i) and (ii) all Patent Rights therein and
thereto. The term "Patent" does not include Copyrights, photographs or images
or textual materials that do not qualify for Patent protection under United
States law. 
---|---|--- 
  



   | W.| "Patent Rights" means all rights, title, and interest in, to and
under any Invention or Patent and associated rights therein and thereto,
including, without limitation, the right to file for any such Patent and to
have any such Patent issued in the name of the owner or assignee, the right
to claim any priority right to which the Inventor, or anyone claiming under
him or her, may be entitled, all rights of a Patent owner under 35 U.S.C.
271, the right of Patent enforcement and defense, and the right to sue
and/or collect for past damages. 
---|---|--- 
  



   | X.| "Software" means any computer code (such as a source code or
object code, open or closed), program and/or instruction set for computers
and the like, in any computer language, that provides a service or a function.
Software includes such code, program, and set regardless of the manner in
which fixed, whether in hardware, Software, firmware or otherwise.
Software may be wholly original, or be derivative in nature. 
---|---|--- 
  



   | Y.| "Service Mark" means any word, name, nickname, abbreviation,
symbol, logo, insignia, seal, crest, design or any combination thereof
adopted and used to advertise or promote a service and to distinguish that
service from that of another. 
---|---|--- 
  



   | Z.| "Trademark" means any word, name, nickname, abbreviation, symbol,
logo, insignia, seal, crest, design or any combination thereof adopted and
used to identify the source of goods and distinguish them from those
manufactured or sold by others. 
---|---|--- 
  



   | AA.| "Trade Secret" means any type of information that (a) derives
independent economic value, actual or potential, from not being generally
known to or not being readily ascertainable by proper means by, other persons
who can obtain economic value from its disclosure or use of the information,
and (b) are the subject of reasonable efforts to maintain its secrecy,
including, without limitation, business plans or strategy, customer lists and
information, Data, formulas for manufacturing a product, manufacturing
processes, marketing techniques or Software.  
---|---|--- 
  



   | BB.| "Work" means any original work of authorship fixed in a tangible
or intangible form of expression, in whatever form (regardless of media or
format, including without limitation, oral, electronic or on paper), and
protectable by Copyright, including, without limitation, abstracts,
architectural designs, articles, audiovisual presentation, dissertation,
digital works, images, Institutional Works, manuscripts, mask
works, photographs, research protocols, scholarly publications, syllabi,
textbooks, theses, treatment protocols, semiconductor chips, Software, web
page and web site designs and protocols.  
---|---|--- 
  



    



 



    



     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 6 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  



  

 _IMPLEMENTATION_

  



   | I.| _OWNERSHIP OF INTELLECTUAL PROPERTY_ 
---|---|--- 
  



   | A.| _Ownership of Intellectual Property In General_   
---|---|--- 
  



  

Except as otherwise provided in this policy, the Hospital owns all
Intellectual Property of Hospital Personnel, including any Inventions
conceived, reduced to practice, or developed in whole or in part by Hospital
Personnel in the course of research, teaching, clinical duties, or
other Hospital duties or activities or involving the use of Hospital
Facilities, Hospital Funds, and/or other Hospital Resources.

  



   | 1.| It is presumed that Hospital Personnel in conceiving, reducing to
practice or developing any Intellectual Property utilized Hospital
Facilities, Hospital Funds, or other Hospital Resources unless the Hospital
Personnel is able to prove by clear and persuasive evidence to the
satisfaction of the Hospital that (a) the Intellectual Property was conceived
and developed entirely outside the scope of the Hospital Personnel\'s
relationship with the Hospital, entirely on their own time, and without the
use of any Hospital Facilities, Hospital Funds or other Hospital Resources,
and (b) no other Hospital Personnel participated in the conception or
development of the Intellectual Property within the scope of their
relationship with the Hospital, on Hospital time, or using Hospital
Facilities, Hospital Funds, or other Hospital Resources. The Hospital will
exclude as de minimis incidental and limited use of Hospital computers, email
and telephones in determining whether Hospital Resources were used, but such
use may bear on other issues such as whether the Intellectual Property was
conceived and developed entirely outside the scope of the
Hospital Personnel\'s relationship with the Hospital and entirely on their
own time. 
---|---|--- 
  



   | 2.| When an Inventor, Author, or other creator of Intellectual
Property has created Intellectual Property and believes that the Intellectual
Property was created wholly outside the scope of this policy, the Inventor,
Author, or other creator must promptly advise the IPA of the creation of the
Intellectual Property and provide the IPA with a written statement of all the
relevant circumstances leading to the creation of the Intellectual Property
and any other pertinent information or documentation and request confirmation
that the Hospital has no interest in the Intellectual Property. The IPA, or
his/her designee, may require additional information from the Inventor,
Author, or other creators and/or may conduct such additional investigation as
he/she considers appropriate. After receiving the requested information
and completing any additional investigation, the IPA, or his/her designee,
makes a recommendation to the IIPAC as to whether the Intellectual Property
was created wholly outside the scope of this policy. The IIPAC may conduct
additional investigation if it desires and then makes a final determination.
If it is determined by the IIPAC that the Intellectual Property was created
wholly outside the scope of this policy, the IPA, or his/her designee, will
provide the Inventor, Author, or other creator with a letter that the Hospital
has no right, title or interest in the Intellectual Property. The IPA, or
his/her designee, or the IIPAC may condition the release of such a letter on
all of the Inventors, Authors, or other creators executing an attestation, in
form and substance acceptable to the IPA, or his/her designee, or the IIPAC
with respect to the facts and acknowledging their obligations under this
policy. 
---|---|--- 
  



    



 



    



     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 7 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  



   | B.| _Agreements Affecting Ownership_   
---|---|--- 
  



  

It is Hospital policy to avoid entering into agreements with third parties
containing terms that provide to third parties ownership of the Hospital's
rights in, to or under Intellectual Property developed, in whole or in part,
by Hospital Personnel and/or using Hospital Facilities, Hospital Funds, or
other Hospital Resources. However, where the Hospital enters into an agreement
that affects ownership, including where the Intellectual Property results
from sponsored research or other sponsored work involving agreements or
arrangements that control the Intellectual Property, the terms of the
applicable agreements or arrangements will determine the ownership of, and
rights to, affected Intellectual Property.

  



   | C.| _Restriction on Third Party Agreements_   
---|---|--- 
  



  

Certain Hospital Personnel, including Hospital Staff members of the Hospital
Medical Staff (as defined in the Hospital's Medical Staff Bylaws), Scientists
and other persons who are faculty members at the University of Pennsylvania
who perform some or all of their duties under the auspices of the Hospital,
must obtain advance review and approval and meet other requirements with
respect to consulting relationships. Advance review and approval for other
Hospital Personnel is available on a voluntary basis. See the _Hospital 's
Conflicts of Interest_ _Policy (A-3-1)_. In any event, Hospital Personnel may
not enter into any agreement concerning consulting or other work if such
agreement could jeopardize the Hospital\'s rights under this policy or is
otherwise in conflict with this policy or the Hospital's other policies,
including the Hospital's Conflicts of Interest Policy. The terms of any
consulting or other agreement may in no way abrogate or limit the rights of
the Hospital or the obligations of Hospital Personnel to the Hospital unless
the Hospital is a party to the agreement and an authorized administrative
signatory of the Hospital who holds the title of Vice President or above has
executed the agreement on behalf of the Hospital. Vendor support for research
also is governed by the _Interactions with Vendors Policy (A-3-7)._

  



   | D.| _Freedom from Third Party Claims_   
---|---|--- 
  



  

It is the responsibility of Hospital Personnel prior to engaging in research
to ensure that the Intellectual Property generated by such research,
including the rights to any Invention conceived or reduced to practice during
such research, is free of claims of third parties. As set forth in "C" above,
certain Hospital Personnel must obtain advance review and approval and
meet other requirements with respect to consulting relationships and advance
review for others is available on a voluntary basis. In any event, where any
Hospital Personnel (i) intends to engage in research funded by entities other
than Hospital, (ii) intends to collaborate, with investigators from
corporations or institutions other than Hospital, or (iii) has any reason to
believe that others may make a claim of ownership to Intellectual
Property stemming from their research, then such Hospital Personnel must
assure that the IPA is aware of such circumstances at the earliest feasible
time and far enough in advance so that potential issues concerning the rights
to such Intellectual Property can be resolved before their conception or
reduction to practice or other creation.

  



    



 



    



     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 8 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  



   | E.| _Ownership of Copyrights In General_   
---|---|--- 
  



  

As more fully described in Sections I.E.1. through I.E.4. below, all rights
in Copyright generally remain with the Author(s) unless the Work is an
Institutional Work.

  



   | 1.| _Books, Articles, and Similar Works_ 
---|---|--- 
  



  

In keeping with academic tradition, the Hospital does not claim ownership of
books, articles, and similar works that otherwise contain no Intellectual
Property owned by the Hospital, where the intended purpose is to disseminate
the results of academic or scholarly activities by students,
residents, fellows, post-docs, trainees, and faculty members. Such works
include those of students created in the course of their educations, such as
dissertations, papers, and articles. By way of example, Copyright in an
article submitted to a scholarly or professional journal normally vests in
the Author(s) of the contribution initially, and may be transferred to the
publisher by express agreement. Similarly, the Hospital claims no ownership
of popular nonfiction, novels, poems, musical compositions, or other works of
artistic imagination that are not Institutional Works.

  



   | 2.| _Institutional Works Protectable By Copyright_ 
---|---|--- 
  



  

The Hospital retains ownership of all Institutional Works and resulting
Intellectual Property therein and thereto. Institutional Works means all
works of authorship (i) commissioned by the Hospital, created for Hospital
purposes or supported by a direct allocation of funds through the Hospital
for the pursuit of a specific project, including without limitation, "works
made for hire," which includes work assigned to Hospital Personnel or
developed by Hospital Personnel during or within the scope or performance of
their Hospital employment or engagement (regardless of whether the work is in
the course of sponsored research, unsponsored research, or non-research
activities), including without limitation, a computer program developed by
employed or contracted staff in Hospital's Information Systems Department for
the Hospital's use; a web-based application, service or tool, a toolkit that
is written by physicians, nurses and social workers in one of Hospital's
disease centers for parents of children with that disease, that includes,
with Hospital permission, Hospital-developed protocols; a book written by a
Hospital faculty physician that would have met the requirements of Section
I.E.1. except that it was written with more than insubstantial assistance
from Hospital nurses and administrators during periods when they were acting
within the scope of their relationship with the Hospital; (ii) created using
Hospital Facilities, Hospital Funds, or other Hospital Resources; (iii)
created by Hospital Personnel at the Hospital that would otherwise be of the
type included in Section I.E.1., but are created during periods they are
supposed to be performing their assigned Hospital duties (i.e., in
dereliction of their Hospital duties) or utilize Hospital Facilities,
Hospital Funds, or other Hospital Resources (faculty may make insubstantial
use of their secretaries, computers, etc.), including without limitation, a
musical composition written by a salaried employee who composed the work
during work hours in lieu of providing the specific services at the Hospital
the employee was required to provide; or (iv) otherwise subject to third party
contractual obligations, (collectively, "Institutional Works"). With respect
to Works commissioned directly or indirectly by the Hospital, it is the
responsibility of all Hospital Personnel to ensure that all non-Hospital
Personnel sign an appropriate written agreement conveying ownership of
Institutional Works and Copyrights therein and thereto to the Hospital;
however, failure to obtain such agreement does not adversely impact any
rights the Hospital has in such Institutional Works and Copyrights.

  



    



 



    



     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 9 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  



   | 3.| _Determination of Equities in Copyright_ 
---|---|--- 
  



  

As set forth in Sections I.E.2., the Hospital asserts the Copyright interest
in materials generated as a result of assigned Hospital duty or using Hospital
Facilities, Hospital Funds, or other Hospital Resources. Accordingly, the
Copyright should be secured in the name of The Children\'s Hospital of
Philadelphia. Federal Copyright registration should not be sought without
informing and obtaining advice from the IPA or the Office of General Counsel.

  



   | 4.| _Sponsor 's Rights to Income From Copyright_ 
---|---|--- 
  



  

Where the Hospital entered into an agreement or arrangement that supported
all or part of the development of the copyrightable materials, the Hospital
and the Author(s), Inventor(s), creator(s) or other participant(s) in the
project may be obliged to adhere to the conditions of the grant or contract
as stipulated by the sponsor. For example, the sponsor may have a right to
part, or all, of the income derived from the sale of sponsor-supported
materials that are copyrighted.

  



   | F.| _Software_   
---|---|--- 
  



  

Software, to the extent not protectable by Patent law, generally is governed
by the provisions in Section 1.E. relating to Copyright; provided, however, in
those situations where the Copyright remains with the Author(s) and does not
vest in the Hospital, the Hospital enjoys the rights set forth in
Sections I.F.1. and I.F.2. Software protectable by Patent law is not subject
to the provisions of this policy relating to Copyright or Software, but is
subject to the other provisions of this policy.

  



    



 



    



  

     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 10 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  

  

  



   | 1.| _Hospital Royalty Free Right to Use Software_ 
---|---|--- 
  



  

In recognition of the special relationship between the Hospital and Hospital
Personnel, and the practical difficulty of defining the equities in the
various circumstances under which Software may emerge, the Hospital has the
absolute, unrestricted right to use without charge, for any purpose, any
Software created by, or through, the efforts of Hospital Personnel developed
within the scope of the Hospital Personnel\'s relationship with the Hospital
or using Hospital Facilities, Hospital Funds or other Hospital Resources.

  



   | 2.| _Hospital Non-Exclusive Right To Market Software_ 
---|---|--- 
  



  

In addition to Section I.F.1., the Hospital has a non-exclusive right to
market or license any Software created by Hospital Personnel within the scope
of Hospital Personnel\'s relationship with the Hospital or using Hospital
Facilities, Hospital Funds or any other Hospital Resources. If the Hospital
exercises its marketing right, whether acting alone or in concert with an
external developer, its revenues will be allocated in accordance with Section
III hereof.

  



   | 3.| _Request to Waive Non-Exclusive Marketing Rights To Software_ 
---|---|--- 
  



  

The Author(s) of any item of Software subject to Section I.F.2. may request
in writing to the IPA that the Hospital waive its non-exclusive marketing
rights. Such request should include a description of the Software sufficient
to determine whether commercial potential exists. The IPA, or his/her
designee, may require additional information from the Author(s) and/or may
conduct such additional investigation as he/she considers appropriate. After
receiving the requested information and completing any additional
investigation, the IPA, or his/her designee, makes a recommendation to the
IIPAC as to whether to the Hospital should waive its non-exclusive marketing
rights. The IIPAC may conduct additional investigation if it desires and then
makes a final determination in its sole discretion whether to grant or deny
this request.

  



   | 4.| _Hospital Retention of Commissioned Software_ 
---|---|--- 
  



  

In the case of Software that vests in the Hospital, all Authors, Inventors,
creators, or other participants in the project are required, upon the request
of the Hospital, to waive in writing any intellectual and/or financial
interest in the product they might otherwise enjoy.

  



   | 5.| _Sponsor 's Rights To Income From Software _ 
---|---|--- 
  



  

Where the Hospital entered into an agreement or arrangement that supported
all or part of the development of Software, the Hospital and the Author(s),
Inventor(s), creator(s) or other participant(s) in the project may be obliged
to adhere to the conditions of the grant or contract as stipulated by the
sponsor. For example, the sponsor may have a right to part, or all, of the
income derived from the sale of sponsor-supported Software.

  



    



 



    



  

     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 11 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  

  



   | II.| _ADMINISTRATION OF INTELLECTUAL PROPERTY_ 
---|---|--- 
  



   | A.| _Implementation of Procedures_ 
---|---|--- 
  



  

The IPA and/or the Translational Medicine and Science Board Committee may, from
time to time, establish procedures relating to the disclosure to the
Hospital and administration of Intellectual Property, including without
limitation, Inventions and Copyrights. These procedures may require the
submission of manuscripts, papers, grants, notes, workpapers, summaries of
oral presentations, and other information designed to facilitate the
disclosure, evaluation, and/or protection of Intellectual Property.

  



   | B.| _Disclosure Requirement_ 
---|---|--- 
  



  

In order to preserve the Hospital\'s rights to Intellectual Property,
including, without limitation, Inventions and Copyrights, and assure
compliance with the relevant Patent and Copyright laws, all Intellectual
Property and supporting or underlying Data relating to Intellectual Property
are to be disclosed fully and as promptly as feasible by each Inventor,
Author, or other creator to the IPA or the Department of Technology Transfer
by completing a Technology Disclosure Form available from the Department of
Technology Transfer and/or online on the Hospital's intranet (in The
Children's Hospital of Philadelphia Research Institute section under Tech
Transfer). Disclosure is required of all Intellectual Property conceived,
reduced to practice or developed by Hospital Personnel while they are Hospital
Personnel, even if the Hospital Personnel believes that the Hospital does not
have rights to the Intellectual Property; provided, however that disclosure
is not required for Books, Articles, and Similar Works to which the Hospital
claims no rights, as described above in I.E.1.

  



   | C.| _Invention Disclosure Necessary to Avoid Forfeiture_ 
---|---|--- 
  



  

Disclosure of an Invention to the IPA or Department of Technology Transfer
must substantially precede the first occasion of an Inventor\'s publicly
disclosing (orally, in a poster, in an abstract, or otherwise), publishing
(in print or on-line), commercially using, publicly using, or offering the
Invention for sale. Failure to disclose such Inventions in advance of public
disclosure may result in the irrevocable loss of rights to the Invention in
the United States or in various foreign countries pursuant to their respective
Patent laws.

  



   | D.| _Intellectual Property Assignment Agreement_ 
---|---|--- 
  



  

All Hospital Personnel agree and are required to execute an Intellectual
Property assignment agreement or such other forms acknowledging the Hospital's
rights pursuant to this policy, when requested by the Hospital to do so, and
further agree that such execution may be a condition precedent to beginning
or continuing employment, membership on the Hospital Medical and Research
Staffs, participation in research, applying or receiving research grants,
contracts or awards, or use of Hospital Facilities, Hospital Funds or other
Hospital Resources. Notwithstanding the above, all Hospital Personnel agree
to be and are bound by this policy, as it may be amended from time to time,
irrespective of whether they have signed such an agreement and the absence of
a signed agreement does not adversely impact any rights the Hospital has in
Intellectual Property. The Intellectual Property Assignment Agreement is
available from the Department of Technology Transfer and/or online on the
Hospital's intranet (in The Children's Hospital of Philadelphia Research
Institute section under Tech Transfer).

  



    



 



    



  

     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 12 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  



   | E.| _Assistance and Cooperation in Protecting Intellectual Property_ 
---|---|--- 
  



  

Where the Hospital is entitled to own Intellectual Property, including
without limitation, Inventions and Works, pursuant to this policy, each
Inventor, Author, or other creator will: (a) assign to the Hospital his/her
right, title, and interest in, to and under Intellectual Property,
including Patent Rights and/or Copyrights; (b) execute Patent and Copyright
applications and related documents relating to the Intellectual Property when
requested by the Hospital; (c) execute such other agreements and undertakings
as the Hospital believes to be reasonably necessary or appropriate to protect
Intellectual Property; (d) give all reasonable help in the procurement,
maintenance, and enforcement of the Patents and Copyrights; and (e) otherwise
reasonably assist the Hospital and/or its assignee(s) in securing and
maintaining of all Intellectual Property in the name of the Hospital (or its
assignee).

  



   | F.| _Evaluation of Disclosures_ 
---|---|--- 
  



  

Upon receipt of a disclosure relating to Intellectual Property, the Hospital
will, in its sole discretion, decide upon the method for evaluating and
administering the subject Intellectual Property.

  



   | G.| _Procedures For Protection of Inventions_ 
---|---|--- 
  



  

With respect to Inventions, the Hospital may elect in its sole discretion
whether or not to seek Patent protection, or pursue any other alternative
procedures intended to protect, maintain, and best fulfill the objectives of
this policy. In most instances where the Hospital elects to seek Patent
protection, the Hospital\'s primary interest will be in obtaining United
States Patent protection, if available. The Hospital will not normally file
Patent applications in all countries in which Patents might be granted, but
may, at its discretion, file for Patents in certain foreign countries. If an
Inventor is interested in personally funding all, or part, of the expense of
foreign filing for an application the Hospital would not otherwise file,
he/she should so notify the IPA in writing within six (6) months from the
filing of the Patent application in the United States, whereupon the Inventor
and IPA, or his/her designee, will discuss the terms upon which such foreign
filing should be undertaken. The IPA, or his/her designee, will then determine
whether the Inventor should be permitted to do so. Factors to be considered
include whether there is more than one Inventor and, if so, whether all co-
Inventors are in agreement with respect to the proposed course of action,
whether there is agreement as to how royalties relating to the foreign filing
will be shared; and whether the Inventor is willing and able to bear the full
cost of the foreign filing. If the Inventor is permitted to fund all, or
part, of the expense of foreign filing for an application the Hospital would
not otherwise file, the Hospital and all Inventors will enter into a written
agreement with respect to the terms and conditions that apply (such as
requiring that the Inventor advance funds on a schedule that will assure that
the Hospital has no liability). The IPA, or his/her designee, will make all
decisions with respect to the preparation and filing, prosecution,
reexamination, reissue, licensing, and/or enforcement of Patent applications
and/or Patents that are the subject of this policy, and has the right to make
the final decision whether or not, and upon what terms, to begin, settle, or
terminate any dispute, litigation, or other matter arising pursuant to this
policy.

  



    



 



    



  

     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 13 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  



   | H.| _Inventor 's Right To Request Release of a Patentable Invention _ 
---|---|--- 
  



  

If the Hospital does not apply for a Patent within one (1) year of the full
and complete disclosure (as determined by the IPA) of an Invention to the
Hospital, or if, after the Hospital has filed a Patent application, the
Hospital decides to abandon Patent prosecution, an Inventor may request in
writing, directed to the IPA, that the Hospital release the Inventor\'s rights
to his/her Invention to the Inventor. The IPA, or his/her designee, will
review the request and make a recommendation to the IIPAC, which will make the
determination. Unless the Hospital has reasonable grounds for refusing a
release, such as an agency funding the research must agree and refuses or
the Invention is not patentable, the Hospital will release its interest in
the subject Invention and the Inventor will be free to apply for a Patent in
his/her own name at his/her own expense.

  



   | 1.| The release of an Invention is not a release of improvements,
enhancements or derivatives of the Invention; and the Inventor is obligated
to disclose and assign such improvements, enhancements and derivatives and any
other Inventions as new Inventions pursuant to this policy. 
---|---|--- 
  



   | 2.| If the Hospital releases the Inventor's rights to his/her
Invention and the Inventor subsequently licenses or otherwise commercializes
the Invention, the Inventor is required to distribute to the Hospital ten (10)
percent of the Net Income and ten (10) percent of any equity or other thing
of value received (or receivable) by the Inventor for so long as the Inventor
receives (or is able to receive) Gross Income, equity or other value for the
Invention. 
---|---|--- 
  



   | 3.| If the Hospital releases the Inventor's rights to his/her
Invention, the Inventor is required to grant, and is deemed to have granted,
to the Hospital a royalty-free, irrevocable, non-exclusive license to make or
use the Invention for the purposes of the Hospital. 
---|---|--- 
  



   | 4.| If the Hospital releases an Inventor's rights, but there is more
than one Inventor, the Hospital will release an undivided interest, as
defined by United States Patent laws, to each Inventor unless directed
otherwise in writing by all the Inventors prior to such release. 
---|---|--- 
  



    



 



    



  

     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 14 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  

  

  



   | I.| _License Agreements Favored_ 
---|---|--- 
  



  

In those cases in which the Hospital expects to obtain or has obtained Patent
protection, the Hospital normally will seek to license or otherwise arrange
for the commercial development of the Invention. In those cases in which the
Hospital does not expect to obtain Patent protection, the IPA will
determine on a case-by-case basis whether to seek to license or otherwise
arrange for the commercial development of the Intellectual Property.

  



   | 1.| The Department of Technology Transfer will notify Inventors of
prospective licensees in an early stage of the negotiation process. If the
Inventor objects to the prospective licensee, he/she may, within thirty (30)
days of such notification, file a written protest with the IPA, or his/her
designee, who will render a written decision within thirty (30)
days thereafter. 
---|---|--- 
  



   | 2.| In the event that an arrangement for commercial development is not
made within a reasonable period (a reasonable period where the Hospital
expects to obtain or has obtained Patent protection, is a reasonable period
after the date of issuance of a Patent), an Inventor may request in writing,
directed to the IPA, that the Inventor be allowed independently to pursue
commercial development on the Hospital\'s behalf. The IPA, or his/her
designee, will consider the request and make a recommendation to the IIPAC,
which may in its sole discretion grant (with or without conditions) or deny
this request. 
---|---|--- 
  



   | 3.| Inventors or Hospital Personnel involved in the potential
licensing or other commercialization of an Invention or otherwise
Intellectual Property, whether assisting the Department of Technology
Transfer, acting independently as set forth in Section II.I.2. or otherwise,
are required to disclose to the Conflicts of Interest Committee any
relationship with a prospective licensee or other party and are required to
otherwise comply with the Hospital's _Conflicts of Interest Policy (A-3-1_ ). 
---|---|--- 
  



   | J.| _Release of Intellectual Property Other Than Patentable
Inventions_ 
---|---|--- 
  



  

There may be situations with Intellectual Property, other than patentable
Inventions, where the Hospital has determined it has no interest, or where the
Hospital fails in a reasonable time to protect the Intellectual Property or
to license or commercialize the Intellectual Property. In such situations, a
creator of the Intellectual Property may request in writing, directed to the
IPA, that the Hospital release to the creator rights in his/her Intellectual
Property or allow the creator independently to pursue commercial development
on the Hospital\'s behalf. The IPA, or his/her designee, will review the
request and make a recommendation to the IIPAC, which will make the
determination. Because these situations can vary significantly, the IIPAC
will determine if and under what conditions such action is appropriate.

  



   | 1.| The release of such Intellectual Property is not a release of
improvements, enhancements or derivatives of the Intellectual Property and
the creator is obligated to disclose and assign such improvements,
enhancements and derivatives and any other Intellectual Property as new
Intellectual Property pursuant to this policy. 
---|---|--- 
  



    



 



    



  

     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 15 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  



   | 2.| If the Hospital releases the creator's rights to his/her
Intellectual Property and the creator subsequently licenses or otherwise
commercializes the Intellectual Property, the creator is required to
distribute to the Hospital ten (10) percent of the Net Income and ten (10)
percent of any equity or other thing of value received (or receivable) by the
creator for so long as the Inventor receives (or is able to receive) Gross
Income, equity or other value for the Intellectual Property. 
---|---|--- 
  



   | 3.| If the Intellectual Property is released, the creator will grant
to the Hospital a royalty-free, irrevocable, non-exclusive license to make or
use the Intellectual Property for the purposes of the Hospital. 
---|---|--- 
  



   | 4.| If the Hospital releases a creator's rights, but there is more
than one creator, the Hospital will release an undivided interest, as defined
by United States Patent laws, to each creator unless directed otherwise in
writing by all the creators prior to such release. 
---|---|--- 
  



   | K.| _Resolution of Questions and Disputes_ 
---|---|--- 
  



   | 1.| All questions or disputes concerning the interpretation and
application of this policy will be submitted in writing to the IPA for
resolution. 
---|---|--- 
  



   | 2.| Any person whose rights are affected by any decision, action, or
failure to timely act of the IPA, or his/her designee, Chief Scientific
Officer of the Hospital, or his/her designee, or IIPAC pursuant to this policy
may appeal in writing, within thirty (30) days (or such shorter period as may
be set forth in this policy) of such decision, action, or failure to timely
act, to the President and Chief Executive Officer of The Children\'s Hospital of
Philadelphia. The President and CEO, or his/her designee, will review the
appeal, conduct any additional investigation he/she considers appropriate,
and, within a reasonable time after receiving the appeal, render a final,
binding, and non-appealable decision. The President and CEO, or his/her
designee, may, but is not required to, consult with the Translational
Medicine and Science Board Committee, or a subcommittee thereof appointed by
its Board Chair, in reaching a decision. The President and CEO, or his/her
designee, will report the decisions from appeals to the Translational
Medicine and Science Board Committee. A failure to timely appeal or to cooperate
in connection with an appeal will result in the affected person losing
his/her right to appeal and the decision, action, or failure to timely act
standing. 
---|---|--- 
  



    



 



    



  

     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 16 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  

  



   | L.| _Limitation of Hospital Liability_ 
---|---|--- 
  



  

The Hospital will not be liable for any damages resulting from any acts or
omissions relating to any Intellectual Property, including administrative
and/or legal errors in its assessment of Intellectual Property, the failure
to properly protect Intellectual Property (including with respect to
prosecuting Patents, Trademarks, Service Marks and Copyrights), agreements
entered into or that are not entered into with respect to sponsored research,
licensing or other matters, failure to notify an Inventor of decisions such as
not to seek patent or other protection, failure to notify an Inventor of
licensing negotiations, failure to release rights in Intellectual Property on
a timely basis to an Inventor or any other matter relating to the subject
matter of this policy or to Intellectual Property of the Hospital or Hospital
Personnel.

  



   | M.| _Use of Hospital Name, etc._ 
---|---|--- 
  



  

Nothing in this policy is intended to confer rights in or authorize the use
of the name, Trademarks, or Service Marks of the Hospital, or of other
Intellectual Property of the Hospital except as specifically allowed pursuant
to this policy. Any commercial use of the name, nickname, abbreviation, logo,
Trademarks, Service Marks or other identifying terms, symbols or marks of the
Hospital, or of other Intellectual Property of the Hospital except as
specifically allowed pursuant to this policy, without prior written consent is
strictly prohibited.

  



   | N.| _Other Situations_ 
---|---|--- 
  



  

This policy applies to all Hospital Personnel. It does not attempt to deal in
detail with every possible situation that might arise, but rather to provide
general guidelines that will be supplemented and interpreted on a case by
case basis by the IPA, or his/her designee, in a manner consistent with the
objectives of this policy.

  



   | O.| _Notebooks, etc_. 
---|---|--- 
  



  

Laboratory notebooks and other documents, in whatever form (regardless of
media or format, including without limitation, oral, electronic or on paper),
pertaining to Hospital research activities are the property of the Hospital
and are required to be available to the Hospital at all times and may be
copied and/or used by the Hospital without limitation for the purposes of this
policy and for other appropriate purposes. Hospital Personnel who leave the
Hospital must make arrangements, prior to leaving, with the IPA, or his/her
designee, that assure the continued availability of laboratory notebooks and
other documents to the Hospital as the Hospital considers appropriate.
Where the Hospital requires the original materials, copies will be made
available to Hospital Personnel.

  



    



 



    



     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 17 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  

  



   | P.| _Failure to Cooperate_ 
---|---|--- 
  



  

All Hospital Personnel are required to cooperate fully and honestly with
respect to all matters that are included in this policy, including those
involving the disclosure, evaluation, protection, and commercialization of
Intellectual Property, determining the relative rights and equities of
parties, and disputes relating to Intellectual Property. Failure to so
cooperate may result in a loss of rights, including the loss of right to
share income from Intellectual Property, and can result in the termination of
employment, termination of membership on the Hospital Medical and Research
Staffs, and/or loss of the right to participate in research, apply or receive
research grants, contracts or awards, or use Hospital Facilities, Hospital
Funds or other Hospital Resources

  



   | Q.| _2000 Patent Policy_ 
---|---|--- 
  



  

Revisions in this policy from the version effective November 1, 2006 ("2006
Policy") are relatively minor. However the policy promulgated
effective November 1, 2006 made substantial changes to the Patent Policy
effective July 20, 2000 ("2000 Policy"). Intellectual Property having an
Effective Disclosure Date prior to November 1, 2006 and on or after July 20,
2000, and certain Intellectual Property prior to that date, is subject to the
2000 Policy. For Intellectual Property having an Effective Disclosure Date
between July 1, 2005 and October 31, 2006, inclusive, Hospital Personnel were
given the opportunity to irrevocably elect to have the Intellectual Property
subject to the 2006 Policy in lieu of the 2000 Policy, subject to a process
set forth in the 2006 Policy.

  



   | III.| _DISTRIBUTION OF INCOME_ 
---|---|--- 
  



   | A.| _Right to Share Income_ 
---|---|--- 
  



  

Income from the licensing or other commercialization of Intellectual Property
will be distributed as set forth in this Section III; provided, however, (i)
Program Income, as defined by the Hospital's Policy on Program Income as in
effect from time to time (available from the Department of Technology
Transfer or online on the Hospital's intranet in The Children's Hospital of
Philadelphia Research Institute section under Tech Transfer), is not subject
to distribution pursuant to this Section III and any distribution of income
from Program Income is governed by that policy. All Income distributed
pursuant to this Section III, other than the Inventor Share, is to be used in
support of research activities; and (ii) vendors and other third parties have
no right to any income under this policy.

  



    



 



    



  

     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 18 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  



  

   | B.| _Distribution of Net Income_ 
---|---|--- 
  



  

Net Income will be distributed as follows:

  



       | 1.  |   | Inventor Share (see Section III.C.)  | 30.0  |
%  | 
---|---|---|---|---|---|--- 
     |   |   |   |   |   | 
     | 2.  |   | Inventor Laboratory Share (see Section III.D.)  |
12.5  | %  | 
     |   |   |   |   |   | 
     | 3.  |   | Inventor Department Share (see Section III.E.)  |
12.5  | %  | 
     |   |   |   |   |   | 
     | 4.  |   | Hospital Research Share (see Section III.F.)  |
45.0  | %  | 
  



  

This Net Income sharing schedule pertains to amounts stemming from each item
of Intellectual Property or collection of related Intellectual Property (such
as from each Invention or collection of related Inventions). Where such
Intellectual Property is licensed pursuant to a single licensing or
commercialization agreement, whether prospectively or retrospectively, this
schedule applies once as to income stemming from such agreement (and not
successively as later improvements or enhancements may occur).

  



   | C.| _Inventor Share_ 
---|---|--- 
  



  

The Inventor Share, as set forth in Section III.B., is the total amount
payable to all Hospital Personnel who are Inventors, Authors, or other
creators of the Intellectual Property generating the Net Income.

  



   | 1.| If there is only one such Inventor, Author, or other creator, the
total Inventor Share is payable to that person. 
---|---|--- 
  



   | 2.| Where there is more than one such Inventor, Author, or other
creator, and all such persons unanimously agree in writing how the Net Income
should be distributed among them (by executing, and submitting to the IPA, the
Hospital's Inventors Agreement for Distribution of Net Income), prior to the
Hospital entering into a licensing or other agreement that may result in
Gross Income, then the Net Income will distributed in accordance with such
agreement. 
---|---|--- 
  



   | 3.| Where there is more than one such Inventor, Author, or other
creator, and all such persons have not unanimously agreed on the distribution
by executing and submitting the Hospital's Inventors Agreement for
Distribution of Net Income prior to the Hospital entering into a licensing or
other agreement that may result in Gross Income, then the IPA, or his/her
designee, will determine an appropriate allocation of Net Income among the
Inventors, Authors, or other creators. Any affected Inventor, Author, or
other creator may appeal the allocation to the President and CEO in accordance
with Section II.K.2. 
---|---|--- 
  



    



 



    



     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 19 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  



   | 4.| Each Inventor, Author, or other creator will be entitled to
receive his/her Inventor Share of Net Income in accordance with this policy
whether or not he/she remains Hospital Personnel. In the event of the death of
an Inventor, Author, or other creator, such Net Income will be paid to
his/her estate. 
---|---|--- 
  



   | D.| _Inventor Laboratory Share_ 
---|---|--- 
  



  

The Inventor Laboratory Share of Net Income, as set forth in Section III.B.,
is the total amount that may be available to the principal Hospital laboratory
or laboratories of the Inventors, Authors, or other creators of the
Intellectual Property generating the Net Income.

  



   | 1.| The total Inventor Laboratory Share is limited to a maximum of
Three Hundred and Fifty Thousand Dollars ($350,000) available for any given
July 1 fiscal year, irrespective of the number of principal Hospital
laboratories involved. Half of any excess above the maximum with respect to
any fiscal year is added to the Inventor Department Share and the other half
is added to the Hospital Research Share. 
---|---|--- 
  



   | 2.| If there is only one Inventor, Author, or other creator, or if
there is more than one such Inventor, Author, or other creator and they share
the same principal Hospital laboratory, then the total Inventor Laboratory
Share is available to that principal Hospital laboratory. If there is only
one Inventor, Author, or other creator and such person leaves the
Hospital, or if all of the Inventors, Authors, or other creators share the
same principal Hospital laboratory and all such persons leave the Hospital,
the Inventor Laboratory Share is added to the Inventor Department Share. 
---|---|--- 
  



   | 3.| Where there is more than one Inventor, Author, or other creator
and they do not share the same principal Hospital laboratory, then the
Inventor Laboratory Share is available to their respective principal Hospital
laboratories in the same proportion that the Inventor Share is allocated
among them. In the event that one or more of the Inventors, Authors, or other
creators leave the Hospital, but at least one Inventor, Author, or other
creator remains, then the Inventor Laboratory Share is available to the
principal Hospital laboratories of the remaining Inventors, Authors, or other
creators in the same proportion that the Inventor Share is allocated among
them without regard to the Inventor Share of the leaving Inventor(s),
Author(s), or other creator(s). If all of the Inventors, Authors, or other
creators leave the Hospital, the Inventor Laboratory Share is added to the
Inventor Department Share. 
---|---|--- 
  



   | 4.| Where an Inventor, Author, or other creator does not have a
principal Hospital laboratory, or remains at the Hospital but ceases to have
a principal Hospital laboratory, the Inventor Laboratory Share attributable to
such person is added to the Inventor Department Share. 
---|---|--- 
  



    



 



    



  

     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 20 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  

  



   | 5.| In the event that Inventors are students, residents, fellows,
post-docs, trainees, technicians, occupants of the Hospital laboratories,
volunteers of the Hospital, their principal Hospital laboratory is the
laboratory, if any, in which they worked resulting in their becoming
Inventors. Where they do not have a principal Hospital laboratory, the
Inventor Laboratory Share attributable to such person is added to the
Inventor Department Share. 
---|---|--- 
  



   | 6.| The Hospital will advise the Inventor's Laboratory (or Inventors'
Laboratories, if applicable) on or about January 31 of each year of the
amount of Inventor Laboratory Share received by the Hospital in the
immediately prior calendar year and available to the Inventor's Laboratory
for research purposes in the upcoming July 1 fiscal year. The Inventor's
Laboratory may submit a proposal, including a budget, with respect to how it
proposes to spend all or part of the available Inventor Laboratory Share for
research purposes in the upcoming fiscal year beginning July 1. The proposal
must be approved by the applicable Division Chief and Department Chair and
submitted to the Chief Scientific Officer for his/her approval no later than
March 31. If the Chief Scientific Officer, or his/her designee, approves the
proposal, then the amounts will be available for expenditure in accordance
with the budget, which will be administered by the Vice President - Research
Administration. If the Chief Scientific Officer, or his/her designee, does
not approve the proposal, or all of the proposal, then the
Inventor's Laboratory may appeal the decision to the President and CEO within
two weeks after the decision of the Chief Scientific Officer, or his/her
designee, in accordance with Section II.K.2. 
---|---|--- 
  



   | 7.| Any portion of the Inventor Laboratory Share not approved for
expenditure for the upcoming fiscal year beginning July 1, or not expended in
such upcoming fiscal year in accordance with the approved budget, will be
added to the Hospital Research Share. 
---|---|--- 
  



   | 8.| The principal Hospital laboratory of an Inventor, Author, or other
creator is determined as of March 31 with respect to of the amount of
Inventor Laboratory Share received by the Hospital in the immediately prior
calendar year. If an Inventor, Author, or other creator changes principal
Hospital laboratories after March 31, the principal Hospital Laboratory for
purposes of the Inventory Laboratory Share for the upcoming July 1 fiscal year
remains that in effect on March 31, but the succeeding year's principal
Hospital Laboratory for purposes of the Inventory Laboratory Share is
determined based on the principal Hospital Laboratory of the Inventor,
Author, or other creator as of the succeeding March 31. 
---|---|--- 
  



    



 



    



  

     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 21 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  



   | E.| _Inventor Department Share_ 
---|---|--- 
  



  

The Inventor Department Share of Net Income, as set forth in Section III.B.,
together with any amounts added to the Inventor Department Share in accordance
with Section III.D., is the total amount that may be available for research
purposes to the primary Hospital Department or Departments of the Inventors,
Authors, or other creators of the Intellectual Property generating the Net
Income. For purposes of the Inventor Department Share, a Department is a
clinical department of the Hospital, currently the Departments of
Anesthesiology and Critical Care Medicine, Child and Adolescent Psychiatry;
Pathology and Clinical Laboratories, Pediatrics, Radiology, and Surgery.

  



   | 1.| The total Inventor Department Share, including any amounts added
to the Inventor Department Share in accordance with Section III.D, is limited
to a maximum of Five Hundred Thousand Dollars ($500,000) available for any
given July 1 fiscal year, irrespective of the number of primary Hospital
Departments involved. Any excess above the maximum with respect to any fiscal
year is added to the Hospital Research Share. 
---|---|--- 
  



   | 2.| If there is only one Inventor, Author, or other creator, or if
there is more than one such Inventor, Author, or other creator and they share
the same primary Hospital Department, then the total Inventor Department Share
is available to that primary Hospital Department. If there is only one
Inventor, Author, or other creator and such person leaves the Hospital, or if
all of the Inventors, Authors, or other creators share the same primary
Hospital Department and all such persons leave the Hospital, the Inventor
Department Share remains with the Inventor Hospital Department. 
---|---|--- 
  



   | 3.| Where there is more than one Inventor, Author, or other creator
and they do not share the same primary Hospital Department, then the Inventor
Department Share is available to their respective primary Hospital Departments
in the same proportion that the Inventor Share is allocated among them. In
the event that one or more of the Inventors, Authors, or other creators leave
the Hospital, the Inventor Department Share remains with the Inventor Hospital
Departments. 
---|---|--- 
  



   | 4.| Where an Inventor, Author, or other creator does not have a
primary Hospital Department, the Inventor Department Share attributable to
such person is added to the Hospital Research Share. 
---|---|--- 
  



   | 5.| In the event that Inventors are students, residents, fellows,
post-docs, trainees, technicians, occupants of the Hospital laboratories,
volunteers of the Hospital, their primary Hospital Department is the
Department to which they are assigned, if any. Where they do not have a
primary Hospital Department, the Inventor Department Share attributable
to such person is added to the Hospital Research Share. 
---|---|--- 
  



    



 



    



  

     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 22 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  



   | 6.| The Hospital will advise the Inventor's Department (or Inventors'
Departments, if applicable) on or about January 31 of each year of the amount
of Inventor Department Share received by the Hospital in the immediately
prior calendar year and available to the Inventor's Department for research
purposes in the upcoming July 1 fiscal year. The Inventor's Department may
submit a proposal, including a budget, with respect to how it proposes to
spend all or part of the available Inventor Department Share for research
purposes in the upcoming fiscal year beginning July 1. The proposal must be
submitted to the Chief Scientific Officer for his/her approval no later than
March 31. If the Chief Scientific Officer, or his/he designee, approves
the proposal, then the amounts will be available for expenditure in
accordance with the budget, which will be administered by the Vice President
- Research Administration. If the Chief Scientific Officer, or his/her
designee, does not approve the proposal, or all of the proposal, then the
Inventor's Department may appeal the decision to the President and CEO within
two weeks after the decision of the Chief Scientific Officer, or his/her
designee, in accordance with Section II.K.2. 
---|---|--- 
  



   | 7.| Any portion of the Inventor Department Share not approved for
expenditure for the upcoming fiscal year beginning July 1, or not expended in
such upcoming fiscal year in accordance with the approved budget, will be
added to the Hospital Research Share. 
---|---|--- 
  



   | 8.| The primary Hospital Department of an Inventor, Author, or other
creator does not change for purposes of the Inventor Department Share even if
an Inventor, Author, or other creator changes primary Hospital Departments. 
---|---|--- 
  



  

       | F.  | _Hospital Research Share_ 
---|---|--- 
    



  

The Hospital Research Share of Net Income, as set forth in Section III.B.,
together with any amounts added from the Inventor Laboratory Share, as set
forth in Section III.D., and from the Inventor Department Share, as set forth
in Section III.E., is the amount available to the Hospital for research
purposes, to be expended as determined by the President and CEO, or his/her
designee. The President and CEO may, at his option, choose to establish a
hospital fund that includes the Hospital Research Share to the extent it
exceeds Two Million Dollars ($2,000,000) in any calendar year, If
established, such fund will not constitute an endowment and is available to be
used for research purposes as determined by the President and CEO, or his/her
designee.

  



  

       | G.  | _Sale of Revenue Stream_ 
---|---|--- 
    



  

Should the Hospital decide to sell the revenue expected to be generated from
the licensing or other commercialization of Intellectual Property, or
otherwise monetize the value of Intellectual Property, the Inventor Share of
Net Income will be based on the monies received, and the President and CEO, or
his/her designee, will determine, in his/her absolute discretion, how the
Hospital will calculate the Inventor Laboratory Share and the Inventor
Department Share.

  



    



 



    



  

     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 23 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  



   | H.| _Equity_ 
---|---|--- 
  



  

The Hospital will consider, in appropriate cases, whether to accept, and/or
whether to allow Inventors, Authors, or other creators to accept, equity in
lieu of, or in addition to, other compensation for Intellectual Property,
and, if so, under what terms and conditions. In such situations, the
President and CEO, or his/her designee, will determine how such equity will be
treated in calculating and distributing Net Income in accordance with this
policy.

  



   | I.| _Timing of Distribution of Net Income_ 
---|---|--- 
  



  

Upon receipt of Gross Revenues, the Department of Technology Transfer, or
his/her designee, will initiate distribution of Net Income. Net Income will be
distributed on a quarterly basis, with amounts received by the end of the
second month of a calendar quarter distributed on or about the end of that
quarter. The IPA, or his/her designee, will inform Inventors, Authors, or
other creators and other interested parties of any exceptional circumstances
that may result in a delay in distribution.

  



   | IV| _THE INSTITUTIONAL INTELLECTUAL PROPERTY ADMINISTRATOR_   
---|---|--- 
  



   | A.| _Intellectual Property Administrator_ 
---|---|--- 
  



  

The Institutional Intellectual Property Administrator, or the IPA, is the
Director of the Department of Technology Transfer or such other person
designated by the Chief Scientific Officer of the Hospital.

  



   | B.| _Duties of IPA_ 
---|---|--- 
  



  

The IPA has the following responsibilities with respect to Intellectual
Property, including without limitation, Inventions and Copyrights, and the
administration of this policy:

  



   | 1.| To administer this policy, provide general guidance regarding the
policy, and promote the fair and uniform application of this policy; 
---|---|--- 
  



   | 2.| To establish liaison with appropriate investigators and staff to
monitor research and to assist in the identification of Intellectual Property
developed by Hospital Personnel, including Inventions. 
---|---|--- 
  



   | 3.| To receive all disclosures of Intellectual Property, including
Inventions; 
---|---|--- 
  



   | 4.| To determine, in accordance with this policy, the ownership of
Intellectual Property developed by Hospital Personnel or involving the use of
Hospital Facilities, Hospital Funds, and/or other Hospital Resources, the date
that specific Intellectual Property within the scope of this policy is
conceived, disclosed, and reduced to practice, and the relative rights and
equities of parties involved in the creation of Intellectual Property; 
---|---|--- 
  



    



 



    



  

     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 24 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  



   | 5.| In consultation with the Inventor(s), Author(s), or other
creator(s), and with the IIPAC, to evaluate Intellectual Property in which
the Hospital has an interest, including possible commercial uses and potential
marketing opportunities; 
---|---|--- 
  



   | 6.| To seek to license or otherwise commercialize Intellectual
Property in which the Hospital has an interest, as appropriate, including the
negotiation of licenses and agreements; 
---|---|--- 
  



   | 7.| To establish liaisons with governmental and private sponsors of
research to ensure compliance with provisions in sponsored research and other
sponsored agreements regarding Intellectual Property; 
---|---|--- 
  



   | 8.| To work with the IIPAC to determine whether, the extent to which,
and the manner in which the Hospital, through the Office of General Counsel,
should attempt to protect specific Intellectual Property in which the Hospital
has an interest, including the filing of Patents and Copyrights; 
---|---|--- 
  



   | 9.| To determine the sharing of Net Revenue in accordance with this
policy with respect to specific Intellectual Property subject to this policy; 
---|---|--- 
  



   | 10.| To recommend when Intellectual Property should be returned to the
Inventor(s), Author(s), and other creator(s); 
---|---|--- 
  



   | 11.| To assist in obtaining funds for research that may result in the
creation or further development of Intellectual Property; 
---|---|--- 
  



   | 12.| To maintain complete records regarding disclosures of
Intellectual Property, actions taken with respect to the protection of
Intellectual Property, the dates that specific Intellectual Property within
the scope of this policy is conceived, disclosed, and reduced to practice,
the appropriate distribution of Net Income from Intellectual Property in
which the Hospital has an interest, the resolution of contested matters, and
other matters relating to this policy; 
---|---|--- 
  



   | 13.| To review this policy periodically with the Office of General
Counsel to determine whether changes should be made; 
---|---|--- 
  



   | 14.| To report to the Hospital, including the Translational Medicine and
Science Board Committee, on matters bearing on Intellectual Property and this
policy; 
---|---|--- 
  



   | 15.| To seek counsel, as appropriate, from the IIPAC on the
prioritization of investments in the Hospital's technology portfolio,
licensing strategies, and other matters. 
---|---|--- 
  



   | 16.| To assure that Intellectual Property administration complies with
Bayh-Dole and other legal requirements; and. 
---|---|--- 
  



    



 



    



  

     ![](tlogo.jpg)  | **THE CHILDREN 'S HOSPITAL OF PHILADELPHIA**  |
 

**No. A-3-4**

  

---|---|--- 
   **ADMINISTRATIVE**   | **Title:**   | Page 25 of 25 
   **POLICY MANUAL**   |   | **Effective Date:** 
     | **PATENT AND INTELLECTUAL PROPERTY POLICY**   | **7/1/09** 
  



   | 17.| To seek legal advice and counsel from the Hospital's Office of
General Counsel, and when it is agreed that the assistance of outside counsel
is desirable, to ask the General Counsel of the Hospital, or his/her
designee attorney in the Office of General Counsel, to select patent,
licensing, and/or other counsel to assist the Hospital's research enterprise,
including the Department of Technology Transfer. 
---|---|--- 
  



   | C.| _Accountability of the IPA_ 
---|---|--- 
  



  

In fulfillment of his/her responsibilities, the IPA is accountable to the
Chief Scientific Officer and to the President and Chief Executive Officer of The
Children\'s Hospital of Philadelphia.

  



  

 _RESPONSIBILITY FOR MAINTENANCE OF THIS POLICY_ :

  



  

VICE PRESIDENT - RESEARCH ADMINISTRATION

  



     Supersedes  | Approved by:  | 
---|---|--- 
     |   | 
   11/1/2006  | Signature:  | 
     |   | Steven M. Altschuler, MD - President and Chief Executive
Officer 
  

  

This Administrative Policy is the property of The Children\'s Hospital of
Philadelphia and is protected by U.S. and international copyright laws and may
not be used or reproduced without the prior written consent of The
Children\'s Hospital of Philadelphia. This Policy is to be used solely by
employees of the Hospital, the Hospital Medical Staff and those acting on the
Hospital\'s behalf in connection with Hospital matters or in their Hospital
duties. This Policy may not be copied, photocopied, reproduced, entered into
a computer database or otherwise duplicated, in whole or in part in any
format. Any personal or other use is strictly prohibited.

  



  

The Children\'s Hospital of Philadelphia (C) 2009 All Rights Reserved

  



    



 



    

  



  

Patent and Intellectual Property Policy No. A-3-4 (Effective Date: 7/1/09)

  



  

 _INDEX_

  



     _Section Titles_   |   | _Page_ 
---|---|--- 
     |   | 
   PURPOSE  |   | 1 
     |   | 
   POLICY  |   | 1 
     |   | 
   SCOPE  |   | 1 
     |   | 
   RELATED POLICIES  |   | 2 
     |   | 
   DEFINITIONS  |   | 2 
     |   | 
   IMPLEMENTATION  |   | 6 
  



       | I.  | OWNERSHIP OF INTELLECTUAL PROPERTY  |   | 6 
---|---|---|---|--- 
     |   |   |   |   | 
     |   | A.  | Ownership of Intellectual Property in General  |  
| 6 
     |   | B.  | Agreements Affecting Ownership  |   | 7 
     |   | C.  | Restriction on Third Party Agreement  |   | 7 
     |   | D.  | Freedom from Third Party Claims  |   | 7 
     |   | E.  | Ownership of Copyrights in General  |   | 8 
     |   | F.  | Software  |   | 9 
     |   |   |   |   | 
     | II.  | ADMINISTRATION OF INTELLECTUAL PROPERTY  |   | 11 
     |   |   |   |   | 
     |   | A.  | Implementation of Procedures  |   | 11 
     |   | B.  | Disclosure Requirement  |   | 11 
     |   | C.  | Invention Disclosure Necessary to Avoid Forfeiture  |
  | 11 
     |   | D.  | Intellectual Property Assignment Agreement  |   |
11 
     |   | E.  | Assistance and Cooperation in Protecting Intellectual
Property  |   | 12 
     |   | F.  | Evaluation of Disclosures  |   | 12 
     |   | G.  | Procedures for Protection of Inventions  |   | 12 
     |   | H.  | Inventor's Right to Request Release of a Patentable
Inventions  |   | 13 
     |   | I.  | License Agreements Favored  |   | 14 
     |   | J.  | Release of Intellectual Property Other Than Patentable
Inventions  |   | 14 
     |   | K.  | Resolution of Questions and Disputes  |   | 15 
     |   | L.  | Limitation of Hospital Liability  |   | 16 
     |   | M.  | Use of Hospital Name, etc  |   | 16 
     |   | N.  | Other Situations  |   | 16 
     |   | O.  | Notebooks, etc.  |   | 16 
     |   | P.  | Failure to Cooperate  |   | 17 
     |   | Q.  | 2000 Patent Policy  |   | 17 
   



  

   



 



    



  

 **Patent and Intellectual Property Policy No. A-3-4 (Effective Date: 7/1/09)

  



     

     _Section Titles_   |   | Page 
---|---|--- 
     |   |   |   | 
     | III.  | DISTRIBUTION OF INCOME  |   | 17 
     |   |   |   |   | 
     |   | A.  | Right to Share Income  |   | 17 
     |   | B.  | Distribution of Net Income  |   | 18 
     |   | C.  | Inventor Share  |   | 18 
     |   | D.  | Inventor Laboratory Share  |   | 19 
     |   | E.  | Inventor Department Share  |   | 21 
     |   | F.  | Hospital Research Share  |   | 22 
     |   | G.  | Sale of Revenue Stream  |   | 22 
     |   | H.  | Equity  |   | 23 
     |   | I.  | Timing of Distribution of Net Income  |   | 23 
     |   |   |   |   | 
     | IV.  | THE INSTITUTIONAL INTELLECTUAL PROPERTY ADMINISTRATOR  |
  | 23 
     |   |   |   |   | 
     |   | A.  | Intellectual Property Administrator  |   | 23 
     |   | B.  | Duties of IPA  |   | 23 
     |   | C.  | Accountability of the IPA  |   | 25 
    

  

  



    



    

  

      '

